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Abstract 
Otitis media with effusion (OME) is a disease characterised by inflammation of the middle 
ear and changes in middle ear mucosa from a columnar to a more secretory type epithelium, 
with a proliferation of goblet cells and mucus glands. There is excessive production of 
mucus, resulting in the accumulation of a viscous effusion in the middle ear cleft. Various 
factors have been implicated in the aetiology of the disease including bacteria, Eustachian 
tube dysfunction, allergy and craniofacial abnormalities. It has been suggested that 
laryngopharyngeal reflux could be an inflammatory co-factor and possible cause of many 
upper respiratory disorders including OME. 
The aims of this thesis were to examine effusions for the presence of gastric juice and were 
also concerned with the biochemical and rheological characterisation of effusions. 
Acidic proteinase (pepsin) activity measured at pH2.2 using the N-terminal assay was 
detected in 29% of effusions and 91% of these samples contained pepsin/pepsinogen 
protein at elevated levels compared to serum (using an ELISA). As other serum protein 
levels in effusions were of the same order as serum reference levels, the source of the 
activity was unlikely to be from a transudate of plasma and rather due to the reflux of 
gastric contents into the middle ear. The data suggests that reflux may be a primary factor in 
the initiation of OME in children. 
Middle ear effusions are mucin-rich secretions that demonstrate a lack of degradation on 
storage. They contained at least two distinct mucin populations, MUC5B is the major mucin 
and MUC5AC is present at much lower levels. MUC5B had a significant correlation with 
effusion specific viscosity suggesting that it is responsible for the rheological properties of 
the effusion. 
Interleukin-8 (IL-8) levels in effusions had significant correlation with MUC5AC and it 
may be that MUC5AC is produced in response to IL-8 in the middle ear during the 
inflammatory process of glue ear. Neither IL-6 nor IL-8 levels correlated with MUC5B 
content. It is likely that a different stimulus or other cytokine is responsible for the 
regulation of MUCSB. There was a significant correlation between IL-6 and IL-8 levels in 
effusions demonstrating that one cytokine could stimulate the secretion of the other. 
Further studies developing from the work presented in this thesis would involve analysis of 
effusions for other components of gastric juice, such as gastric lipase and intrinsic factor, to 
i 
confirm the role of reflux in OME. A study following children from the diagnosis stage 
through the disease course and grommet insertion for glue ear with awareness of signs and 
symptoms of reflux would assess the proportion of children with glue ear associated with 
reflux. An animal model for reflux could be set up, instilling gastric juice components into 
the middle ear via the nasopharynx/ET to see if an effusion develops. Effusions could be 
analysed for other cytokines (such as IL-10 or TNF-a) to see if levels correlate with 
MUC5B content. 
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CHAPTER 1 
INTRODUCTION 
Chapter 1 Introduction 
The middle ear constantly secretes mucus, which is transported via cilia from the middle 
ear through the Eustachian tube toward the nasopharyngeal orifice (Ohashi and Nakai, 
1991) where it can be swallowed (Figure 1.1). The mucociliary transport system 
defends the middle ear against inhaled or invading particles including dust, irritant 
gases, bacteria, viruses and allergens. It protects the host by trapping and sweeping 
away these particles, preventing attachment to the respiratory epithelium and is thought 
to play an essential role in evacuating the middle ear pathogens that ascend along the 
Eustachian tube (Lin et al., 2001). 
1.1 Otitis media 
Otitis media is an inflammation of the middle ear without reference to aetiology or 
pathogenesis. There are two subtypes: acute otitis media and otitis media with effusion. 
The rapid onset of signs and symptoms of inflammation in the middle ear is 
characteristic of acute otitis media (AOM). One or more local or systemic signs are 
present, otalgia, otorrhea, fever, the recent onset of irritability, vomiting or diarrhoea. 
The tympanic membrane is bulging and is opaque with limited or no mobility, 
indicative of a middle ear effusion. There may be discharge through a perforation of the 
tympanic membrane. By seven days in most cases the effusion has resolved and the 
individual is asymptomatic (Faden et al., 1998). 
Otitis media with effusion (OME) is a chronic inflammation of the middle ear in which 
an effusion is present but signs and symptoms of acute infection such as otalgia and 
fever are absent, and the tympanic membrane remains intact (Bluestone, 1999), which is 
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the most important distinction between OME and AOM. Hearing loss however is 
usually present in both conditions. 
Otitis media with effusion can be graded by the duration of the disease, for example, 
acute (less than three weeks), subacute (three weeks to three months) or chronic (longer 
than three months) (Cheng and Young, 1997). A different system subdivides otitis 
media (including AOM) by the different histological and clinical characteristics 
observed, such as purulent (acute) (POM), serous (SOM), mucoid (MOM) and chronic 
(COM) (Agius et al., 1995). Serous and mucoid otitis media frequently develop from 
Eustachian tube dysfunction and a serous or mucoid effusion develops in the middle ear 
cleft. In chronic otitis media, irreversible tissue pathology is observed and COM is 
frequently associated with increased numbers of mast cells in the middle ear cleft 
tissues (Hurst et al., 1999). An overlap between the different types of otitis media is 
typical and intermediary types are also present as the definitions are not fully inclusive. 
The research described in this thesis is based on studies on middle ear effusions (mucoid 
and serous) from children diagnosed with chronic otitis media with effusion where the 
effusion has been present for three months or more, therefore acute otitis media and 
acute and subacute OME will not be discussed further. 
1.1.1 Development of OME 
Otitis media with effusion (OME) is the most common cause of deafness in children in 
the developed world (Hunter et al., 1994). The disease is characterised by inflammation 
of the middle ear and changes in middle ear mucosa from a columnar into a secretory 
type epithelium, with a proliferation of goblet cells and mucus glands (Sade, 1966; Lim 
et al., 1973). This leads to excessive production of mucus and the accumulation of an 
2 
effusion in the middle ear cleft that cannot be cleared by the normal mucociliary 
transport mechanisms. 
The presence of this effusion in the middle ear dampens ossicular mobility and impedes 
sound transmission, causing hearing losses of 15-50dB in the affected ear (Karver, 
1998). When the effusion resolves, hearing usually returns to normal (Bluestone, 1999). 
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Figure 1.1 Anatomy of the ear (Straetemans et al., 2001) 
Outer ear (OE), middle ear (ME), inner ear (IE), tympanic membrane (TM), Eustachian 
tube (ET) and nasopharynx (NP) 
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1.1.2 Effusion composition 
Effusions are composed of water, cells and cell debris, bacteria, electrolytes, 
inflammatory mediators (Jung, 1988; Yabe, 1991) and various high molecular weight 
compounds. These include mucus glycoproteins (8-32% of non-dialysable solids 
(NDS)), which are large complex molecules that are actively secreted into the effusion 
and are responsible for the viscous properties (Carrie et al., 1992), protein (12-16% of 
NDS), which mainly comes from serum leakage (Mogi and Honjo, 1972), lipids 
(37-40% of NDS) and DNA (2-15% of NDS) (Fitzgerald et al., 1987; Carrie et al., 
1992; Yabe, 1994). The presence of DNA, lipids and some protein would be as a result 
of epithelial, bacterial and inflammatory cell breakdown. 
Different groups of inflammatory mediators, regulating different stages of the 
inflammatory response have been identified in middle ear effusions. Cytokines are 
potent mediators of inflammation and regulators of the immune response, produced by 
macrophages, neutrophils, lymphocytes and fibroblasts in response to stimuli such as 
endotoxin and viruses. Tumour necrosis factor-alpha (TNFa), interferon-gamma 
(IFNT), interleukin-l-beta (IL-lß), interleukin-2 (IL-2), interleukin-6 (IL-6) and 
interleukin-8 (IL-8) have all been identified in middle ear effusions (Yellon et al., 1991; 
Yellon et al., 1992; Hotomi et al., 1994; Johnson et al., 1997). Retention of cytokines in 
the middle ear cleft during OME may result in an ongoing inflammatory state that has 
the potential for mucosal changes, fibrosis, bone erosion and hearing loss. It may be 
possible that the cytokines remain in the middle ear from a previous inflammatory 
event, protected by the effusion from being metabolised. 
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There is a large variation in the appearance and nature of middle ear effusions. They 
vary from a clear effusion without distinct signs of infection to a cloudy or purulent 
fluid (Sade, 1979). There is also a variation in the consistency of effusions, from watery 
(serous) with a low viscosity to gel-like (mucoid) with a high viscosity. Effusions are 
usually classified on the basis of clinical inspection and their ability to flow on inversion 
(Carrie et al., 1992). 
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1.1.3 Aetiology of OME 
1.1.3.1 Risk factors 
Various social factors have been implicated in the aetiology of OME, most of which are 
related to socio-economic status (such as poverty, poor nutrition or a large family) and 
all of which are probably mediated by an increased susceptibility to infection. A 
decreased socio-economic status increases the importance of environmental factors, 
which contribute to the risk of developing OME (Castagno and Lavinsky, 2002). 
A number of risk factors are related to the home environment: 
1. Presence of siblings in the home leads to an increased incidence of OME 
(Sassen et al., 1997). This risk probably relates to exposure to potential middle 
ear pathogens and respiratory viruses harboured in siblings. 
2. Breast-feeding exerts a protective effect against the development of OME. The 
mechanism of protection is likely to be the effect of maternal antibodies on 
middle ear pathogens (Owen et al., 1993; Duffy et al., 1997). 
3. Exposure to tobacco smoke is a risk factor that impacts on the development and 
persistence of otitis media, especially early in life (Kraemer et al., 1983; Owen 
et al., 1993). 
Children who attend day-care centres have a 2-3 fold increased risk of OME (Owen et 
al., 1993; Nafstad et al., 1999). Day-care plays a pivotal role in the spread of respiratory 
pathogens, bacterial and viral, to young and immunologically naYve children who can 
quickly become colonised with middle ear pathogens (Anainsson et al., 1992). 
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1.1.3.2 Bacteria 
Bacteria, especially Haemophilus influenzae, Streptococcus pneumoniae and Moraxella 
catarrhalis have been cultured from up to 40% of middle ear effusions from children 
with OME (Giebink, 1989; Bluestone et at, 1992; Liederman et at, 1998; Rayner et al., 
1998; Kalcioglu et at, 2002). The remainder of effusions are considered to be sterile by 
culture. Polymerase chain reaction (PCR)-based detection systems were shown to detect 
bacterial DNA in up to 80% of culturally sterile effusions (Post et at, 1995; Post et at, 
1996; Liederman et al., 1998) and a new culture-negative bacterium found solely in 
patients with OME was identified and named Alloiococcus otitidis (Faden and Dryja, 
1989). This bacterium was present in up to 46% of effusions (Hendolin et al., 1999). To 
further prove the validity of the PCR results in the detection of viable bacteria, workers 
have demonstrated the presence of bacterial messenger RNA (mRNA) in culture 
negative middle ear effusions (Rayner et al., 1998). As mRNA has a half-life of seconds 
and can only be produced by viable microorganisms, this was considered further 
evidence of live pathogenic bacteria present in effusions. 
In a chinchilla model it was demonstrated that free DNA and DNA from dead bacteria 
was cleared from the middle ear after three days (Aul et al., 1998) showing that DNA 
from viable bacteria alone was detected by PCR. The animal model represents an acute 
infective effusion and the rapid degradation of free DNA in this environment does not 
necessarily mean that the same process will occur in a middle ear effusion from an 
individual with OME, a disease involving chronic inflammation. It has been shown by 
viscosity studies that human middle ear effusion homogenates incubated with DNA and 
DNase 1 inhibit the breakdown of DNA in a concentration-dependent manner by their 
ability to inhibit nuclease activity (Piezhong et al., 2000) and that the reported presence 
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of non-culturable bacteria based on DNA (and RNA) detection by PCR (Post et al., 
1996; Rayner et al., 1998) could still represent fossilized remains and not viable 
bacteria. 
It has been suggested that the culture-negativity of effusions was due to the inability of 
culture to detect the active pathogen rather than a lack of pathogens and that bacteria 
were existing as a biofilm in a sessile state rather than a motile `planktonic' state 
(Rayner et al., 1998). Biofilms are known to be common in natural environments, on 
industrial equipment and increasingly in the human body, both on implanted medical 
devices and on certain tissue surfaces. In the biofilm state the bacteria are resistant to 
environmental stresses and are impervious to antibiotic treatment due to a decreased rate 
of replication and existence in a slow-growing or starved state. The antimicrobial agent 
may fail to penetrate the full depth of the biofilm (Costerton et al., 1999; Wimpenny et 
al., 2000). They are also resistant to the host's humoral defence system as there is a lack 
of accessibility to the bacteria by immunoglobulins and complement (Costerton, 1999), 
however they may still elicit an immune response resulting in the production of an 
effusion. 
In a biofilm model of otitis media (Post, 2001), bacterial biofilms were clearly visible 
(using scanning electron microscopy) on middle ear mucosal samples of chinchillas 
with experimental otitis media induced by injection of non-typeable H influenzae 
compared to the absence of a biofilm in control animals. From a time series experiment, 
an increasing density of bacteria and development of a matrix-encased biofilm was 
observed as time progressed. This study provides direct evidence for biofilm formation 
demonstrated using H. influenzae in this chinchilla model however there is no evidence 
for biofilm formation within the middle ear in humans. Several authors (Biedlingmaier 
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et al., 1998; Saidi et al., 1999; Post, 2001) demonstrate biofilm formation on the 
grommet (the ventilating tube surgically placed through the tympanic membrane to 
restore aeration to the middle ear space (section 1.1.4) in vitro and in vivo. Bacterial 
attachment to this type of implant can become a source of chronic infection as they can 
rarely be eradicated without removal of the grommet and it is possible that planktonic 
cells periodically released from the bacterial biofilm could restart acute infection. 
1.1.3.3 Viruses 
Studies have indicated that viruses may play a role in the pathogenesis of OME (Arola 
et al., 1990; Shaw et al., 1995). Respiratory syncytial virus, rhinovirus, adenovirus and 
coronavirus nucleic acid have all been identified in effusions (Shaw et al., 1995; 
pitkaranta et al., 1998; Moyse et al., 2000). Direct evidence of co-infection by virus and 
bacteria in 11 % of effusions was demonstrated in one study, supporting the concept that 
respiratory viruses, either alone or in combination with bacteria, are commonly 
associated with OME (Pitkaranta et al., 1998). It is uncertain however whether the 
detection of viral nucleic acid represents persistent infection, residual non-infectious 
RNA or intercurrent infections. Viral upper respiratory tract infections may promote 
secondary bacterial infections by altering bacterial adherence, modulating host immune 
and inflammatory responses and impairing Eustachian tube function (Fireman, 1997). 
OME exhibits a bimodal distribution with peaks in spring and autumn, this is consistent 
with the rise in respiratory viruses or inhaled allergens demonstrating their possible role 
in the aetiology of the disease (Faden et al., 1998). 
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1.1.3.4 Allergy 
Allergy is considered to be a possible risk factor in OME. Allergic rhinitis has been 
identified in 42 % of children with OME (Mogi et al., 1992) and there appears to be a 
higher incidence of chronic OME in children with allergy as compared with children 
without any evidence of allergy. This may be just an accidental association as there is 
no direct conclusive evidence that upper respiratory tract allergy induces OME 
(Fireman, 1988) but it may delay the resolution of the effusion by affecting Eustachian 
tube function. 
1.1.3.5 Eustachian tube dysfunction 
Eustachian tube dysfunction is thought to be involved in the development of OME. The 
Eustachian tube (ET) links the nasopharynx and the middle ear cavity. It is made of one- 
third bone (at the tympanic orifice) and two-thirds cartilage (at the pharyngeal orifice) 
and ciliated columnar epithelia predominates. The ET is essential in maintaining a 
healthy, well-aerated middle ear cavity. It ventilates the middle ear, protects it from 
pathogenic organisms in the nasopharynx via the mucociliary transport system, 
equilibrates pressure across the tympanic membrane and allows clearance of secretions 
from the middle ear into the nasopharynx. The tube opens intermittently to maintain 
ambient pressures in the middle ear, this occurs during swallowing, yawning or 
sneezing (Pinckney and Currarino, 1980). 
In infants, the ET length is between 13 and 18mm compared to between 31 and 38mm 
by the age of seven years. The tube is at an angle of approximately 10° to the horizontal 
from the tympanic orifice to the pharyngeal orifice in infants compared to 45° in adults 
(Proctor, 1967). This could lead to possible clearance problems in children, but more 
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importantly it is possible that the angle of the tube in infants could have an effect on the 
function of the active opening mechanism of the ET (Ovesen and Borglum, 1998). 
Contraction of the tensor veli palatini (TVP) muscle opens the narrowest portion of the 
ET lumen to ventilate the middle ear (Sudo et al., 1997). It has been demonstrated using 
a three-dimensional computer graphics reconstructive technique that in conjunction with 
the change in size and shape of the ET cartilage with age, the distance from the TVP 
muscle to the ET lumen is greater in children than in adults. A superiorly orientated 
rotation of the TVP muscle relative to the other components of the ET occurs with age 
(Sadler-Kimes et al., 1989) and this angulation in adults may establish a mechanical 
efficiency for opening the tube that is absent in infants and young children. This may 
account for the opening or closing failure of the ET in infants and young children 
leading to obstruction or abnormal patency. 
Obstruction of the ET can cause middle ear negative pressure, retraction of the tympanic 
membrane and hearing loss. This environment may promote the growth of bacteria and 
viruses already present in the middle 
ear 
and lead to inflammation and ultimately the 
development of a middle ear effusion. Abnormal patency of the ET results in the tube 
being open even at rest, which usually permits gas to flow readily from the nasopharynx 
into the middle ear. This effectively regulates middle ear pressure, however unwanted 
secretions from the nasopharynx, i. e. reflux or bacteria, can more readily gain access to 
the middle ear when the tube is abnormally patent. 
Another explanation for the ineffective active opening of the tube may be related to the 
cartilage support. The amount and stiffness of the cartilage support in the ET are 
markedly less in infants than in older children and adults (Swarts and Rood, 1993) and 
the tubal cartilage is more compliant, therefore there may also be opening failure of the 
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ET due to its persistent collapse and the lumen may not open in response to contraction 
of the TVP muscle, resulting in a functional obstruction. 
The constricted shape of the ET lumen in children (which is of a narrow, tubular 
configuration) means that it can be easily occluded with serous or mucoid effusions and 
may also prove to be a barrier to effective clearance of bacteria from the middle ear 
cavity (Suzuki et al., 1998). Intrinsic mechanical obstruction of the ET can occur due to 
swelling, oedema or a lack of mucosal surfactants (Ovesen and Borglum, 1998) either 
within the ET or at its orifice in the nasopharynx and this can compromise ET function. 
Extrinsic obstruction can be due to the pressure of enlarged adenoids and in one study 
adenoidectomy and insertion of grommets was shown to improve the resolution rate 
(measured by time with recurrent effusion) of OME by 18% compared to the resolution 
rate with grommets alone (Gates et al., 1987). At the end of the study however, the 
proportion of children remaining free of recurrence was the same in the two groups and 
therefore the role of adenoidectomy in the treatment of OME remains controversial. If 
adenoidectomy does improve the resolution rate this may be due to the removal of a 
physical obstruction of the ET or a source of ascending infection (Suzuki et al., 1999). 
An early theory to explain the mechanism of ET dysfunction in OME was that 
obstruction of the ET orifice in the nasopharynx would lead to a negative pressure in the 
middle ear as oxygen is absorbed and not replaced. As a result of the negative pressure, 
a transudate of fluid from the blood vessels would fill the ear causing an effusion. This 
is the `hydrops ex vacuo' theory. The biochemical composition of the effusion found in 
OME is that of a usual inflammatory exudate, containing high molecular weight 
substances, and not just of a transudate of serum (Sade and Ar, 1997) and the `hydrops 
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ex vacuo' theory does not explain the inflammation and metaplasia seen in the affected 
ear (Sade, 1966). 
There is morphological increase in the dimensions of the ET lumen with age when it 
becomes larger and more like the shape of two cones connected by the narrow ends. 
This leads to an increased ability to clear secretions actively from the middle ear and to 
ventilate the middle ear more effectively. 
1.1.3.6 Ciliary function 
The middle ear and the ET contain ciliated epithelia (Houtmeyers et at, 1999). The first 
evidence of an active mucociliary transport system in the middle ear was demonstrated 
in 1967 (Sade, 1967). Ciliated cells and goblet cells are abundant in the middle ear in 
the area near the ET orifice and their density becomes lower distal to the tube (Shimada 
and Lim, 1972). The ET is a pseudostratified columnar ciliated epithelium composed of 
ciliated cells, goblet cells and basal cells (Ohashi and Nakai, 1991). Cilia beat at around 
10Hz within a layer (7-10µm) of low viscosity periciliary fluid upon which lies the 
more viscous mucus layer (0.5-2µm) (Quraishi et al., 1998). The periciliary fluid layer 
is at a depth just less than the height of a fully extended cilium (Fig. 1.2). The tips of the 
cilia engage the overlying mucus layer and propel it towards the nasopharynx. 
In OME there is a decrease in the number of ciliated cells and an increase in the number 
of secretory cells (Inagaki et al., 1988) and it is likely that in this situation the system 
would fail to transport the mucus layer, thus impairing the clearance of the effusion. 
Reduced mucociliary function may be an important factor in the development of OME 
and the disease is present in approximately 84% of patients with primary ciliary 
dyskinesia (Jahrsdoerfer et al., 1979; Pedersen and Mygind, 1982; Mygind et al., 1983; 
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Greenstone et al., 1985). Studies have shown that endotoxin is involved in the clinical 
development of OME and that the dysfunction of cilia caused by endotoxin may be 
responsible. Reduced ciliary activity was observed in the guinea pig middle ear in a 
dose-response manner, one and three days after inoculation with endotoxin from 
Klebsiella pneumoniae, measured by a direct and quantitative photoelectric method 
(Ohashi et al., 1989). 
The mucociliary clearance of mucus is affected by its viscosity as the mucus has to be 
able to support a load and at the same time not distort the tips of the cilia in order to be 
cleared successfully. As mucus becomes more viscous there is a tendency for the ciliary 
beat frequency to decrease (Quraishi et aL, 1998). If mucus is too thick it is difficult for 
the cilia to deform it enough for it to move and if it is too thin the cilia cannot impart 
enough energy to it to transport it. There is an optimum viscosity at which mucus is 
effectively transported (Fig. 1.3) (Silberberg, 1983) and the viscosity of the mucus is 
determined by the nature and concentration of the mucins. 
15 
Figure 1.2 The effect of the depth of the periciliary layer on mucociliary 
clearance (Kubba et al., 2000) 
(a) 
(b) 
`C . ý"s ýý. 7. ý=T ash= 3' ýe . 
(a) The ideal situation, where the tips of the cilia just penetrate the gel layer on their 
forward strokes, propelling it over the epithelium. 
(b) The periciliary layer is too shallow, so that the cilia are coupled to the gel layer 
throughout the forward and backward strokes, with no net movement over the 
epithelium. 
(c) The periciliary layer is too deep, so that the cilia are unable to impart enough energy 
to it to produce any movement of the gel layer. 
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Figure 1.3 The relationship between mucus concentration (viscosity) and 
mucociliary clearance rate 
t 
a cg 
F 
This relationship has been modelled mathematically (Silberberg, 1983) and confirmed 
using partially purified middle ear mucus preparations at varying concentrations, 
measuring their rate of transport on the ciliated epithelium of a frog palate (Majima et 
al., 1985). 
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1.1.3.7 Cleft palate 
Otitis media with effusion affects 92-97% of children with cleft palate in their first year 
and persists in 70% at age 4 (Dhillon, 1988; Robinson et al., 1992). The high incidence 
is caused by impaired muscular compliance of the ET resulting in ineffective opening of 
the tube (Huang et al., 1997). There is evidence that bacterial infection may play a 
significant role in the development of OME in children with cleft palate due to 55% of 
effusions being culture positive (Jousimies-Somer et al., 1986). This is possibly due to 
the compliance of the ET allowing bacteria to reflux into the middle ear and that due to 
their inability to suckle, the majority of cleft palate infants are fed on formula milk 
which does not contain maternal antibodies against middle ear pathogens (Owen et al., 
1993; Duffy et al., 1997). 
1.1.4 Diagnosis and treatment 
The diagnosis of OME is difficult because the disease process is often asymptomatic, 
there are no signs of acute infection as in AOM such as fever, pain or discharge. It may 
go undetected by the parent, teacher and even the child. Diagnosis is usually made by 
physical examination of the ear. Otoscopic examination of the ear of a child with OME 
reveals the tympanic membrane to be retracted, dull and opaque. The colour of the 
tympanic membrane can range from light pink to amber and even dark blue (if there has 
been haemorrhaging). The presence of air bubbles or air-fluid levels makes the 
diagnosis more evident. Tympanometry is a very useful test for the diagnosis and 
effective screening of OME. It measures changes in acoustic impedance of the tympanic 
membrane-middle ear system with changes in air pressure in the external auditory canal. 
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Various medical and surgical measures have been applied to OME (Fitzgerald et al., 
1988; Cantekin and McGuire, 1998; Gilbert, 1999), but no overall single measure is 
considered to be completely effective (Fraser et al., 1977; van Buchem et al., 1981). 
This is possibly because OME is prone to both seasonal variation and remission and that 
many cases of OME resolve spontaneously, therefore it is difficult to assess the cure 
rate. 
Surgical intervention generally involves removal of the effusion by myringotomy and 
insertion of a grommet into the tympanic membrane. The grommet restores middle ear 
ventilation, enables aeration of the middle ear and alleviates hearing loss. Grommet 
insertion is by far the most common short-term measure for treating the symptoms of 
OME and the most common operation performed on children in the UK (Maw and 
Bawden, 1993). However, grommet insertion does not offer a cure and the procedure is 
not free of complications and long-term sequelae related to the middle ear and tympanic 
membrane, such as cholesteatoma, tympanosclerosis, presence of granulation tissue or 
ossicular fixation, especially in children who have required grommet insertion on more 
than one occasion (Moller, 1984; Chopra, 2000) 
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1.2 Mucus and the upper respiratory tract 
1.2.1 Mucus 
Mucus is a unique, complex, viscous biological secretion, a mixture of water (95%), 
proteins and glycoproteins (3%), lipids (1%) and salts (1%) (Creeth, 1978). 
Mucus secretions protect the epithelia of mammalian respiratory, gastrointestinal and 
reproductive tracts and are secreted over the eye. Mucus provides a selective barrier 
adapted to the specific physiology of each mucosa and its primary function is to protect 
the underlying mucosal epithelium from damaging agents and shear forces. 
In the respiratory tract, including the modified respiratory epithelium of the middle ear, 
mucus provides a protective barrier against dehydration, invading microorganisms and 
airborne particles. It is an integral part of the mucociliary escalator and particles trapped 
in the luminal mucus are constantly removed from the airway and towards the pharynx 
by ciliary beating. Maintenance of normal mucociliary function depends on the 
viscoelastic property of mucus, which is determined by the quality and quantity of 
mucins present in it (Kim et al., 1997). If the mucus becomes too viscous the cilia are 
not able to move it, not producing enough mucus can cause mucociliary transport to 
cease. Any abnormalities in mucus secretion may result in impaired clearance and the 
development of pathological airways. Two frequent pathological changes observed in 
respiratory epithelium are squamous metaplasia of the mucociliary epithelium and 
hypersecretion of mucus as a result of hyperplasia of the mucus secreting cells. The 
latter is a common complication frequently observed in many diseases of the respiratory 
tract e. g., otitis media, sinusitis and rhinitis. Traditional strategies for controlling mucus 
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hypersecretion include enhancing the capability of the epithelium to transport mucus 
using mucoactive drugs such as corticosterone (Miyata et al., 1998) and changing the 
rheological properties of the mucus using mucolytic agents (Pearson et al., 1997) to 
reduce mucus viscosity and allow faster removal of the mucus secretion. 
1.2.2 Mucins 
Mucus glycoproteins (mucins) are a heterogeneous group of complex, richly 
glycosylated high molecular weight (approximate Mr 106 to 50x 106) (Harding, 1989) 
molecules, produced by goblet cells of the surface epithelium, submucosal gland and 
surface mucosal cells. 
Mucin subunits are made up of a central protein backbone, 1500 to 4500 amino acids in 
length, with hundreds of carbohydrate side chains attached (Larivee et al., 1994). There 
are areas of dense glycosylation (resistant to proteolysis) and areas of little or no 
glycosylation (susceptible to proteolysis) (Allen and Pearson, 1993) giving a "bottle- 
brush" structure (Allen et al., 1998) (Figure 1.4). Mucins are difficult to sequence by 
conventional techniques using enzymes as much of the structure of the protein core is 
concealed by complex glycosylation, making access difficult. 
They form large expanded molecules in solution and interdigitation of the side chains 
from neighbouring molecules produces the viscous and characteristic gel-like nature of 
mucus secretions (Sellers et al., 1988a). Pig submaxillary mucin or human 
tracheobronchial mucin can form a gel at concentrations of 5-15mgml-I (Sellers et al., 
1988b; McCullagh et al., 1995) whereas gastrointestinal mucins form gels at 
30-50mgm1"1 (Sellers et al., 1988a). 
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Figure 1.4 The subunit structure of mucus glycoprotein showing glycosylated 
"bottle brush" and nonglycosylated regions. Subunits are joined by disulphide 
bridges to form overall linear polymeric mucins. From (Allen, 1989). 
POLYMERIC MUCIN 
CARBOHYDRATE SIDE CHAINS GEL FORMING 
DISULPHIDE 
BRIDGES LINKING 
SUBUNITS TO FORM 
POLYMER 
rý"'r" 
GLYCOSYLATED REGION 
(resistant to proteolysis) 
(resistant to proteolysis) 
NON-GLYCOSYLATED 
REGION 
PROTEOLYSIS 
PROTEOLYTICALLY 
DEGRADED MUCIN 
SOLUBLE 
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(over 80% by wt. of glycoprotein) 
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1.2.2.1 Protein core structure 
The basic unit of a mucin is a single polypeptide chain that forms 10-30% of the weight 
of the molecule (Fitzgerald et al., 1987; Allen, 1989). The protein core of the mucin 
subunit can be divided into two regions (Scawen and Allen, 1977): 
1. Central protease resistant domains 
These domains are heavily glycosylated. They are rich in serine and/or threonine 
and proline (Allen, 1989) and these amino acids constitute 30-50% of the protein 
core (Pearson et al., 1980; Carlstedt et al., 1983; Forstner and Forstner, 1994). This 
part of the mucin contains repetitive regions (Allen et al., 1998) including tandem 
repeat domains varying in length and sequence from 8 to 169 residues (Toribara et 
al., 1993; Guyonnet-Duperat et al., 1995) and is also known as the variable number 
tandem repeat region (VNTR). 
2. Terminal protease sensitive domains 
These domains are virtually devoid of carbohydrate. They are rich in cysteine and 
acidic groups. Cysteine is involved in the formation of disulphide bridges between 
the subunits of the polymer and is therefore important in determining the viscous 
properties of the mucin (Allen and Pearson, 1993). 
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1.2.2.2 Carbohydrate structures 
Carbohydrate forms up to 85% of the mucin molecule, the main sugars being fucose, 
galactose, N-acetylgalactosamine, N-acetylglucosamine and sialic acid (Pigman, 1977; 
Creeth, 1978; Allen, 1983). The absence of uronic acid and only trace amounts of 
mannose (<I%) distinguishes mucin glycoproteins from the proteoglycans of 
connective tissue and serum glycoproteins respectively. 
The carbohydrate side chains vary in composition, structure and size between mucin 
species from different secretions. They form branching chains of between 2 and 20 
sugars (Forstner and Forstner, 1994). In the central VNTR region of the mucin subunit 
they are attached covalently to the serine and threonine by alkali labile O-glycosidic 
linkages from N-acetylgalactosamine at their reducing ends (Allen and Pearson, 1993), 
protecting the protein from proteolytic attack. N-acetylgalactosamine always occurs as 
the linkage sugar to the peptide core (Carlson, 1977). 
The backbone region of the oligosaccharide chain is composed of alternating residues of 
ß-linked galactose or N-acetylgalactosamine. Sialic acid and fucose, and sometimes N 
acetylgalactosamine, are found at the non-reducing ends of the main or branched chains. 
The terminal sugars confer ABO blood group activity on the mucins due to the structure 
of the non-reducing ends of their oligosaccharide chains (Allen, 1989). 
The cysteine-rich regions of the mucins at the N- and C-terminals contain 
N-glycosylation sites. N-glycosylation is thought to be a key signal for subcellular 
targeting of nascent mucin glycoprotein since inhibition of this process arrests 
biosynthesis (McCool et al., 1994). 
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Throughout their length, the carbohydrate chains have sulphate groups attached via ester 
linkages to galactose and N-acetylgalactosamine residues. These and sialic acid residues 
impart a negative charge to the molecule (Forstner and Forstner, 1994) leading to acidic 
mucins rather than fucose-containing neutral mucins (Allen and Leonard, 1985). 
Histological staining such as Periodic acid Schiffs (PAS)-Alcian blue and high iron 
diamine can differentiate between acidic and neutral mucins (Filipe, 1979). 
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1.2.3 Mucin genes 
To date, 18 human mucin genes coding for mucin protein cores have been identified and 
assigned to the MUC gene family as approved by the Human Genome Organization 
Gene Nomenclature Committee. They are divided into two types, secretory and 
membrane associated (Gendler and Spicer, 1995). 
Secretory mucins contribute to the viscous mucus of the respiratory, gastrointestinal and 
reproductive tracts. They typically form very large oligomers through the linkage of 
glycoprotein monomers. The glycoproteins are secreted from the cell and remain at the 
apical surface of epithelial cells in the form of a mucus gel. 
Membrane associated mucins have a hydrophobic, membrane-spanning domain and 
have not been observed to form oligomeric complexes (Figure 1.5). They form part of 
the cell-surface glycocalyx and can protect epithelial cells against pathogens or from 
being injured by inflammatory cells through preventing them from binding to the cell 
surface. 
Of the secreted mucins four, MUC2, MUC5AC, MUC5B and MUC6 are known to be 
gel forming (Desseyn, 2000) and their four genes are contained within a single 400kb 
genomic DNA fragment on chromosome 11 band p15.5 (Pigny et al., 1996). Each has a 
large central tandem repeat region and the amino and carboxyl terminals of the protein 
cores of these mucins are structurally related to each other (Figure 1.6). The cDNA 
sequences flanking the central VNTR region for MUC2, MUC5AC and MUC5B code 
for cysteine-rich domains designated B, C, CK (cysteine knot) and D (D1, D2, D', D3 
and D4) domains, which are similar to the cysteine-rich A-domain flanking regions in 
the serum glycoprotein prepro-von Willebrand factor (vWF), a blood-clotting factor 
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(Gum Jr et al., 1992; Klomp et al., 1995; Lesuffleur et al., 1995; Buisine et al., 1998; 
Desseyn, 2000) (Figure 1.7,1.8). MUC6 is structurally remote as a large portion of the 
region downstream of the VNTR has been lost during evolution (Toribara et al., 1997). 
The D domains present in all these secreted mucins are proposed to be involved in the 
dimerisation of mucin molecules (Gum Jr, 1995; Gipson et al., 2001). 
Several membrane-bound mucins are also related to each other, especially those 
localized to chromosomal locus 7q22, MUC3A, MUC3B, MUC11, MUC12 and 
MUC 17 (Williams et al., 1999; Pratt et al., 2000; Gum Jr et al., 2002). 
The predominant feature of all the mucin genes is the presence of tandem repeats of 
defined sequences of nucleotides (this has not been confirmed as yet for MUC 18) 
There is no homology between the tandem repeat sequences of the mucin genes. Each 
mucin also has distinct tissue expression that can be determined by detection of mRNA 
and also the protein product (Audie et al., 1993; Gendler and Spicer, 1995; Ho et al., 
1995; Van Klinken et al., 1995). The tissues in which each mucin is expressed and the 
chromosomal location of the genes are shown in Table 1.1. 
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Figure 1.5 Diagrammatic representation of the structure of a membrane-bound 
mucin, MUC1 (adapted from (Gendler and Spicer, 1995; Gum Jr, 1995)) 
Glycosylated domain with variable numbers 69 amino acid 
(between 41 and 85) of a 20 amino acid repeat cytoplasmic tail 
H 
NH2 COOH 
127 amino acid 31 amino acid 
signal peptide 227 amino acid membrane-spanning 
domain degenerate repeats domain 
MUC 1 is over 1300 amino acid residues in length and consists of three distinct 
segments. The amino terminal signal peptide domain consists of a signal peptide and 
degenerate repeats. There is a large glycosylated domain made up of variable numbers 
of a 20 amino acid repeat which is less glycosylated than MUC2 (Fig. 1.8) due to a 
lower density of potential O-glycosylation sites. The carboxyl terminal consists of 
degenerate repeats containing potential N-glycosylation sites, a hydrophobic membrane- 
spanning domain of 31 amino acids, which serves to anchor the mucin to the membrane 
and a cytoplasmic domain of 69 amino acids. 
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Figure 1.6 The hypothetical evolution of the four human mucin genes clustered 
on the chromosome 11p15 from a common ancestor of the human vWF gene (from 
(Desseyn, 2000)). 
Ancestor 
MUC II p 15 Ancestor 
(D 1-D2-D'-D3-D4-B-C-CK) 
Duplication of 
the C domain 
and 
triplication of 
the B domain 
MUC2-5ACB Progenitor 
Exons lost 
vWF 
Chromosome 12 
MUC6 MUC2 MUC5AC MUC5B 
Iq- Tel. Chromosome 11 pl, Cen. 
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(D 1-D2-D'-D3-[Cys-subdomain]- 
D4-B-C-CK) 
Figure 1.7 A schematic diagram of the carboxyl terminal MUCSB core protein 
(and similar proteins) and von Willebrand factor (Desseyn et al., 1997a) 
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The conservation of nearly all the cysteine residues and of several other amino acids of 
vWF and of the three l 1p15.5 human mucins Mt1C2, MUC5AC and MUC5B is readily 
apparent, suggesting a very similar tertiary structure that can be dissected into six 
domains. The MUC 11 p 15-type domain follows the central exon, the A3uD4 domain has 
similarities to the domain located between A3 and D4 in vWF, and there is one D4-like 
domain, one B-like domain, one C-like domain and one CK domain. 
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Figure 1.8 Diagrammatic representation of the structure of a secreted mucin, 
MUC2 (Allen et al., 1998) 
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MUC2 protein core is over 5100 amino acids residues in length and consists of five 
different segments. Segment A contains a variable number of tandem repeats (VNTR), 
the site of 0-glycosylation with N-acetyl galactosamine at the reducing end of the 
carbohydrate chains. The branched carbohydrate chains of 4-20 sugars form a closely 
packed sheath around the central protein core. Segment B is another repetitive region 
rich in serine and threonine, putative sites for glycosylation. The two glycosylated 
segments of the protein core are separated by segment C containing cysteine. Segments 
D and E at the C and N terminal ends, respectively, are extensive peptide chains, rich in 
cysteine and containing D domains which have sequence homology to the prepro vWF. 
Segments C, D and E contain 31 potential N-glycosylation sites and segment D contains 
a cysteine `knot' of eleven conserved cysteine residues found in the other known 
secretory mucin gene products (MUC5AC, MUC5B and MUC6). 
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Table 1.1 Tissue expression and chromosomal location of the 18 mucin genes. 
S= secretory mucin, M= membrane bound. 
Mucin gene Chromosomal Tissue expression References 
location 
MUC1 1g21-23 M All epithelia, breast, pancreas, (Russell et al., 
small intestine, urinary bladder 1998) 
MUC2 11p15.5 S Airways, tear ducts, small (Griffiths et al., 
intestine, colon 1990; Gum Jr et 
al., 1992) 
MUC3A 7q22 M Gall bladder, small intestine, (Pratt et al., 2000) 
colon 
MUC3B 7q22 M As 3A plus heart, liver, (Pratt et al., 2000) 
thymus, pancreas 
MUC4 3q29 M Trachea, lung, stomach, colon, (Moniaux et al., 
uterus, prostate, small intestine 1999) 
MUC5AC 1 lp15.5 S Middle ear, airways, stomach, (Hovenberg et al., 
cervix 1996; Labat et al., 
1999) 
MUC5B 11p15.5 S Middle ear, airways, (Desseyn et al., 
submaxillary gland, 1997b; Kawano et 
endocervix, gall bladder, al., 2000) 
pancreas 
MUC6 11 p 15.5 S Stomach, gall bladder, cervix (Toribara et al., 
1993) 
MUC7 4g13-21 S Salivary glands, airways (Bobek et al., 
1993) 
MUC8 12q24.3 M Airways (Shankar et al., 
1997) 
MUC9 1q13 M Oviducts (Lapensee et al., 
1997) 
MUCH 7q22 M Colon (Williams etal., 
1999; Moniaux et 
al., 2001) 
MUC12 7q22 M Colon (Williams et al., 
1999; Moniaux et 
al., 2001 
MUC13 3g13 M Airway columnar epithelium (Williams et al., 
and goblet cells, colon 2001) 
MUC15 11pl4 M Tonsil, breast, thymus, adult (Pallesen et al., 
spleen, prostate, ovary, small 2002) 
intestine, colon 
MUC16 19pl3.3 M Ovarian epithelia (Yin and Lloyd, 
2001) 
MUC 17 7q22 M Trachea, lung, pancreas, colon, (Gum Jr et al., 
small intestine 2002) 
MUC18 l 1g23 M Cell adhesion molecule - (Wu et al., 2001 a; 
prostate Wu et al., 2001b 
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The following mucin genes have been shown to be expressed by human middle ear 
mucosa using in situ hybridisation, MUC1, MUC2, MUC4, MUC5AC, MUC5B and 
MUC7 (Hutton et al., 1998b; Severn et al., 1999). The expression of a mucin gene does 
not necessarily lead to secretion of the product however, as no MUC2 has been reported 
in middle ear effusions (Hutton et al., 1998a). 
1.2.3.1 MUC1 
MUC 1 is a transmembrane protein present in the apical plasma membrane of epithelial 
cells (Pemberton et al., 1992). MUC 1 was the first mucin core to be cloned and full- 
length cDNA and genomic clones for human MUCI have been published (Gendler et 
al., 1990). The cDNA sequence of MUC1 encodes a protein of over 1300 amino acids 
(Figure 1.5) and is contained in seven exons spanning between four and seven kb pairs 
depending on the number of repeat units present (Lancaster et al., 1990). MUC1 
exhibits polymorphism and the core protein can be glycosylated in different ways 
therefore the mature glycosylated forms appear distinct and the mucin is not of a 
specific molecular mass and structure. MUC 1 from the mammary gland has a M, of 250 
to 500kDa and is 50% carbohydrate (Shimizu and Yamauchi, 1982) and MUC 1 from 
the pancreas has a molecular weight over 1000kDa and is 80% carbohydrate (Lan et al., 
1987). 
1.2.3.2 MUC2 
MUC2 was the first human secretory mucin to be cloned and completely sequenced 
(Gum Jr et al., 1992; Gum Jr et al., 1994; Gendler and Spicer, 1995). The sequence is 
contained in 15.6kb pairs and codes for a large secreted protein over 5100 amino acids 
in length (Gum Jr et al., 1994) (Figure 1.8). The MUC2 gene is highly repetitive, 
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comprising of two repeat domains, one a tandem repeat region with approximately 100, 
fairly precise, 23 amino acid repeats and the second with a 347 amino acid irregular 
repeat (Toribara et al., 1991). Cysteine-rich subdomains are located upstream and 
downstream of the central repeat region and have sequence similarity with vWF, 
suggesting that these domains are important in the end to end polymerisation of subunits 
via disulphide bridges resulting in polymeric mucin molecules (Gum Jr et al., 1992). 
1.2.3.3 MUC4 
The genomic organisation of MUC4 has been determined. The 5' region and the central 
part of the MUC4 gene were characterised first (Nollet et al., 1998). The central, tandem 
repeat domain varies from 2334-6334 amino acids due to VNTR polymorphism with 
repeats of 16 amino acid residues. The C-terminal region contains a hydrophobic 
transmembrane domain and a short cytoplasmic tail. The 3' structure has more recently 
been determined (Escande et al., 2002) and is shown to have an extended structure that 
would suggest that the mucin is present above the cell membrane far higher than the 
other membrane-associated proteins. It is possible that a MUC4 complex could be 
involved in a signalling pathway that is required for proliferation and differentiation of 
epithelial cells (Moniaux et al., 1999). 
1.2.3.4 MUC5B 
The MUCSB gene is 40.1 kb in length with 49 exons encoding a 5701 amino acid 
peptide with a M, of approximately 627,000. The structural organisation of the peptide 
deduced from the nucleotide sequence of the central region of MUCSB has been 
determined (Desseyn et al., 1997b). It is a single large exon of 10713 base pairs 
containing the entire tandem repeat domain and is the biggest described for a vertebrate 
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gene. It codes for a 3570 amino acid peptide and 19 subdomains have been identified. 
Both the 3' (Desseyn et al., 1997a) and 5' (Van Seuningen et al., 2000) flanking regions 
of MUC5B have been characterised and have cysteine-rich domains similar to the other 
genes present on chromosome 11p15.5 (MUC2, MUC5AC and MUC6) and with vWF. 
1.2.3.5 MUC5AC 
MUC5AC has been partially characterised. The organisation and complete nucleotide 
sequence of the 3' end of the MUC5AC gene is known (Meerzaman et al., 1994; 
Lesuffleur et al., 1995; Buisine et al., 1998). The tandem repeat domain is 8 amino acid 
residues in length, this is much shorter than that of MUC5B (Guyonnet-Duperat et al., 
1995). More recently, the amino terminal and 5' flanking region of the MUC5AC mucin 
gene has been isolated (Li et al., 1998) and the full length of MUC5AC mRNA is 
approximately 12-14kb. The comparative molecular analysis of MUC5AC and the other 
genes of the 11 p 15.5 gene family reveal common cysteine-rich domains supporting the 
idea that they have evolved from a common ancestral gene (Buisine et al., 1998). 
1.2.3.6 MUC7 
MUC7 has been fully characterised (Bobek et al., 1993) and encodes for a protein of 
357 amino acid residues with a M,. of 37kDa. The MUC7 peptide does not polymerise, 
an exception among the secreted mucins. The MUC7 gene encodes for the protein core 
of low molecular weight mucin (MG2) in saliva. The VNTR region is composed of six 
tandem repeats of 23 amino acid residues (Bobek et al., 1993) and is heavily 
glycosylated (Gururaja et al., 1998). There is a minimal degree of VNTR polymorphism 
(Bobek et al., 1996). 
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In summary, MUC 1 and MUC4 are membrane bound mucins and possess no structural 
domains. They are involved in mucosal protection. MUC2, MUC5AC and MUC5B are 
polymeric secreted mucins with cysteine-rich regions homologous to each other and to 
von Willebrand Factor. MUC7 is a monomeric secreted mucin with no structural 
homology to any of the other secreted mucins. 
1.2.4 Control regions in mucin genes for upreguiation of expression 
Increased mucin gene expression has been shown to occur via two mechanisms; by 
upregulation of MUC transcription (Basbaum et al., 1999) and/or by mRNA stability 
(Rose et al, 2000). 
Most in vitro studies have focused on the regulation of MUC2 and MUCSAC genes by 
various mediators. The regulation of MUC5B has not been as well investigated, but it 
has been demonstrated that several mediators that increase MUCSAC expression (such 
as acrolein, an aldehyde present in tobacco smoke) have no effect on MUCSB (Borchers 
et al., 1999). It has been demonstrated in vitro that different cytokines have different 
effects on the stimulation of mucin secretion (Smirnova et al., 2001; Smirnova et al., 
2002), which is possibly due to each cytokine having a particular signal transduction 
pathway (Taga et al., 1989; Wiegmann et al., 1992) and that induction of secretion of 
MUC5AC appears to be easier than MUC5B. The amount of protein generated from 
each mucin transcript can be varied by message stabilisation. Mucin mRNA 
stabilisation has been documented following the treatment of cells with cytokines 
(Borchers et al., 1999; Rose et al., 2000) and this could lead to more efficient 
translation of the message, increasing gene expression. 
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Recent studies of the 5' flanking regions of MUC5AC and MUCSB genes have 
identified nuclear factor KB (NF-iB) binding sites within the functional promoter 
regions for both genes (Li et al., 1998; Van Seuningen et al., 2000). NF-xB is a 
transcription factor present in virtually all cells. It regulates the transcription of an 
exceptionally large number of genes, especially those involved in the immune and 
inflammatory responses. TNF-a operates through this mechanism and so MUC5AC and 
MUC5B should both be upregulated in the presence of this cytokine. Cis-elements have 
been found in the 5' flanking region of MUCSB (Chen et al., 2001), which are 
potentially involved in the regulation of MUC5B gene expression by steroids such as 
retinoic acid (De Bolos et al., 1998) and regulate the growth and differentiation of 
tracheobronchial epithelial cells including mucin gene expression (Gray et al., 2001). 
The MUC5AC and MUCSB genes are present in the same cluster at chromosomal 
location 11 p 15.5 (Pigny et al., 1996) and have common sites for transcription factors 
within functional promoter regions (Li et al., 1998; Van Seuningen et al., 2000) yet due 
to differences observed in the induction of the two mucin genes by cytokines, they are 
unlikely to be controlled in the same manner, which may lead to their involvement in 
different stages of the inflammatory process. The mechanisms of signalling systems that 
lead to increased transcription of mucin genes are still to be elucidated. 
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1.2.5 Mucin gene expression in the middle ear 
The middle ear epithelium is modified respiratory in type (Lin et al., 2001), however 
very little is known about mucin gene expression in the normal middle ear due to 
difficulties in obtaining normal human tissues. 
In situ hybridisation studies on middle ear biopsies taken from patients undergoing 
middle ear surgery showed MUC1, MUC2, MUC4, MUC5AC, MUC5B and MUC7 to 
be expressed by human middle ear mucosa (Severn et al., 1999). MUC 1, MUC2, 
MUC4 and MUC5AC appeared to be expressed by surface epithelial cells whereas 
MUC5B and MUC7 expression was in glandular epithelial cells. The tissue expression 
of the mucin genes in middle ear mucosa is consistent with mucin gene expression 
patterns in other tissues using Northern blot analysis (Severn et al., 1997), in situ 
hybridisation and reverse transcriptase PCR (Takeuchi et al., 1995; Aust et al., 1997). 
MUC3 and MUC6 were not found in the middle ear mucosa. This is not surprising for 
MUC6 expression, which has never been identified in respiratory epithelia (Biesbrock et 
al., 1995). 
Middle ear effusions contain at least two different populations of mucin molecule, 
coded for by MUC5B and MUC5AC (Hutton et al., 1998a; Kawano et al., 2000; Lin et 
al., 2001). This is supported by evidence of MUC5AC protein in middle ear goblet cells 
and MUC5B protein in submucosal mucus glands using relevant specific antisera by 
immunohistochemistry (Hutton et al., 1998b; Chung et al., 2002). 
In one study by Hutton (Hutton et al., 1998a), mucins from human middle ear effusions 
were isolated and characterised in order to determine the mucin gene products secreted 
by the middle ear mucosa. Up to 15% of thick (and 5% of thin) middle ear effusions 
38 
contained MUC5AC and epitopes present on MUC5B were also present in mucins in 
the effusions suggesting that MUC5B may also be present. 
Kawano (Kawano et al., 2000) studied middle ear mucosa specimens from patients 
undergoing surgical procedures for chronic otitis media (present for three months or 
more). Using Alcian blue-PAS staining of mucosal sections it was observed that the 
epithelium was highly secretory and that the apical layer and gland-like structures were 
abundant in glycoconjugates and the submucosal layer was rich in inflammatory cells. 
In situ hybridisation and immunohistochemistry studies demonstrated that gland-like 
structures of the middle ear submucosa in chronic otitis media expressed MUC5B 
mucin mRNA and their product, MUC5B mucin. It was clear in this study that 
expression of the MUC5B mucin gene was related to infiltration of inflammatory cells 
in the submucosa and it was therefore suggested that inflammatory cell products (such 
as cytokines) are involved in the production of MUC5B by upregulating expression of 
the MUC5B mucin gene. 
In a recent study by Lin (Lin et al., 2001), mucin gene expression in the middle ear of 
patients with chronic otitis media was compared to the normal middle ear and a pool of 
middle ear effusions was also analysed. In situ and Northern blotting studies 
demonstrated expression of MUC5B in both the `normal' and inflamed ear however the 
gene expression was 4.2 fold higher in the inflamed ear. MUC4 gene expression was 
detected only in the inflamed ear and at lower levels than MUM. MUC5AC was not 
detected at all. The upregulation of mucin gene expression was accompanied by an 
increase of MUC5B- and MUC4-producing cells in the middle ear mucosa and the 
presence of MUC5B and MUC4 mucin in middle ear effusions. These results were 
indicative of a transition from a normal to a hypersecretory epithelium. The mechanism 
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of upregulation of mucin genes is not currently understood but an insight into the 
mechanisms could lead to the development of intervention strategies against mucus 
hyperproduction in chronic otitis media. 
Various in situ hybridisation studies have shown more than one mucin gene to be 
expressed by the epithelial cells in the same tissue making it likely that mucus 
secretions are a carefully controlled balance of mucin gene products. If this balance is 
disturbed in disease, the result could be secretions that are more or less viscous than 
normal. In OME, the viscosity of a secretion can radically affect the role it plays, with a 
protective role in the normal situation replaced by a pathological role when mucin 
secretion is up regulated in the diseased state. Changes in mucin gene expression have 
been demonstrated in metaplastic epithelia (Kim et al., 1996) and mucus cell metaplasia 
in middle ear epithelium is the key event leading to mucus hyperproduction (Kawano et 
al., 2000). 
It is important to identify the factors or mediators involved in the change from a normal 
middle ear epithelium into a highly secretory epithelium and in the regulation of mucin 
gene expression. 
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1.3 Gastro-oesophageal reflux in children 
1.3.1 Gastraoesophageal reflux 
Gastro-oesophageal reflux (GOR) is the retrograde movement of gastric contents 
through the lower oesophageal sphincter (LOS) into the oesophagus. It is caused by 
transient and intermittent LOS relaxation to a zero gradient between the gastric and 
oesophageal lumens (Hart, 1996; Zalzal and Tran, 2000) unrelated to swallowing. GOR 
is generally classified into four types (Zalzal and Tran, 2000). 
1. Physiologic 
Episodic reflux resulting in infrequent vomiting is observed with no abnormalities on 
any diagnostic study. It is common in neonates and infants and decreases during the first 
year of life (Vandenplas et al., 1991). This type of reflux is believed to occur in 
approximately 67% of children at four months of age with resolution in most by ten to 
twelve months (Nelson et al., 1997) 
2. Functional 
Silent or symptomatic reflux, observed in children who exhibit daily vomiting where 
there is no morbid condition. This can be confirmed by intra-oesophageal pH 
monitoring. 
3. Pathologic 
A more severe form of functional reflux, which can interfere with the normal growth 
process or cause gastrointestinal disorders and respiratory alterations. Symptoms 
include epigastric discomfort, regurgitation, heartburn and vomiting. If symptoms 
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increase in severity this can lead to iron-deficient anaemia, failure to thrive and 
oesophagitis (Herbst, 1981; Contencin and Narcy, 1991; Zalzal and Tran, 2000). 
4. Secondary GOR 
This is related to other deficits such as neurological anomalies (including incoordination 
of swallowing and pooling of secretion within the hypopharynx), hiatal hernia 
(associated with LOS incompetence) or Barrett's oesophagus (gastric metaplasia of the 
oesophagus due to acid exposure) (Orenstein et al., 1999) and may require surgery to 
prevent morbidity or mortality. 
Gastric contents may contain (as well as gastric acid and pepsin) bile salts and 
pancreatic enzymes (Hart, 1996), which have the ability to irritate or injure tissues not 
adapted to the presence of these potentially noxious materials. There are defence 
mechanisms present in the lumen and body of the oesophagus, such as secondary 
peristalsis, salivary and oesophageal bicarbonate and mucosal tight junctions that help 
to prevent significant damage. 
Damage to tissues resulting from GOR is termed gastro-oesophageal reflux disease 
(GORD). GORD is a common disease of infancy and is the most frequently referred 
condition to a paediatric gastroenterologist (Orenstein et al., 1999; Carroll et al., 2002). 
GORD has a wide spectrum of expression ranging from symptomatic reflux (where 
symptoms may be marked despite virtually normal amounts of acid reflux, this can 
depend on the individuals sensitivity to the reflux contents (Koufman, 1991)) to severe 
tissue damage. 
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1.3.2 Diagnosis 
The preferred gold standard method of diagnosing reflux is by prolonged ambulatory 
dual probe pH monitoring (Koufman, 1991; Smit et al., 2000). The goal of this method 
is the continuous measurement of pH while in a normal-life resembling situation. A 
catheter with two (or more) electrodes is guided through the nose into the oesophagus, 
connected to a recorder. For distal pH monitoring, an electrode is placed 5cm above the 
manometrically determined LOS. Every 4-8 seconds, pH measurements are taken and 
stored. For more proximal pH monitoring, a second electrode is placed in the 
hypopharynx, 2cm above the upper oesophageal sphincter (UOS) (Figure 1.9). 
Many parameters can be measured using ambulatory pH monitoring: 
Number of reflux episodes (pH < 4) 
Percentage of time that pH is <4 
Number of reflux episodes of at least 5 minutes duration 
Average oesophageal clearance time per reflux episode 
Longest reflux episode 
Total time of recorded pH <4 
GOR is diagnosed if the oesophageal pH is lower than pH4 for more than 4% of the 
recording time. A drop below pH4 at the pharyngeal probe preceded by a precipitous 
drop at the oesophageal probe is considered evidence of laryngopharyngeal reflux 
(LPR) (Koufinan, 1991). 
Ten or fewer episodes of pharyngeal reflux may be physiological in children less than 
one year of age (Halstead, 1999). 
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Figure 1.9 Technique of double-probe ambulatory intra-oesophageal and 
pharyngeal pH monitoring (Koufman, 1991) 
Larynx -- 
Upper oesophageal 
sphincter (UOS) 
Oesophagus 
Diaphragm 
Gastro-oesophageal 
junction (LOS) 
Pharyngeal probe 
2cm above UOS 
Oesophageal probe 
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1.3.3 Extra"oesoahaoeal manifestations 
Symptoms of GOR are usually limited to the oesophagus due to the effectiveness of the 
UOS in preventing reflux to the oropharynx and beyond but under certain circumstances 
GOR can breach this barrier. Gastropharyngeal reflux, also called laryngopharyngeal 
reflux (LPR), is the movement of gastric contents beyond the oesophagus up to the 
laryngeal and pharyngeal areas where there is the potential of causing a variety of 
otolaryngological and pulmonary complications such as asthma, bronchitis and 
pneumonia (Contencin and Narcy, 1991; Euler, 1998). Head and neck manifestations of 
GOR have also been implicated in subglottic stenosis (Euler, 1998; Halstead, 1999), 
laryngitis, rhinitis and sinusitis (Koufman, 1991), sudden infant death syndrome 
(Ariagno et al., 1982) apnea in the premature infant (Herbst et al., 1979) and other 
otorhinolaryngologic conditions (Contencin et al., 1995; Yellon, 1997). It has been 
suggested through pH monitoring studies that acid reflux from the stomach could 
determine or maintain an inflammatory process in the nasopharynx as it does in the 
larynx (Contencin and Narcy, 1991). Over 40% of children with GOR have respiratory 
manifestations (Andze et al., 1991) and not uncommonly, respiratory disorders are the 
only presenting symptoms in reflux patients (Stiegmann et al., 1987; Bouchard et al., 
1999; Zalzal and Tran, 2000). 
It has been speculated that GOR is involved in the pathogenesis of OME (Shilkin, 1994; 
Halstead, 1999; Velepic et al., 2000) and the anatomic and immunologic immaturity of 
the Eustachian tube is an explanation for this (Bluestone and Klein, 1996). 
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1.3.4 Laryngopharynpeal reflux and OME 
Due to age-related differences in the length and angle of the ET (13-18mm in length 
and 100 to the horizontal in children compared to 31-38mm and 450 to the horizontal in 
adults (Proctor, 1967)), it is more likely that secretions can reflux into the middle ear 
from the nasopharynx in infants. 
The tensor veli palatini (TVP) muscle is responsible for the ventilation of the middle ear 
and is superiorly orientated relative to the ET lumen in adults due to the angle of the ET. 
This angulation means that the ventilation mechanism of the ET is more efficient in 
adults than in infants and young children. Obstruction (opening failure) and abnormal 
patency (closing failure) are two types of ET dysfunction that can predispose to OME. 
Abnormal patency of the ET, when the tube is open even at rest, can allow unwanted 
secretions from the nasopharynx, including reflux contents, to gain access to the ET and 
to the middle ear cleft due to the short length of the tube. 
With age, the ET lumen becomes wider and has an increased volume and is capable of 
ventilating the middle ear and clearing secretions more effectively. These functional 
changes occur at an age when the prevalence of childhood OME decreases (Sadler- 
Kirres et al., 1989) leading to the conclusion that the anatomic differences may be a 
predisposing factor for the development of OME in children. 
Reflux of barium into the nasopharynx, ET and middle ear (Pinckney and Currarino, 
1980) was observed during upper gastrointestinal examination of four infants, three with 
GOR and one with incoordination of swallowing. The presence of acid reflux in the 
nasopharynx has been documented (Contencin and Narcy, 1991) from a 24-hour 
continuous nasopharyngeal pH monitoring study in infants and children and a possible 
relationship between OME and GOR was observed by Velepic et at (Velepic et al., 
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2000) in a continuous oesophageal pH monitoring study of children with either OME 
lasting four months or more (n=16) or recurrent otitis media with more than five 
episodes a year (n=14). Pathological GOR was diagnosed in 60% of the patients, nine 
from each group and there was no statistical significance between the two types of 
disease. None of these patients had complained of GOR symptoms. These studies 
demonstrate that a relationship may occur between GOR and OME and it is clear that 
further studies are necessary. 
If gastric contents (including pepsin and acid) are refluxed into the ET and middle ear 
cleft there are two possible scenarios, one involving a single reflux episode and bacteria 
and the other multiple reflux episodes: 
1. A single reflux episode may cause damage and inflammation, leading to the 
production of an effusion that may occlude the immature ET lumen due to its 
narrow tubular configuration (Suzuki et al., 1998). Bacteria present in the 
middle ear or refluxed from the nasopharynx may cause a secondary infection 
and prolong the inflammatory response, leading to a chronic disease state. 
2. A first reflux episode from the nasopharynx would cause inflammation and the 
secretion of neutralising substances such as mucus and HCO3- but not enough to 
cause ET obstruction. Some pepsin may not be completely denatured, remaining 
inactive at the high pH and if subsequent reflux events occur the pepsin may be 
reactivated causing further damage and inflammation. 
Exposure of the ET and middle ear to acid reflux would cause direct tissue damage, 
leading to inflammation, oedema (Cherry and Margulies, 1968) and ciliostasis (Holma 
et aL, 1977). Ciliostasis of the ET mucosa would disable the mucociliary clearance 
47 
mechanism, potentiating the formation of a middle ear effusion (Ohashi et al., 1986; 
Park et al., 1993). 
1.3.5 Gastric juice composition 
Gastric juice is a fluid secretion containing hydrochloric acid (pH0.9-1.5) and a group 
of proteolytic enzymes, pepsins. Hydrochloric acid is secreted by parietal cells that are 
mainly present in the fundus and body regions of gastric mucosa. Pepsins are secreted 
extracellularly by chief cells in a precursor form, pepsinogen, which is rapidly 
converted to an active proteinase under acidic conditions (Samloff, 1971). Pepsin and 
acid are the natural aggressors present in gastric juice. 
Two immunological groups of pepsinogens have been isolated with different tissue 
origins, pepsinogen I (PGI), secreted by the oxyntic glands of the fundic mucosa and 
pepsinogen II (PGII), secreted by the pyloric glands of the antrum, duodenum and 
oxyntic glands (Allen et al., 1989). PGI contains pepsinogens 1-5 and PGII contains 
pepsinogens 6 and 7. The proenzyme pepsinogen is converted to pepsin in the gastric 
gland under acidic conditions. It is a multistage process that is spontaneous at pH<4.5. It 
is presumed that each pepsinogen gives rise to a specific pepsin (Hirschowitz, 1984), 
with pepsins 1,2,3a, 3b, 3c and 4 (pepsins A) corresponding to PGI whilst pepsins 5 
and 6 (pepsins C) belong to PGII. 
Pepsinogens have been isolated and sequenced and complete amino acid sequences 
have been determined for many species including human, pig and chicken (Baudys and 
Kostka, 1983; Sogawa et al., 1983; Lin et al., 1989). Pepsinogens consist of a single 
polypeptide chain of approximately 370 amino acids e. g. porcine pepsinogen A is 371 
amino acids in length (Hartsuck et al., 1977). The overall structures of porcine 
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pepsinogen A, human pepsinogen A (of which the major pepsin is pepsin 3) and human 
progastricsin (the precursor of pepsin 5) are alike, however the similarity between 
porcine and human pepsinogens is greater than between human pepsinogen A and 
human progastricsin (Richter et al., 1998). 
Native pepsinogen contains a prosegment and a pepsin moiety. The pepsin moiety 
consists of two domains, related by a two-fold axis of symmetry. At the junction of the 
two domains is an extended substrate binding cleft which contains two catalytically 
important aspartate residues Asp-32 and Asp-215 (James and Sielecki, 1986) (Figure 
1.10). This binding cleft is covered and occupied by the prosegment, which is bound to 
the pepsin moiety mainly through electrostatic interactions. The active site is fully 
formed in the proenzyme therefore the prosegment serves to block entry of the substrate 
to the active site and is crucial in maintaining the molecule in its inactive form at neutral 
pH. 
The prosegment is present at the N-terminus of the molecule and contains relatively 
high amounts of basic residues whereas the pepsin moiety is characteristically highly 
acidic (Kageyama, 2002). The following is the activation sequence for porcine 
pepsinogen A: 
At neutral pH, the carboxyls of the pepsin moiety are negatively charged and the 
positive charge of the prosegment is essential to stabilise the pepsinogen molecule in its 
inactive conformation (Andreeva and James, 1991). At pH<4.5 the carboxyls of the 
pepsin moiety become protonated, disrupting the electrostatic interactions between the 
prosegment and the active enzyme, allowing the prosegment to undergo the 
conformational changes that initiate the activation reaction. The active site is then 
exposed and the pepsinogen molecule cleaves off its own prosegment autocatalytically 
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via a direct or a sequential pathway. The prosegment is 44 amino acids long in the pig 
(Foltmann, 1981) and 47 amino acids long in the human (Kageyama and Takahashi, 
1980) and activation occurs by a similar mechanism. After cleavage of the prosegment 
there are two further conformational changes, the dissociation of the prosegment from 
the active site and then a change in the conformation of the first thirteen residues at the 
N-terminus of the active enzyme from a random-coil to aß sheet (McCaman and 
Cummings, 1988), resulting in an active pepsin molecule whose secondary structure 
consists almost entirely of ß sheets (Konno et al., 2000). It has not been possible to 
isolate the intact 44 amino acid prosegment peptide after cleavage from the active 
porcine pepsin molecule, instead several shorter peptides (corresponding to peptides I- 
16,17-24,25-44,17-44 and 44-45) can be isolated (Dunn et al., 1978), resulting from 
multiple proteolytic cleavages (James and Sielecki, 1986) of which peptide 1-16 is 
pepstatin. This peptide was found to interact and strongly inhibit the activity of pepsin 
at pH5.5 (Dunn et al., 1978). 
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Figure 1.10 Tertiary structure of porcine pepsinogen A (Richter eta!., 1998) 
The active enzyme moiety is shown in red, consisting of two domains. At the junction 
of the two domains is the extended substrate-binding cleft, containing the two active site 
aspartates (Asp-32 and Asp-215) shown in blue. The binding cleft is covered and 
occupied by the prosegment, shown in purple. 
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There are seven human pepsins; pepsin 3 is always the most abundant of pepsins present 
in gastric juice, followed by pepsin 5. The other pepsins are present in much smaller 
quantities except for pepsin 1, which makes a variable contribution to peptic activity. 
Using polyacrylamide gel electrophoresis (PAGE) it was found that pepsin 1 was the 
largest (43810 molecular weight) and pepsins 2,3 and 5 have molecular weights of 
39950,37150 and 31620 respectively (Roberts and Taylor, 1972). 
Pepsins are aspartic proteinases and differ in their pH optima and relative proteolytic 
activity depending on the substrate type (such as albumin or haemoglobin), pH, 
temperature, and solute and substrate concentrations. They are active at acidic pH with 
optimum proteolytic activity at about pH2 (Foltmann, 1981). Solutions of pepsin lose 
activity at pH less than 4 due to degradation by autolysis. 
Pepsins are liable to irreversible denaturation at pH>7.2 (Piper and Fenton, 1965;. 
Hirschowitz, 1984), whereas pepsinogens are not denatured by pH as high as pH 10. 
Pepsins are enzymatically inactive at pH6 but are stable and will become active when 
the pH is lowered towards their pH optima (Piper and Fenton, 1965). In neutral or 
alkaline solution, pepsin is known to undergo a conformational transition to an 
irreversibly denatured state that is partially structured rather than fully unfolded (Konno 
et al., 2000). Energy calculations have predicted that the C-terminal lobe is more stable 
at high pH than the N-terminal lobe and it has been demonstrated that alkaline 
inactivation of pepsin is due to a selective denaturation of its N-terminal lobe (Lin et al., 
1993). 
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1.3.6 Treatment in children 
There are a variety of approaches of treatment of gastro-oesophageal reflux and 
laryngopharyngeal reflux and they fall into three general categories (Andze et al., 1991; 
Smit et al., 2000; Zalzal and Tran, 2000; Carroll et al., 2002): 
Non-pharmacological Pharmacological Surgical 
Head elevation 
Milk thickening 
Positioning changes 
Reduced pacifier use 
Avoidance of 
substances that may 
decrease LOS tone such 
as chocolate, coke, 
cacao, mint or 
peppermint 
Antacids 
H2 antagonists 
Prokinetic agents 
(stimulate stomach 
emptying) 
Proton pump blockers 
If severe complications are 
suffered, fundoplication may be 
considered, a procedure where the 
fundus is wrapped around the 
lower oesophagus, reinforcing the 
LOS and preventing gastric 
contents from refluxing into the 
oesophagus as easily 
Treatment depends on age, severity of symptoms, oesophagitis and outcome of initial 
treatment. The first stage is generally a modification in lifestyle and is non- 
pharmacological and there is a lack of evidence for the success of these therapies 
(Carroll et al., 2002). If symptoms of reflux persist then drug treatment may be 
necessary. Medical treatment (i. e. not requiring surgery) is successful in over 80% of 
cases (Andze et al., 1991). 
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CHAPTER 2 
MATERIALS & METHODS 
Chapter 2 Materials and Methods 
2.1 Reagents 
Unless otherwise indicated all chemicals were obtained from BDH Merck Ltd., Fisher 
Scientific UK or the SIGMA-Aldrich Company Ltd. and were of AnalaR grade where 
available. 
2.2 Source and collection of samples 
Middle ear effusions were collected by Professor John Birchall at Queens Medical 
Centre, Nottingham and by Mr Sean Carrie at the Freeman Hospital, Newcastle upon 
Tyne. The samples were obtained from children aged between two and eight years 
undergoing myringotomy after diagnosis of persistent otitis media with effusion (with 
the presence of an effusion for three months or more). Effusions were removed from the 
middle ear cavity by suction supplied by a vacuum line with a specially designed 
instrument and collected into small containers. The effusions were immediately frozen 
and stored at -20°C until required. 
Samples were categorised by the clinician into two groups by visual inspection. Viscous 
(mucoid) effusions that did not flow upon inversion of the container were classified as 
`thick effusions'. Samples that did flow (serous) were classified as `thin effusions'. 
Effusion colour varied from a pale straw yellow through to dark yellow, brown and 
deep red. Some thin effusions were colourless and translucent. Both types of sample 
varied in volume from 20-4O0µl. Effusion samples were individually analysed unless 
otherwise stated. 
54 
2.3 Preparation of effusion samples 
2.3.1 Proteinase activity studies 
Middle ear effusion samples were thawed at 4°C and added to a known volume of 
0.01M HCl (pH2.2) or 0.067M phosphate buffer (pH8). The effusion-acid and effusion- 
buffer (alkali) mixtures were homogenised using a hand-held Griffiths tube 
homogeniser until a consistent homogenate was produced (2-3 minutes). The 
homogenates were centrifuged for 1 hour at 700g and 4°C to remove insoluble material 
from the effusions. The resulting supernatants were removed and stored overnight (20 
hours) at the respective pHs. The pH8 samples were returned to pH2.2 by dialysis for 4 
hours in 0.01M HCl before analysis of proteolytic activity in the samples was carried 
out. See diagram below. 
Effusion-acid mixture 
pH2.2 
Only pepsin present 
20 hours, 4°C 
N-terminal assay 
Homogenisation 
Centrifugation 700g at 4°C 
Supernatants removed 
Effusion-buffer mixture 
pH8 
Only pepsinogen present 
20 hours, 4°C 
1 
Returned to pH2.2,4h 
N-terminal assay 
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2.3.2 Mucin and cvtokine studies 
Effusion samples were thawed at 4°C and washed out of the collection containers using 
a known volume of ice-cold 0.067M phosphate buffer, pH6.5 containing a cocktail of 
proteolytic inhibitors to prevent degradation by endogenous proteolytic enzymes. The 
protease inhibitors included are shown in Table 2.1. The resulting effusion-buffer 
mixtures were homogenised as previously described using a hand-held Griffiths tube 
homogeniser to obtain a consistent homogenate. 
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Table 2.1 Concentration and action of protease inhibitors within the 
proteolytic inhibitor cocktail 
Protease inhibitor Concentration 
(MM) 
Mode of action 
Phenylmethyl- 3 Inhibitor of serine proteases, e. g. elastase 
sulphonyl fluoride (hydrolyses peptide bond at C-terminal side) 
(PMSF) and some cathepsins and trypsin (remove 
N-terminal dipeptides) 
Sodium iodoacetate 1 Inhibitor of thiol-dependent proteases, e. g. 
cathepsin B and other thiol-dependent 
enzymes 
Benzamidine 15 Specific inhibitor of trypsin and trypsin-like 
Hydrochloride serine proteases (hydrolyse proteins, peptides 
and amino acids) 
Nat EDTA 10 Inhibitor of metallo-dependent proteases, e. g. 
Ca2+ dependent enzymes, collagenases 
N-ethylmaleimide 10 Prevents disulphide group exchange 
a-amino caproic acid 100 Inhibitor of plasminogen activation to serine 
protease plasmin (hydrolyses peptide and 
ester bonds) 
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2.4 Analytical Methods 
2.4.1 N-terminal assay 
Proteolytic activity, measured at pH2.2 was determined by the N-terminal assay of 
Hutton (Hutton et al., 1986), a modification of Lin (Lin et al., 1969) using succinyl 
albumin as the substrate for proteolytic cleavage. Bovine serum albumin was 
succinylated by the method of Furihata (Furihata et al., 1978). The N-terminal assay 
directly assesses the ability of any pepsin present to hydrolyse peptide bonds. These 
newly liberated N-terminals can then be tri-nitrophenylated and quantified 
colorimetrically. 
Pepsin levels (µgml'1) were measured by its ability to hydrolyse peptide bonds at pH2.2 
using succinyl albumin as substrate. Standard curves were prepared using porcine 
pepsin A, 0-1µg in 2O0µ1 O. O1M HCl (pH2.2). Samples and substrate were prepared in 
0.01M HCI. All other reagents were prepared in distilled water. 
Enzyme (0.2ml, 0.1-1µg pepsin standard and known sample dilutions) were mixed with 
0.5m1 of substrate (8mgm1"1 succinyl albumin in 0.01M HC1, pH2.2) to start the 
reaction. Samples were mixed and incubated for 30 minutes at 37°C. The reaction was 
stopped by the addition of 4% (w/v) sodium bicarbonate (0.5m1) followed by 0.05% 
(w/v) trinitrobenzene sulphonic acid (TNBS, 0.5m1). Colour was developed by 
incubating at 50°C for 10 minutes followed by addition of 0.5m1 of 10% sodium 
dodecyl sulphate (SDS) and 0.25m1 of 1M HC1 to complete the reaction and stop further 
colour development. Absorbance was measured at 340nm. 
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Time zero controls were prepared by addition of substrate at the end of the 30 minutes 
incubation, just before addition of sodium bicarbonate. This gave a measure of all free 
N-terminals existing before hydrolysis on both enzyme and substrate. 
The standard curve using porcine pepsin was only linear between concentrations of 0 to 
1µg enzyme in the total reaction volume (0.7m1) and therefore this range of 
concentration was used to calculate pepsin activity in the samples. The optimum activity 
of pepsin is at pH2.2 (Roberts and Taylor, 1972) therefore the N-terminal assay is 
carried out at this pH to ensure consistency. 
2.4.2 Slot Blot / Enzyme Linked Immunosorbent Assay 
Nitrocellulose membrane (pore size 0.451im or 0.2µm) supported on blotting paper was 
wetted and inserted into a minifold 72 well slot blot apparatus (Schleicher and Schuell) 
and connected to a vacuum source. Standards and samples were added to individual 
wells and allowed to absorb onto the membrane under vacuum. The nitrocellulose 
membrane was removed from the apparatus and placed into a container and an enzyme 
linked immunosorbent assay (ELISA) performed. To block non-specific binding, the 
membrane was incubated in phosphate buffered saline (PBS) containing 2% bovine 
serum albumin (BSA) overnight at 4°C. The membrane was then incubated in primary 
antibody diluted in 1% BSA/PBS at room temperature for 1 hour. Unbound antibody 
was removed by rinsing in 2 changes of 0.5% TWEEN 20/PBS followed by 3 changes 
of PBS. Horseradish peroxidase (HRP) conjugated secondary antibody diluted in 1% 
BSA/PBS was added and incubated for 1 hour. After rinsing as described previously, 
colour was developed with 0.05% 3,3'-diaminobenzidine tetrahydrochloride (DAB), 
0.03% hydrogen peroxide (H202) in PBS for 5 minutes. After rinsing in tap water the 
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membrane was air-dried and absorbance measured at 595nm using a Shimadzu scanning 
densitometer. 
2.4.2.1 Antibodies 
Unless otherwise explained, all antibody dilutions used had been predetermined either 
by the manufacturer or previous research. 
Purified mucin from thick effusions of anatomically normal children was used to 
prepare polyclonal antiserum (TEPA) in rabbits. This antiserum reacts strongly with 
human salivary mucin (of which MUC5B is the major fraction) (Hutton et al., 1998a). 
The specificity of the TEPA antiserum had previously been determined by 
immunohistochemical and papain digestion studies (Hutton et al., 1998a). The pattern 
of staining with the TEPA antibody (Hutton et al., 1998b) showed negative results in 
stomach and ileum tissues, positive results in salivary glands and strong staining of the 
mucous glands of the middle ear mucosa. No staining was observed in non mucus 
secreting cells and tissues. Papain digestion studies demonstrated that the antibody was 
not recognising the major carbohydrate-containing domain or any epitopes on that 
domain. TEPA almost certainly recognises a protein epitope in the non-tandem repeat 
region (Hutton et al., 1998a). This antibody was used at a dilution of 1: 10000. 
Mouse anti-human gastric mucin MUC5AC antibody, NCL-HGM-45M1, was obtained 
from Novocastra Laboratories Ltd. Newcastle. This monoclonal IgGI antibody was 
raised to mucin isolated from ovarian cyst fluid and recognised a mucin epitope located 
in the non-glycosylated region of the gastric mucin MUC5AC peptide core. The 
antibody was used at a dilution of 1: 200. 
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Rabbit anti-human MUC7 antibody was made at Newcastle University molecular 
biology unit. The polyclonal antiserum was raised to a synthetic peptide with the amino 
acid sequence NLLNRIIDDMVEQ found in a unique region of the C-terminal domain 
of the human MUC7 gene product. This sera was used at a dilution of 1: 1000. 
Goat anti-pepsin (porcine stomach) antibody was obtained from Biodesign 
International, Maine, USA. This was an IgG fraction obtained from monospecific 
antiserum by a multistep process including delipidation, salt fractionation and ion- 
exchange chromatography. The antibody was used at a dilution of 1: 2000. 
Rabbit anti-human fibrinogen antibody was obtained from DAKO, Copenhagen, 
Denmark. This polyclonal antiserum was raised to fibrinogen isolated from human 
plasma and was unable to distinguish between fibrin and fibrinogen. The sera was used 
at a dilution of 1: 2000. 
Secondary antibodies were obtained from SIGMA-Aldrich. These were goat anti-rabbit 
IgG (whole molecule) peroxidase conjugate used at a dilution of 1: 10000, goat anti- 
mouse IgG (whole molecule) peroxidase conjugate used at a dilution of 1: 5000 and 
mouse anti-goat IgG peroxidase conjugate used at a dilution of 1: 10000. 
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2.4.3 Solid Phase Sandwich ELISA 
A quantitative sandwich enzyme immunoassay technique (Voller et al., 1978) was used 
for the determination of human interleukin-6 and interleukin-8 cytokines in middle ear 
effusions. 
2.4.3.1 Interleukin-6 (IL-6) 
A Human IL-6 ELISA OPTEIATM Kit was obtained from BD Biosciences, San Diego, 
USA. Standards and samples were added in duplicate to microplate wells pre-coated 
with anti-human IL-6 monoclonal antibody and incubated at room temperature for two 
hours. Unbound material was removed by washing the wells five times with a detergent 
solution (PBS with Tween-20 and thimerosal as a preservative). Avidin-horseradish 
peroxidase conjugate was mixed with biotinylated anti-human IL-6 monoclonal 
antibody and added to the wells to produce an antibody-antigen-antibody "sandwich". 
The plate was incubated for one hour at room temperature then the wells were washed 
seven times with detergent solution. TMB substrate solution (3,3', 5,5'- 
tetramethylbenzidine) was added to each well and the plate was incubated for 30 
minutes at room temperature in the dark. The TMB substrate produced a blue colour in 
direct proportion to the amount of IL-6 present in the initial sample. After 30 minutes 
the stop solution containing IM phosphoric acid was added to the wells. This changed 
the colour from blue to yellow and the microwell absorbances were measured at 450nm 
using a Multiskan Ascent Microplate photometer (Thermo Labsystems Ltd., UK). 
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2.4.3.2 Interleukin-8 (IL-8) 
A Quantiglo Human IL-8 Chemiluminescent Immunoassay was obtained from R&D 
Systems, Abingdon, Oxon. Standards and samples were added in duplicate to 
microplate wells precoated with a murine monoclonal antibody against IL-8 and 
incubated for two hours at room temperature. Any unbound material was removed by 
washing the wells four times with a wash buffer (buffered surfactant with preservative). 
Polyclonal antibody against IL-8 conjugated to horseradish peroxidase was added to the 
wells and the plate was incubated for three hours at room temperature. The wells were 
washed as above. The immunoassay development and quantification step was based on 
a light emitting substrate. For the purposes of this assay this substrate was replaced by a 
peroxidase substrate 2,2'azino-bis(ethylbenzthiazoline-6-sulfonic acid) which was 
added to the wells for 30 minutes and the reaction stopped by the addition of an equal 
volume of 1% SDS. A blue-green soluble reaction product developed that was directly 
proportional to the amount of IL-8 present in the sample and the absorbances were 
measured at 405nm using a Multiskan Ascent Microplate photometer (Thermo 
Labsystems Ltd., UK). 
2.4.4 Glycoprotein Assay 
Glycoprotein was quantified using the periodic acid-Schifft s (PAS) assay (Mantle and 
Allen, 1978). Standard curves were prepared using 0-150µl of lmgml"1 pig gastric 
mucin (SIGMA-Aldrich) (that was subsequently papain digested) and made up to a total 
volume of lml of distilled water. 200pl of periodic acid solution (0.2% (v/v) periodic 
acid (BDH) in 7% acetic acid) was added to 1 ml of standard or sample and incubated at 
37°C for 1 hour. Schiffs solution (SIGMA-Aldrich) (0.017% (w/v) sodium 
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metabisulphite (BDH) in Schiffs reagent (fuschin-sulphite reagent)) was pre-incubated 
at 37°C for 1 hour. 200µ1 of Schiffs solution was added to each tube and left for 30 
minutes at room temperature to develop colour. Absorbance was measured at 555nm 
against the reagent blank and the amount of glycoprotein in the sample determined from 
the standard curve. 
2.4.5 Protein assay (Bradford) 
Protein was estimated using the Bio-Rad assay kit (Bradford, 1976) (Bio-Rad 
Laboratories Ltd, UK). Standard curves were prepared using bovine serum albumin to 
give a range between 0 and 20µg, in a total volume of 0.8m1 distilled water. Samples 
were diluted as necessary to a volume of 0.8m1.0.2m1 Coomassie blue reagent (BioRad 
reagent) was added to each sample and standard. After incubation at room temperature 
for 30 minutes, the absorbance was measured at 595nm and the sample protein content 
determined from the standard curve. 
2.4.6 Protein and nucleic acid estimation 
Protein and nucleic acid content were estimated by measurement of absorbance at 
280nm and 260nm. The protein and nucleic acid content of samples was extrapolated 
from a nomograph based on the extinction coefficients for enolase and DNA (Warburg 
and Christian, 1942) 
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2.5 Mucin Studies 
2.5.1 Dilute solution viscosity studies 
Measurements were made using a Couette rotating cup viscometer (Contraves low shear 
30) controlled by an electronic speed programmer (Rheoscan 20), which allowed the 
speed of the cup to be increased under controlled conditions. The temperature of the 
apparatus was maintained by a thermostatically controlled water bath circulating water 
through the viscometer block. The speed (shear rate) programme produced a range of up 
to 30 fixed speeds in a geometric progression or generated continuously variable speeds 
throughout the same range. 
Effusions were homogenised in 0.067M phosphate buffer, pH6.5 containing a 
proteolytic inhibitor cocktail. 2ml of the homogenate was placed in the cup, and the 
bob, suspended by a torsion wire, was lowered into the sample giving a 0.1 mm annulus 
of sample between the cup and bob. Viscosity measurements were made at 37°C in the 
rotating cup between speeds of 1.7s"1 and 128.5s-'. Before any measurements were 
made, samples were sheared twice, through and back through the whole shear range to 
disrupt any weak non-specific non-covalent interactions. Speed versus angular 
deflection (in degrees) plots were obtained (% deflection being plotted on the Y axis 
and speed on the X axis of an X. Y. recorder), the gradients of which are directly 
proportional to the viscosity of the solution under test. Gradients were also produced for 
buffer alone and the ratio of these sample gradients to buffer gradient calculated to be 
the relative viscosity (il., ). 
Relative viscosity (rInl). _% deflection of test solution /% deflection of buffer 
Specific viscosity (lisp). = Relative viscosity -I 
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2.5.2 Dialysis and freeze drying 
After effusion viscosity had been measured, samples were placed into visking dialysis 
tubing (Medicell International Ltd., UK). Exhaustive dialysis of samples was achieved 
in 20 litres of distilled water at 4°C with continuous stirring for at least three days with 
six changes of water daily. Dialysis tubing had a molecular weight cut off point of 
12-15000Da. The samples were rinsed out of the dialysis tubing using distilled water, 
frozen at -80°C for one hour and freeze dried on a Modulyo freeze drier attached to a 
Pirani 10 vacuum pump and subsequently stored at -20°C. 
2.5.3 Equilibrium Density Gradient Centrifugation 
To purify effusion material (or saliva samples) by removal of protein and nucleic acid, 
equilibrium density gradient centrifugation in caesium chloride (CsCI) was used 
(Starkey et al., 1974). CsCI was added to the samples in solution to give a starting 
density of 1.42gm1'1 and the solution centrifuged at 100,000g for 48hours at 4°C, using 
a fixed angle rotor. 
Without disturbing the resulting gradient, the content of each tube was separated into 
nine equal fractions. The density of each fraction was measured, followed by exhaustive 
dialysis against distilled water at 4°C. Dialysed fractions were assayed for glycoprotein 
and protein and an estimation of nucleic acid was made. Fractions rich in protein and 
nucleic acid were generally discarded. Fractions rich in glycoprotein were pooled, 
freeze dried and stored at -20°C. 
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2.6 Size Fractionation Methods 
2.6.1 Gel Filtration 
Gel filtration was used to attempt to separate high molecular weight purified salivary 
mucin (MUC5B) from lower molecular weight mucin (containing MUC7) and low 
molecular weight protein contaminants. A Sepharose CL-4B column (1.5 x 30cm) and a 
Sepharose CL-2B column (1.5 x 130cm) were prepared as described in "Gel Filtration: 
Principles and Methods" published by Amersham Biosciences UK Ltd. (2000). 
The void volume (V0) and total volume (VT) of columns were determined by 
fractionating a solution of 0.5% (w/v) blue dextran containing 0.05% (w/v) methyl 
orange. Both columns were eluted with 0.2M sodium chloride containing 0.02% (w/v) 
sodium azide. The Sepharose CL-4B column was eluted by downward flow under 
gravity and the CL-2B column was eluted by upward flow with the aid of a peristaltic 
pump. Freeze dried CsCI purified mucin was reconstituted at concentrations of 
1-3mgml' in 0.2M NaC1/0.02% NaN3 and 1 or 2m1 volumes were loaded on the 
column. 1 or 3m1 fractions were collected and assayed for glycoprotein. Excluded 
fractions which eluted at Vo, were pooled as the respective high molecular weight mucin 
(MUC5B). Glycoprotein-rich fractions that were in the included volume were pooled 
and assayed for the presence of MUC7 by ELISA. 
2.6.2 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS PAGE) 
SDS PAGE was conducted using the Pharmacia PHAST gel system (Pharmacia Ltd. ). 
Freeze dried samples or standards were solubilised in either 0.0625M Tris buffer, pH 
6.8, containing 2% (w/v) SDS, 10% (v/v) glycerol, 0.001% bromophenol blue (non- 
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reducing buffer), or 0.0625M Tris buffer, pH 6.8, containing 2% (w/v) SDS, 10% (v/v) 
glycerol, 0.001% bromophenol blue and 5% mercaptoethanol (reducing buffer). 
Samples were heated at 100°C for two minutes in a boiling waterbath before being 
applied to the gels (PhastgelTM Gradient 4-15% or 8-25%). Gels were run at constant 
current of 100mA for 260Vh until the tracking dye had reached the end of the running 
gel. Gels were stained for glycoprotein using the PAS method (Van Seuningen et al., 
1992) (Table 2.2). The gels were then scanned for glycoprotein at 555nm using a 
Shimadzu scanning densitometer. 
The amount of polymeric material present in a sample was calculated by determining 
the amount of material that remained at the point of application compared to the amount 
that had moved from the point of application to the interface between the stacking and 
running gel and into the running gel. This SDS-PAGE method has previously been 
validated (Rankin et al., 1995; Newton, 1998). 
Purity of mucin (detection of protein contaminants) was assessed using SDS PAGE and 
staining gels overnight in 0.05% (w/v) coomassie blue, 25% (v/v) propan-2-ol and 10% 
(v/v) acetic acid. Gels were then destained for one day in 25% (v/v) propan-2-ol and 
10% (v/v) acetic acid followed with overnight destaining with 10% (v/v) propan-2-ol 
and 10% (v/v) acetic acid. Gels were then scanned for protein at 585nm using a 
Shimadzu scanning densitometer. 
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Table 2.2 Method of staining gels for glycoprotein using the PAS method 
Step Time (min) Temp (°C) 
1 20% trichloroacetic acid 5- 20 
2 deionised water 5 20 
3 0.7% periodic acid + 5% acetic acid 10 20 
4 deionised water 2 20 
5 deionised water 2 20 
6 Schiff's reagent 10 20 
7 5% potassium disulphite + 5% acetic acid 5 20 
8 5% methanol + 7.5% acetic acid 10 50 
9 5% methanol + 7.5% acetic acid 5 50 
10 50% methanol + 30% acetic acid 10 50 
11 50% methanol + 30% acetic acid 5 50 
12 50% methanol + 30% acetic acid 2 50 
13 5% glycerol + 10% acetic acid 10 50 
(From Van Seuningen & Davril, 1992) 
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2.6.3 Immunoblot Procedure (Western WNW 
Western blotting was used to detect proteins present in samples using their molecular 
weight and antigenic properties. 
After separation of the sample / standard by SDS PAGE, proteins were transferred from 
the polyacrylamide gels to nitrocellulose membranes using a PhastTransfer Semi-dry 
Electrophoretic Transfer System (Pharmacia Ltd. ) within the PhastSystem. This process 
was undertaken immediately after the electrophoresis run as proteins begin diffusing 
within the gel as soon as the run is completed. 
The polyacrylamide gel was separated from its backing (but not fully detached) and a 
nitrocellulose membrane (0.2µm pore size) pre-wetted with transfer buffer (25mM Tris, 
192mM glycine, 20% methanol and pH8.3) was placed on the surface of the gel. The 
gel assembly was turned over and the membrane peeled from the gel backing. A 
"transfer sandwich" was made in the Electrode Cassette, which incorporated the 
electrodes required for protein transfer. The sandwich consisted of three pre-wetted 
filter papers (in transfer buffer), the gel with attached membrane so that the membrane 
was in direct contact with the filter paper and then three more pre-wetted filter papers 
on top of the gel (see diagram below). The cathode was placed on top of the filter papers 
and the Electrode Cassette was loaded into the separation compartment of the 
PhastSystem. This was now ready for protein transfer. 
70 
The complete transfer sandwich 
Gel 
Immobilising 
membrane 
The conditions used for the protein transfer were as follows: 
Voltage 20V 
Current 25mA 
Power 1W 
Temperature 15°C 
Volthours 5Vh 
lode 
3 filter 
papers 
de 
After protein transfer was achieved, the transfer sandwich was removed and the 
membrane peeled away for further identification of protein bands. It was not possible to 
stain the gel to check for transfer as its backing had been removed. The membrane was 
incubated in phosphate buffered saline (PBS) containing 2% bovine serum albumin 
(BSA) overnight at 4°C to block non-specific binding and then probed with antibodies 
using an ELISA technique (Section 2.4.2). 
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2.7 Histological Methods 
2.7.1 Microscope slide preparation & tissue sectioning 
Clean microscope slides were soaked in 0.01% (w/v) poly-L-lysine solution for five 
minutes and left to air-dry overnight. Paraffin embedded specimens were sectioned 
10µm thick with a Cryotome (Shandon). Sections were floated on water and onto poly- 
L-lysine coated slides and air-dried. 
2.7.2 Haematoxylin and Eosin Staining 
To observe general histological architecture of tissue sections, slides were stained with 
haematoxylin and eosin (H & E). After dewaxing, slides were fixed in 10% neutral 
buffered formalin (20 seconds) then briefly immersed in acetic acid/ethanol (25% (v/v) 
glacial acetic acid in absolute ethanol). The slides were transferred into 70% ethanol for 
20 seconds. Slides were then rinsed under slowly running tap water to remove any 
solvent residue and then immersed in Gill No. 2 haematoxylin (Sigma) for two minutes. 
Slides were then rinsed to remove excess dye followed by a rinse in ethanol 70%. They 
were then immersed in Blueing solution (ammoniated alcohol) until they took on a blue 
colour, rinsed and stained in aqueous Eosin Y solution (1%) (BDH). After rinsing well 
in water the slides were dehydrated and mounted with a coverslip using DPX mountant. 
2.7.3 Immunohistochemist 
To determine the presence or absence of antigens in middle ear mucosa biopsy tissue, 
immunohistochemistry (IHC) was employed. The slides were de-waxed and rehydrated 
to PBS. Microwave antigen retrieval was performed in citrate buffer (0.8mM citric acid, 
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82mM tri-sodium citrate, pH6) then slides were rinsed in PBS. Endogenous peroxidase 
activity was blocked by incubating the slides in 1% (v/v) H202 in methanol for 20 
minutes. After rinsing in running tap water, non-specific binding was blocked with 3% 
BSA/PBS for 20 minutes. Slides were drained and then incubated with primary 
antibody diluted in 1% BSA/PBS in a humid chamber for one hour. Unbound antibody 
was removed by rinsing slides in three changes of 1% BSA/PBS. Horseradish 
peroxidase-conjugated secondary antibody, diluted in 1% BSA/PBS was added and 
incubated in a humid chamber for 30 minutes. After rinsing as described previously, 
colour was developed with 0.05% 3'3 diaminobenzidine tetrahydrochloride 
(DAB)/0.03% H202 in PBS for ten minutes. Slides were rinsed, counterstained in 
haematoxylin for two seconds, and rinsed well in running tap water, then dehydrated in 
graded alcohols to histoclear and mounted in a xylene based mountant. 
For details of antibodies used in this procedure see section 2.4.2.1. 
2.8 Statistical Analyses 
Data were expressed as mean ±1 SEM unless otherwise stated in the text. Data were 
analysed by unpaired Student's t-test and were considered significant when P<0.05. 
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CHAPTER 3 
GASTRO-OESOPHAGEAL REFLUX 
AND OME 
Chapter 3 Gastro-oesophageal reflux and OME 
3.1 Introduction 
Paediatric gastro-oesophageal reflux (GOR) has been frequently reported (Vandenplas 
et al., 1988) and linked to the development of many airway disorders such as recurrent 
pneumonia, chronic asthma, rhinitis and sinusitis, recurrent croup, stridor and laryngitis 
(Berguist et al., 1981; Kouf nan, 1991). The presence of acid reflux in the nasopharynx, 
detected by nasopharyngeal pH monitoring, has been documented (Contencin and 
Narcy, 1991) and it has been postulated that GOR may be involved in the pathogenesis 
of an entire spectrum of otorhinolaryngologic conditions (Contencin et al., 1995; 
Yellon, 1997) including otitis media with effusion (Shilkin, 1994; Halstead, 1999; 
Velepic et al., 2000). 
It is thought that the aetiology of OME is related in part to the anatomic and 
immunologic immaturity of the paediatric Eustachian tube (ET) (Bluestone, 1996; Sudo 
and Sando, 1996) and that ET dysfunction is an important factor in the pathogenesis of 
the disease (Bylander-Groth and Stenstrom, 1998). The ET in children is shorter and 
less inclined (13-18mm and 10°) (Proctor, 1967) from the tympanic orifice to the 
pharyngeal orifice than the mature ET in adults (31-38mm and 45°) (Sadler-Kimes et 
al., 1989). These anatomic differences are believed to impair the protective function of 
the ET and this combined with the fact that infants and neonates are often placed in the 
supine position, may allow gastric contents to travel from the nasopharynx into the 
middle ear cleft. Any acid reflux into the middle ear may alter the local immune system 
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and cause inflammation in the pharynx and ET as acidity and acidic proteinase activity 
in these areas is abnormal (Holms et al., 1977; Contencin and Narcy, 1991). 
Many researchers have suggested the link between GOR and OME, however a direct 
relationship has not yet been determined. It has been demonstrated that repeated 
exposure of the rat middle ear to simulated gastric refluxant causes worsening ET 
function with time (Heavner et al., 2001a; Heavner et al., 2001b). Cures or reduction in 
the frequency of recurrent otitis media with anti-GOR treatment have been reported 
(Bouchard et al., 1999; Poelmans et al., 2001). In one study, six children were referred 
for recurring otitis media, these children either had oesophagitis or abnormal pH 
monitoring, after treatment of GOR, four of the patients had complete resolution of their 
symptoms and two were significantly improved (Contencin et al., 1995). The role of 
GOR in OME needs to be further investigated and evidence for gastric juice in the 
middle ear sought. As gastric juice contains pepsins, this can be done by analysis of 
middle ear effusions for the presence of acidic proteinase (pepsin) activity and pepsin 
protein. 
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3.2 Analysis of middle ear effusions for the presence of acidic proteinase 
activity 
3.2.1 Middle ear effusion preparation 
Middle ear effusions (n=65) collected from children undergoing myringotomy for OME 
(at Newcastle and Nottingham ENT) and stored at -20°C were thawed at 4°C before 
use. The samples were randomly chosen from storage and therefore varied in their type 
(from serous to mucoid) and also in their colour (from straw coloured to deep red). 
The effusions were divided into two sets, one containing 35 effusions and the other 
containing 30 effusions and each effusion volume (µl) was recorded. To the first set 
(n=35) was added a known volume of 0.01M HCl (pH2.2) and to the second set (n=30) 
was added an equal volume of 0.067M phosphate buffer (pH8). Each effusion-acid or 
effusion-buffer (alkaline) mixture was gently homogenised and then centrifuged for 
lhour at 700g and 4°C to remove insoluble material. The supernatants were removed 
and stored at 4°C at their respective pHs for 20 hours. The pH8 supernatants were 
returned to pH2.2 by dialysis in 0.01M HCl before analysis of proteolytic activity (see 
section 2.3.1). 
Pepsin has substantial proteolytic activity at pH2.2 and will be irreversibly inhibited at 
pH8 (Piper and Fenton, 1965). Pepsinogen is completely converted to pepsin at pH4.5 
and below (Samloff, 1971). The effusions left at pH2.2 should therefore contain pepsin 
alone. Pepsinogen is stable at pH8-10 so treatment of an effusion supernatant at pH8 
should irreversibly inhibit any pepsin present, and pepsinogen alone would survive. 
After the four hours dialysis at pH2.2 any pepsinogen present would be activated to 
pepsin. See diagram below. 
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These pH manipulations allow the calculation of pepsin content in effusions whilst 
accounting for the presence of serum pepsinogen. 
Effusions at pH2.2 
Contain pepsin only 
(Including enzyme newly 
activated from pepsinogen) 
Acidic proteinase activity from 
pepsin and pepsinogen measured 
Effusions at pH8 
Contain pepsinogen only 
Pepsin has been denatured 
20 hours 
4°C 
Dialysis to pH2.2 
Pepsinogen activated to 
pepsin due to acidic pH 
Acidic proteinase activity 
from pepsinogen alone 
measured 
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3.2.2 Measurement of acidic proteinase activity in effusions 
Proteolytic activity of the effusion supernatants was measured at pH2.2 using the 
N-terminal assay with succinyl albumin as substrate for proteolytic cleavage and 
porcine pepsin A as a standard (as described in section 2.4.1). Time zero controls were 
prepared to measure all free N-terminals on substrate and enzyme existing before 
hydrolysis. 
In the assay, the amount of free N-terminals generated by the hydrolysis of peptide 
bonds from enzyme present in the effusion supernatant was quantified colorimetrically 
by the measurement of the optical density at 340nm of the final reaction volume. After 
subtracting the optical density values corresponding to the amount of N-terminals 
existing before hydrolysis and any reagent absorbance, acidic proteinase activity in 
0.2m1 of each effusion supernatant was calculated from the porcine pepsin standard 
curve. 
The total amount of acidic proteinase activity per effusion and per ml effusion were 
calculated using the following formulae: 
µg acidic 
proteinase x in 0.2ml 
(Original effusion (ml) + buffer / HCl added (ml)) µg acidic 
_ proteinase 
activity per 
effusion 
0.2 
µg acidic proteinase activity per effusion 
x 1000 
effusion volume (µl) 
µg acidic 
proteinase 
activity per ml 
effusion 
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The pH8 to pH2.2 manipulation altered effusion volumes by a maximum of 2.5% 
therefore the original effusion volume was used to calculate pepsin and pepsinogen 
activity in all samples. 
Thirty-five effusion supernatants were stored at pH2.2. Pepsin like activity (from pepsin 
and pepsinogen) was present in eleven (31%) of these. Activity ranged from 
0.023-4.095µg acidic proteinase per effusion, which was equivalent to 0.551-57.93µg 
per ml effusion (Fig. 3.1). 
Thirty effusion supernatants were exposed to pH8 buffer before being returned to pH2.2 
for the assay. Pepsin-like activity (derived from pepsinogen) was found in eight (27%) 
of these. Activity ranged from 0.009-9.167µg acidic proteinase per effusion, equivalent 
to 3.996-147.4µg per ml effusion (Fig. 3.2). 
It is unlikely that this activity is due to pepsinogen as serum pepsinogen levels are much 
lower (49-86ngml"1) unless a massive concentration has occurred. The source cannot be 
gastric juice, as due to its low pH almost all the pepsinogen would have been already 
converted to pepsin. 
It is possible that exposure to pH8 is not sufficient to totally denature pepsin when in 
the presence of effusion or gastric juice components and that some pepsin activity 
remains when the proteinase activity of the effusion is subsequently measured at pH2.2. 
Bacteria have been cultured from up to 40% of middle ear effusions (Giebink, 1989; 
Bluestone et al., 1992; Rayner et at, 1998) therefore bacterial acidic proteinases could 
be present in the effusions, however an aspartate proteinase with this pH optimum has 
not yet been identified in bacteria. 
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Figure 3.1 Acidic proteinase activity (measured at pH2.2) per ml of effusion 
(homogenised in 0.01M HC1). 
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Effusion supernatants (. ) stored at pH2.2 for 20 hours. Acidic proteinase activity was 
measured using the N-terminal assay. 
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Figure 3.2 Acidic proteinase activity (measured at pH2.2) per ml of effusion 
(homogenised in pH8 phosphate buffer). 
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Effusion supernatants (. ) stored at pH8 for 20 hours and returned to pH2.2 by dialysis 
in 0.01M HCl for 4 hours. Acidic proteinase activity was measured using the N-terminal 
assay. 
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3.3 Acidic proteinase activity control assays 
3.3.1 pH profile of porcine pepsin A 
Pepsin is recognised as a proteolytic enzyme maximally active at a highly acidic pH and 
inactivated in neutral or alkaline solution. To investigate the exact pH at which porcine 
pepsin A is irreversibly denatured under the conditions used in the previous experiment, 
the enzyme was subjected to a range of pH and the remaining proteolytic activity was 
measured at pH2.2. 
Sorensen's phosphate buffer (0.067M) was used in the range pH6.4 to pH8 with 0.1 or 
0.2 pH unit increments. pH2.2 HCl was used as the control for maximum activity and 
dilute 0.0001M HCl (pH4) was used as an intermediate value. Porcine pepsin A was 
solubilised in acid or buffer at each pH to give solutions of 3.5µgml''. The solutions 
were left for 20 hours at their respective pH and returned to pH2.2 by dialysis for 4 
hours in 0.01M HCI. Proteolytic activity of the pepsin was measured using the 
N-terminal assay at pH2.2 with porcine pepsin A as standard. 
It was observed that porcine pepsin A remained stable and retained all proteolytic 
activity when exposed to pH as high as pH6.6. After exposure to pH6.7, there was a 
30% reduction in proteinase activity and by pH7.1 all activity was lost and porcine 
pepsin was irreversibly denatured (Fig. 3.3). A 42% reduction in activity was observed 
at pH2.2, the optimum pH for pepsin activity. This is likely to be due to auto-digestion 
of pepsin during the 20-hour pH exposure stage at 4°C before the assay. This reduction 
in temperature would not stop pepsin activity, it would just reduce the rate of activity 
(Piper and Fenton, 1965). 
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Figure 3.3 Levels of active pepsin (µgmr) detected in porcine pepsin solutions 
after exposure to a range of pH. 
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Porcine pepsin solutions ( ) exposed to pH2.2-8 for 20 hours and returned to pH2.2 by 
dialysis in 0.01M HCl for 4 hours. Acidic proteinase activity was measured using the 
N-terminal assay. 
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3.3.2 DH profile of human gastric juice 
To investigate whether pepsin present in gastric juice has the same pH profile as porcine 
pepsin A in solution. 
Gastric juice samples were collected from patients under pentagastrin-stimulated 
conditions, diluted 1: 10 with a pH4.1 buffer comprising 55mM sodium acetate and 
55mM sodium chloride and stored at -20°C until used. For all experiments, gastric juice 
samples from different individuals were pooled. 
Measurement of acidic Proteinase activity (pH2.2) 
The amount of pepsin activity at pH2.2 in the pooled gastric juice was measured in 
order that appropriate dilutions could be made for the pH profile assay. I in 5,1 in 10 
and 1 in 50 dilutions of gastric juice were made in 0.01M HCI. The amount of acidic 
proteinase activity present was measured using the N-terminal assay. 
It was found that the concentration of active pepsin in the human gastric juice pool 
(1: 10 dilution) was approximately 0.25mgm1'1 and in the N-terminal assay system the 1 
in 50 dilution of gastric juice was required in order to obtain results relevant to the 
porcine pepsin A standard curve. 
pH profile assay 
Aliquots of the gastric juice pool were diluted in Sorensen's phosphate buffer (0.067M) 
in the range pH6.4 to pH8 with 0.1 or 0.2 increments and pH2.2 HCl was used as the 
control for maximum activity. The solutions were left for 20 hours at their respective 
pHs and returned to pH2.2 by dialysis for 4 hours in 0.01M HCI. Proteolytic activity 
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within the gastric juice was measured using the N-terminal assay at pH2.2 using porcine 
pepsin A as a standard. The pH profiles of three separate pools of human gastric juice 
were determined. In the third pool, dilute 0.0001M HC1 (pH4) was used as an 
intermediate value. 
It was observed that pepsin within the gastric juice remained stable and retained all its 
proteolytic activity when exposed to pH as high as pH7.0. After exposure to pH7.1 there 
was up to a 53% reduction in proteinase activity and by pH7.8 all activity was lost and 
human pepsin was irreversibly denatured (Fig. 3.4). A reduction in activity was 
observed at pH2.2 and at pH4 (only one sample measured at pH4). This is most likely 
due to auto-digestion. The reduction was more marked in these gastric juice samples 
than in the porcine pepsin solutions, this is most likely due to the higher concentration 
of enzyme present in the gastric juice samples. 
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Figure 3.4 Levels of active pepsin (pgmf-') detected in three pooled gastric juice 
samples after exposure to a range of pH. 
C 
0 
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exposure to pH 
Gastric juice samples (pool 1 (. ), pool 2 (A) and pool 3 (V)) were exposed to pH in 
the range pH2.2-8 for 20 hours and returned to pH2.2 by dialysis in 0.01 M HCl for 4 
hours. Acidic proteinase activity was measured using the N-terminal assay 
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3.3.3 Do components present in the assay protect pepsin from denaturation at RH8? 
3.3.3.1 Gastric juice components 
To investigate if the presence of gastric juice components protect porcine pepsin from 
complete denaturation during 20-hour storage at pH8. 
Pooled human gastric juice was titrated to pH8 using 2M NaOH and divided into two 
2m1 aliquots. To one aliquot was added l0µ1 of lmgml"t porcine pepsin A solution, so 
that up to 1µg could be detected in 2000 in the N-terminal assay. 10µl of pH8 
phosphate buffer was added to the other aliquot. This aliquot was used to control for any 
acidic proteinase activity remaining in the gastric juice sample. A 2m1 aliquot of 
0.067M phosphate buffer (pH8) alone, spiked with 10µg pepsin was used to test 
whether without the presence of gastric juice components, exposure of porcine pepsin A 
to pH8 denatured the enzyme. The gastric juice aliquots and the phosphate buffer were 
stored at pH8 for 20 hours at 4°C then returned to pH2.2 by dialysis. 
Acidic proteinase activity of the gastric juice (spiked and unspiked) and of porcine 
pepsin alone was measured using the N-terminal assay at pH2.2. See summary below. 
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Gastric Juice pH8 I Gastric Juice pH8 ' Phosphate buffer pH8 
10µ1(10µg) l0µ1 phosphate buffer 
(pH8) added 
10µ1(10µg) 
porcine pepsin A added porcine pepsin A added 
Stored at pH8,20 hours, 4°C 
Returned to pH2.2 by dialysis, 4°C 
Acidic proteinase activity measured using N-terminal assay, pH2.2 
The results of the N-terminal assay showed that even after storage of porcine pepsin A 
for 20 hours at a pH that is known to denature the enzyme, an additional 1.04% 
proteinase activity was detected in the gastric juice aliquot spiked with porcine pepsin A 
compared to gastric juice alone (Fig. 3.5). There was no proteinase activity detected in 
the phosphate buffer (pH8) spiked with porcine pepsin. 
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3.3.3.2 Middle ear effusion components 
To investigate if the presence of middle ear effusion components protect porcine pepsin 
from complete denaturation during 20 hour storage at pH8. 
Middle ear effusions (1.67mg) were pooled and diluted to 10ml final volume using 
0.067M phosphate buffer, pH8. The mixture was hand homogenised and centrifuged for 
one hour (see method in section 2.3.1). The resulting supernatant was diluted as shown 
below. 
Dilution µg effusion material / 200gl 
supernatant in assay 
I in 2 16.7 
lin5 6.7 
1 in 10 3.3 
Each supernatant dilution was split into four equal aliquots of 2m1. Two aliquots from 
each dilution were used in this assay. 
To one aliquot of each effusion dilution was added 10µ1 of lmgml"1 porcine pepsin A 
solution, so that up to 1 gg could be detected in 200µl in the N-terminal assay. I Ogl of 
pH8 phosphate buffer was added to the other aliquot. A 2m1 aliquot of 0.067M 
phosphate buffer (pH8) alone, spiked with 10µg pepsin was used to test whether 
without the presence of gastric juice components, exposure of porcine pepsin A to pH8 
denatured the enzyme. All effusion dilutions and the phosphate buffer were stored at 
pH8 for 20 hours at 4°C then returned to pH2.2 by dialysis. 
89 
Acidic proteinase activity of the effusion dilutions (spiked and unspiked) and of porcine 
pepsin alone was measured using the N-terminal assay at pH2.2. See summary below. 
Effusion dilution pH8 
(1 in 2,1 in 5&1 in 10) 
10µ1(10µg) 
porcine pepsin A added 
Effusion dilution pH8 
(l in 2,1 in 5&l in 10) 
10µ1 phosphate buffer 
(pH8) added 
Stored at pH8,20 hours, 4°C 
Returned to pH2.2 by dialysis, 4°C 
Phosphate buffer pH8 
10µl (10µg) 
porcine pepsin A added 
Acidic proteinase activity measured using N-terminal assay, pH2.2 
After incubation of porcine pepsin with middle ear effusion supernatants containing 
varying amounts of effusion material, a small proportion, between 2.26 and 6.04% of 
proteinase activity remained (Fig. 3.5). There was no proteinase activity detected in the 
phosphate buffer (pH8) spiked with porcine pepsin. 
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Figure 3.5 Percentage of proteinase activity of porcine pepsin remaining after 
storage at pH8 with gastric juice or dilutions of middle ear effusion. 
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The presence of gastric juice and middle ear effusion components prevent denaturation 
of porcine pepsin after storage at pH8 and dialysis to pH2.2. Proteinase activity was 
measured using the N-terminal assay. 
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3.3.3.3 Gastric juice and middle ear effusion components 
It was intended to investigate if the presence of both gastric juice components and 
middle ear effusion components protect human pepsins (in gastric juice) from complete 
denaturation during 20 hour storage at pH8. 
It was not possible to carry out this experiment during the course of the thesis due to the 
lack of availability of fresh human gastric juice, however the methodology has been 
explained in the discussion section of this chapter. 
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3.3.4 Does the amount of effusion material present in the N-terminal assay prevent 100% 
detection of pepsin? 
To investigate if the presence of effusion contents in the N-terminal assay system was 
having a masking effect and inhibiting the detection of any pepsin present. 
Middle ear effusions (1.17mg) were pooled and diluted to 11 ml final volume using 
0.01M HCI, pH2.2. The mixture was hand homogenised and centrifuged for one hour 
(see section 2.3.1). The resulting supernatant was diluted as shown below. 
Dilution µg effusion material / 200µl 
supernatant in assay 
I in 2 10.6 
1in5 5.3 
l in 10 2.7 
1 in 16 1.3 
Middle ear effusions (1.67mg) were pooled and diluted to 10ml final volume using 
0.067M phosphate buffer, pH8 (for preparation see section 3.3.3.2). The resulting 
supernatant was diluted as shown below. 
Dilution µg effusion material / 200µl 
supernatant in assay 
I in 2 16.7 
1 in 5 6.7 
I in 10 1 3.3 
The two 2ml aliquots from each dilution kept from the assay preparation described in 
section 3.3.3.2 were used in this assay. The aliquots were returned to pH2.2 by dialysis 
in 0.01 M HC1 for 4 hours at 4°C. 
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A 2m1 aliquot of each supernatant dilution (from effusions homogenised both in pH2.2 
and in pH8) was spiked with 1041 of l mgml"' porcine pepsin A solution so that up to 
1 µg could be detected in 200µ1 in the N-terminal assay. To a second aliquot was added 
10µ10.01M HCI; this part was kept as a measurement of existing N-terminals. 
Acidic proteinase activity of all sample dilutions, spiked and unspiked was measured 
using the N-terminal assay at pH2.2 with porcine pepsin A as standard. See summary 
below. 
pH2.2 homogenised effusions 
2m1 aliquot 12 ml aliquot 
10µ1(10µg) 
porcine pepsin A 
added 
l0µ10.01 M HC1 
(pH2.2) added 
pH8 homogenised effusions 
2m1 aliquot I 2m1 aliquot 
Returned to pH2.2 by dialysis 
(0.01M HCI, 4 hours, 4°C) 
10µ1(10µg) 10µ10.01M HC1 
porcine pepsin A (pH2.2) added 
added 
Stored at pH2.2,20 hours, 4°C 
Acidic proteinase activity measured using N-terminal assay, pH2.2 
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pH2.2 homogenised effusions 
It was found that the unspiked pooled effusions did not contain any acidic proteinase 
activity and that all activity measured was therefore due to the spiked pepsin. There was 
an inverse correlation between the amount of effusion material present in the assay and 
the amount of pepsin that could be detected, demonstrating that effusion contents did 
reduce the amount of activity detected (Fig. 3.6). This correlation was statistically 
significant, P=0.0037, rz=0.958. The weight of the average effusion used for 
measurement of acidic proteinase activity (section 3.2.1) was approximately 82µg 
(n=65), which after dilutions are made corresponded to 4.68µg per 2O0µ1 in the assay. 
This could mean that the effusion contents present are only allowing between 34 and 
67% of acidic proteinase activity due to pepsin to be detected in the N-terminal assay 
system. 
pH8 homogenised effusions 
An inverse correlation was also observed as above between the amount of effusion 
material present and the percentage of spiked pepsin that could be detected. This 
effusion material was not as effective in preventing the pepsin being detected (Fig. 3.7). 
This is presumably due to solubilisation of the effusion at pH8 and then taking it to 
pH2.2. It is possible that pH8 treatment of the effusion reduces any interference 
properties and therefore could reduce any interference in the detection of the pepsin. 
With the estimated effusion content in the assay (n=65) being approximately 4.68µg per 
2O0µl, between 64 and 81% of the added porcine pepsin was detected. Gastric juice 
appeared to have a similar effect as the effusion material, with 67% of the added pepsin 
being detected (Fig. 3.7). 
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The masking effect of pepsin by effusion material was greater when the effusion was 
solubilised at pH2.2 rather than at pH8. The pH manipulation reduced the ability of the 
effusion components to interfere in the N-terminal assay. 
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Figure 3.6 Percentage of added pepsin detected in 200µl effusion supernatant 
containing a range of effusion material (pH2.2). 
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Effusions were homogenised in 0.01M HC1. Dilutions were made of the homogenate 
supernatant after centrifugation to obtain a range of effusion material. A known amount 
of porcine pepsin was added to each dilution and the percentage detected using the 
N-terminal assay was calculated. 
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Figure 3.7 Percentage of added pepsin detected in 2O0µ1 effusion supernatant 
containing a range of effusion material (pH8). 
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Effusions were homogenised in phosphate buffer, pH8. Dilutions were made of the 
homogenate supernatant after centrifugation to obtain a range of effusion material. 
Samples were returned to pH2.2 by dialysis and a known amount of porcine pepsin was 
added to each dilution and also to human gastric juice (pH2.2) and the percentage 
detected using the N-terminal assay was calculated. 
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3.3.5 pH of middle ear effusions 
3.3.5.1 Measurement in deionised water 
lml deionised water was added to middle ear effusions (n=15). Each was hand 
homogenised gently for 2 minutes until a consistent homogenate was produced. The pH 
of the resulting homogenate was measured using a pH probe. 
The pH range of the effusion homogenates was pH7.42-8.25. 
3.3.5.2 Measurement of effusions without dilution 
Measurement of the pH of effusions (n=8) without dilution (neat) was achieved using 
universal indicator paper. This measurement was not as accurate and the pH range was 
found to be pH7 pH9. 
Measurement of the pH of fresh effusions directly after removal from the middle ear 
had the same pH range (Prof. J. P. Birchall, personal communication). 
As shown by the pH profile of pepsin in gastric juice, some pepsin activity may be 
retained at these pHs, particularly between pH7-7.6. 
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3.4 Analysis of middle ear effusions for total pepsinlpepsinogen protein 
3.4.1 Middle ear effusion preparation 
The same middle ear effusions (n=65) that were analysed for acidic proteinase activity 
in the N-terminal assay (section 3.2.1) were also used for the measurement of total 
pepsin/pepsinogen protein content. Effusion supernatants (pH2.2) remaining after 
aliquots were taken for the N-terminal assay were diluted a further 1: 2 and 
1: 5 in 0.01M phosphate buffered saline, pH7.4 and used for determination of total 
pepsin/pepsinogen protein using a slot blot ELISA. 
3.4.2 Measurement of total pepsin/pepsinogen protein in effusions 
Pepsin/pepsinogen content of effusions was determined using a slot blot ELISA with a 
0.2µm pore size nitrocellulose membrane (section 2.4.2) with porcine pepsin A as a 
standard (Fig. 3.8). 
100µl of samples and standards were added to individual wells and allowed to absorb 
onto the membrane under vacuum. The membrane was probed with a monospecific 
antiserum raised to pepsin (porcine stomach), (Biodesign International, USA) at a 
dilution of 1: 2000. This antibody reacts strongly with human pepsin (Ms. M. Panetti, 
personal communication) and recognises the same epitope in pepsinogen as in pepsin so 
cannot differentiate between precursor and active enzyme. Antibody binding was 
measured using the appropriate secondary antibody (anti-goat) conjugated to peroxidase 
with H202 as substrate. 3,3'-diaminobenzidine tetrahydrochloride (DAB) was used for 
colour development. Staining of the slots was quantitated at 595nm. 
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Fifty-nine of sixty-five effusions (91%) gave a positive result with the anti-pepsin 
antibody. Total pepsin/pepsinogen protein present in the 100µl of each effusion on the 
membrane was calculated using the porcine pepsin A standard curve. Pepsin/pepsinogen 
protein per ml of effusion was calculated taking into account all the dilution steps made 
and was in the range 0.8-213.9µg/ml effusion (mean=43.9; SD=57.2) for the positive 
effusions (n=59) (Fig. 3.9 and 3.10). 77% of effusions contained less than 50µg 
pepsin/pepsinogen per ml effusion, demonstrating that only a small number of effusions 
(n=15) had a very high pepsin/pepsinogen content. Normal serum reference levels for 
pepsinogen are 49-86ngml", these levels are much lower than those found in middle ear 
effusions. 
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Figure 3.8 Standard curves of porcine pepsin A. 
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The porcine pepsin standard curve in the range 0.01-10µg protein had a distinct plateau 
occurring after 0.5µg per well (graph A). The range 0.01-0.54g protein (graph B) was 
used to calculate pepsin/pepsinogen protein, as this graph was linear. 
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Figure 3.9 Total pepsin/pepsinogen content in µg per ml of effusion. 
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Total pepsin/pepsinogen content of effusions ( ) was determined using an ELISA with 
porcine pepsin A as standard. 91% of effusions contained a detectable level of 
pepsin/pepsinogen protein in the range 0.8-213.9ggml' effusion. 
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Figure 3.10 Total pepsin/pepsinogen content per ml of each effusion expressed 
by amount of protein present. 
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Total pepsin/pepsinogen content of effusions, demonstrating the distribution of the 
range of protein present. 
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3.5 Total pepsin/pepsinogen content control assays 
3.5.1 Cross reactivity of pepsinooen with pepsin antibody 
To investigate whether there was any cross reactivity of the pepsin antibody with 
pepsinogen, using a slot blot ELISA assay. 
l00µ1 of porcine pepsin A and porcine pepsinogen containing 0.1-10µg pepsin and 
0.5-10µg pepsinogen were added to individual wells and allowed to absorb onto a 
0.2µm pore size nitrocellulose membrane. The membrane was probed (as in section 
3.3.2) with the monospecific antiserum raised to porcine pepsin; antibody binding was 
measured using the appropriate secondary antibody and DAB was used for colour 
development. Staining of the slots was quantitated at 595nm. 
Both porcine pepsin and pepsinogen reacted with the antibody but at different levels 
(Fig. 3.11). At 1µg of protein, there is a ten-fold greater level of antibody reactivity with 
porcine pepsin than porcine pepsinogen. The antibody could not differentiate between 
pepsin and pepsinogen and one must assume that both proteins are being measured 
simultaneously and that results represent the sum of the two proteins. 
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Figure 3.11 Reactivity of porcine pepsin and pepsinogen with the pepsin 
antibody 
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Standard curves of porcine pepsin A (0.1-10µg,  ) and porcine pepsinogen (0.5-10µg, 
f). The pepsin standard curve is saturated above 3µg protein yet the pepsinogen 
standard curve is still linear up to 10µg. This assay appears to be relatively insensitive 
to pepsinogen therefore one can assume that the positive protein in the effusions is 
derived from pepsin not pepsinogen. 
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3.5.2 Measurement of serum protein levels in effusions 
As middle ear effusions are in part a transudate of plasma, two of the major serum 
proteins, fibrinogen and albumin, were measured in effusions as well as the 
pepsin/pepsinogen concentration using a slot blot ELISA assay. A comparison was 
made with normal serum levels to examine whether serum factors were being 
concentrated in the effusions. If the effusions were a ten-fold concentration of plasma, 
then the pepsinogen content could be in the range 0.5-0.9 µgml", which is similar to the 
pepsinogen levels already measured in a small number of the effusions. 
3.5.2.1 Fibrinogen levels 
Known volumes of effusion supernatant (n=8) in PBS were blotted onto nitrocellulose 
sheets (0.45µm pore size for fibrinogen, 0.2µm pore size for pepsin/pepsinogen) along 
with the relevant standards (fibrinogen (fraction I, human plasma) or pepsin A (porcine 
stomach)) and probed with either a polyclonal antiserum raised to human fibrinogen or 
the monospecific antibody raised to pepsin (porcine stomach), both at a 1: 2000 dilution. 
Antibody binding was measured using the appropriate secondary antibody (anti-rabbit 
or anti-goat IgG) conjugated to peroxidase with H202 as substrate. DAB was used for 
colour development as above. 
All effusions contained fibrinogen in the range 0.30-2.30mgml' (mean=1.08; SD=0.69 
(n=8)) (Fig. 3.12). The mean concentration of fibrinogen in the effusions was 
1.077mgm1"1 of effusion. Serum reference levels for fibrinogen are 2.2-4.6mgml" '. The 
pepsin/pepsinogen content of seven of the effusions ranged from 3.29-27.97ggm1"1 
(mean=18.32; SD=10.15 (n=7)). There was not enough sample remaining to measure 
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pepsin/pepsinogen content in the eighth effusion. These values are consistent with levels 
of pepsin/pepsinogen previously measured in effusions. 
3.5.2.2 Albumin levels 
Known volumes of effusion supernatant (n=19) in PBS were blotted onto nitrocellulose 
sheets (0.45µm pore size for albumin, 0.2µm pore size for pepsin/pepsinogen) along 
with the relevant standards (albumin (fraction V, human plasma) or pepsin A (porcine 
stomach) and probed with either a monoclonal antiserum raised to human albumin used 
at a 1: 5000 dilution or the monospecific antibody raised to pepsin (porcine stomach) at a 
1: 2000 dilution. 
Antibody binding was measured using the appropriate secondary antibody (anti-mouse 
or anti-goat IgG) conjugated to peroxidase with H202 as substrate. DAB was used for 
colour development as above. 
All effusions contained albumin in the range 1.78-49.7mgml" (mean=13.29; SD=14.66 
(n=19)) (Fig. 3.13). The mean concentration of albumin in the effusions was 
13.29mgm1"1 of effusion. Serum reference levels for albumin are 35-45mgm1"'. 
The pepsin/pepsinogen content of four of the above effusions ranged from 
5.89-25.35µgm1'1 (mean=16.05; SD=7.96 (n=4)). These values are consistent with 
levels of pepsin/pepsinogen previously measured in effusions. 
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Figure 3.12 Fibrinogen content (mg) per ml effusion. 
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Fibrinogen content of effusions ( ) was determined using an ELISA with human 
fibrinogen as standard. All effusions contained a detectable level of fibrinogen in the 
range 0.3-2.3mgml-l effusion. Serum reference levels are 2.2-4.6mgml-' (- --). 
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Figure 3.13 Albumin content (mg) per ml effusion. 
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Albumin content of effusions ( ) was determined using an ELISA with human albumin 
as standard. All effusions contained a detectable level of albumin in the range 
1.78-49.7mgm1 1 effusion. Serum reference levels 35-45mgm1"' (-). 
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3.5.3 Measurement of serum oepsinogen levels using oeasin antiserum 
This was used to measure the reactivity of the pepsin antiserum with pepsinogen from 
serum and to verify that the level of pepsinogen measured using the antibody was of the 
same order as the given serum reference levels. 
Initial measurements (n=1) with human adult serum were 134ngml"' and were close to 
the normal range (49-86ngml-'). 
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3.5.4 Does the pepsin antibody react with other serum proteins? 
3.5.4.1 Measurement of pepsin antibody reactivity with serum proteins 
It was possible that the pepsin monospecific antiserum was also reacting with other 
proteins present in the effusion, resulting in high values for pepsinlpepsinogen 
(compared to serum levels) even though other serum protein levels were of similar 
concentration in serum and effusions (section 3.5.2). 
Standard curves (1-200µg) of the main human serum proteins, albumin, fibrinogen and 
y-globulins were blotted onto 0.2µm pore size nitrocellulose sheets along with porcine 
pepsin A and pepsinogen standard curves (0.0-1.0µg) and probed with the monospecific 
pepsin antibody in a slot blot ELISA assay. 
There was a small amount of non-specific reactivity observed with albumin and 
y-globulins that was not concentration dependent. Antibody binding of 3.5% and 0.9% 
of that for 1µg of porcine pepsin was observed for 200µg of y-globulins and albumin 
respectively. However, there was concentration dependent cross reactivity between the 
pepsin antibody and fibrinogen (Fig. 3.14a). Antibody binding of 20% of that for I µg of 
porcine pepsin was observed for 200µg of fibrinogen (Fig 3.14a, Fig 3.14b). 
3.5.4.2 Determination of purity of serum protein preparations 
There was potential that the antibody reactivity observed with fibrinogen and 
y-globulins was due to impurities present in the preparations. To test this possibility, 
samples of each protein were separated using SDS PAGE and stained with coomassie 
blue, a protein stain, to see if there was any protein impurity present in the fibrinogen or 
y-globulin preparation that had a molecular weight similar to pepsin, (Mr=34500). 
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Albumin cross-reactivity had been very small and therefore was not investigated any 
further. 
lmgml'1 solutions of fibrinogen, y-globulin, porcine pepsin A and molecular weight 
markers (range 14300 to 65000) were made in non-reducing buffer (0.0625M Tris 
buffer, pH6.8, containing 2% (w/v) SDS, 10% (v/v) glycerol and 0.001% bromophenol 
blue (see section 2.6.2 for complete procedure)). Solutions were heated at 100°C for 2 
minutes and 11A applied to polyacrylamide gels (PhastgelTM Gradient 4-15%). Gels 
were run at constant current until the tracking dye reached the end of the running gel. 
Gels were stained for protein using 0.05% (w/v) coomassie blue, 25% (v/v) propan-2-ol 
and 10% (v/v) acetic acid. After destaining in 25% (v/v) propan-2-ol and 10% (v/v) 
acetic acid followed by 10% (v/v) propan-2-ol and 10% (v/v) acetic acid, gels were 
scanned for protein at 585nm using a scanning densitometer at 585run. 
There were no detectable impurities present in either the y-globulin or the fibrinogen 
preparations (Fig. 3.15) and nothing was observed at the molecular weight for pepsin 
therefore the antibody reactivity observed in the slot blot ELISA cannot be due to 
contamination of the proteins with pepsin/pepsinogen. 
3.5.4.3 Is the pepsin antibody detecting fibrinogen? 
In a previous experiment (described in section 3.5.2), both the fibrinogen and 
pepsin/pepsinogen content of effusions (n=7) was measured. The Pearson correlation 
between the two parameters was calculated, P value=0.3929 and r2 =0.1487 (Fig. 3.16). 
There was no significant correlation between the two protein levels in these effusions, 
therefore the pepsin antibody could not be recognising fibrinogen alone. If the pepsin 
113 
antibody was mainly reacting with fibrinogen, the correlation would be expected to be 
statistically significant. 
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Figure 3.14a Reactivity of serum proteins with pepsin antibody. 
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Concentration dependent reactivity was observed with fibrinogen (A), non-specific and 
concentration independent reactivity was seen with y-globulins (7) and albumin (n) 
with the pepsin antibody in an ELISA assay. 
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Figure 3.14b Reactivity of porcine pepsin A and pepsinogen with pepsin antibody. 
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Concentration dependent reactivity was observed with both pepsin (. ) and pepsinogen 
(. ) with the pepsin antibody in an ELISA assay. These standard curves were used as 
positive controls and also to measure the difference in antibody binding between the 
pepsin and pepsinogen and the serum proteins. 
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Figure 3.15 Separation of serum proteins, pepsin and molecular weight markers 
by SDS PAGE. 
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No protein impurities were observed in either the y-globulin or fibrinogen preparations 
at the molecular weight for pepsin. 
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Figure 3.16 Comparison of pepsin/pepsinogen content and fibrinogen content of 
effusions 
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There was no correlation between the two parameters (P value=0.3929, Pearson 
correlation, n=7) therefore the pepsin antibody does not recognise fibrinogen alone. 
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3.5.5 Calculation of degree of cross reactivity between pepsin antibody and fibrinogen 
3.5.5.1 Calculated (theoretical) cross reactivity 
Theoretical cross reactivity was calculated using the assumption that the pepsin 
antibody would react with all fibrinogen present and with the pepsin/pepsinogen. This 
was estimating a `worst case scenario'. 
1. The average concentration of fibrinogen in effusions had previously been 
calculated to be 1.08mgml"' (Fig. 3.12). 
2. The fibrinogen content in each effusion dilution used in the ELISA was 
calculated. 
3. From the fibrinogen standard curve probed with the pepsin antibody (Fig. 
3.14a), antibody-binding equivalent to the amount of fibrinogen present in each 
effusion dilution was calculated. 
4. The pepsin antibody binding equivalent to the presence of fibrinogen was 
subtracted from the total pepsin antibody binding per effusion, leaving the 
antibody binding relating to pepsin/pepsinogen presence in each effusion 
dilution. 
5. Using the corresponding standard curves, the amount of pepsin/pepsinogen 
present in each effusion was then re-calculated. 
After recalculation of the total pepsin/pepsinogen content of the effusions it was 
observed that an over calculation had been made as the N-terminal assay results and 
ELISA results did not agree. Some effusions which contained acidic proteinase activity 
(from N-terminal assay) and had measurable levels of pepsin/pepsinogen (from ELISA), 
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now appeared to lack pepsin/pepsinogen protein content (e. g. effusions 3 and 4, table 
below). However, 69% of effusions still had measurable levels of pepsin/pepsinogen 
protein after re-calculation (e. g. effusions 24 and 41, table below) and these levels 
remained significantly higher than serum pepsinogen levels. It was apparent that an 
assay to measure actual cross reactivity was necessary. 
Effusion Acidic proteinase Pepsin/pepsinogen Pepsin/pepsinogen 
activity (pH2.2) ml- protein m1' effusion protein ml' effusion 
effusion after re-calculation 
3 2.034 3.37 0 
4 0.551 2.06 0 
24 0.57 38.23 18.47 
41 3.996 55.54 40.20 
3.5.5.2 Measured (actual) cross reactivity 
Clarification of antibody cross reactivity with fibrinogen in the pepsin ELISA was 
carried out as follows (n=3). Mixtures of porcine pepsin and human fibrinogen with 
weight: weight ratios (pepsin: fibrinogen) of 1: 5,1: 10,1: 100 and 1: 1000 (using 0.1,0.25 
and 0.54g pepsin for each ratio) were blotted onto 0.2µm pore size nitrocellulose sheets 
and probed with the pepsin antibody in a slot blot ELISA. Antibody reactivity of each 
ratio was compared to that of pepsin alone and cross reactivity was evaluated. 
Overall interference of fibrinogen with pepsin detection by the pepsin antibody was 
calculated for each weight within each ratio as shown: 
Antibody binding in ratio p: f % Interference due to 
X 100 - 100 = 
fibrinogen 
Antibody binding for pepsin alone 
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This ratio experiment was used to determine the amount of reactivity with the antibody 
that was above or below the level measured with pepsin alone and was calculated as 
percentage interference. With the 1: 5 and 1: 10 ratios, interference due to fibrinogen 
decreased as the amount of pepsin increased from 0.1 to 0.5µg. The overall interference 
of fibrinogen with pepsin detection (calculated as an average of all data for each ratio) 
decreased as the amount of fibrinogen increased from 12% (ratio 1: 5) to 7% (ratio 
1: 10). At ratios of 1: 100 and 1: 1000, the interference became strongly negative at -46% 
and -61% respectively (Fig. 3.17). The ratio of pepsinogen to fibrinogen in serum is 
1: 16000 and the interference due to fibrinogen in the detection of pepsin/pepsinogen is 
most likely negligible therefore the pepsin/pepsinogen protein levels have not been 
adjusted to account for this. 
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Figure 3.17 Interference from fibrinogen in the pepsin ELISA. 
Ratio P: F 
m U C 
d 
d 
r C 
\° 0 
6 
(P) porcine pepsin, (F) human fibrinogen. P: F was a weight: weight ratio. Overall % 
interference for each ratio was expressed as an average of interference observed using 
0.1,0.25 and 0.5µg pepsin. With the 1: 5 and 1: 10 ratios, interference due to fibrinogen 
decreased as the amount of pepsin increased from 0.1 to 0.5µg. 
As the amount of fibrinogen present increased to 1: 100 and 1: 1000, the interference of 
fibrinogen with pepsin detection decreased. 
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3.5.6 Do effusion components interfere with pepsin/pepsinoQen detection in the slot blot 
ELISA assay? 
Effusion supernatants remaining after aliquots were taken for the N-terminal assay were 
diluted a further 1: 2 and 1: 5 in 0.01M PBS, pH7.4 and used for determination of total 
pepsin/pepsinogen protein using a slot blot ELISA. To investigate whether effusion 
components interfered with detection of pepsin/pepsinogen, the amount of protein 
detected from both dilutions for each effusion (after dilution factors were accounted for) 
were compared to see if there was a significant difference between dilutions. 
A paired t test was used to compare the results. The means of the results were not 
significantly different (P=0.7902) and the pairing was significantly effective 
(correlation coefficient, r =0.8542), therefore it can be assumed that effusion 
components do not interfere with pepsin detection in the ELISA at the dilutions used. 
123 
3.5.7 Separation of middle ear effusion components using SDS PAGE 
To investigate if pepsin can be detected in effusions at the reported molecular weight 
after separation of the effusion using SDS PAGE, subsequent Western blotting and 
probing with the pepsin antibody. 
Middle ear effusions (n=4) were hand homogenised separately in 2m1 distilled water 
followed by centrifugation at 700g and 4°C for 1 hour to remove insoluble material. The 
supernatants were removed and freeze dried. 
Two 5mgm1"1 solutions of porcine pepsin were used, one made in distilled water (active) 
and the other exposed to pH9 sodium hydroxide for 48 hours (denatured). Five-times 
concentrated non-reducing buffer was added to both pepsin solutions (at a 1: 4 ratio of 
non-reducing buffer to pepsin solution), which lowered the concentration to 4mgmi '. 
Each lyophilised effusion was solubilised in non-reducing buffer to a concentration of 
10mgml-1 and split into two parts. To one part was added active pepsin and to the 
second part was added denatured pepsin (so that 0.8µg of pepsin would be contained in 
1 µl). 
Samples (1 µl) of the solubilised effusion spiked with pepsin and the pepsin solutions 
alone were subjected to gel electrophoresis using 4-15% gradient polyacrylamide gels. 
After separation, proteins were transferred from the polyacrylamide gels to 
nitrocellulose membranes using a PhastTransfer Semi-dry Electrophoretic Transfer 
System within the PhastSystem (section 2.6.3) and the membrane was probed for the 
presence of pepsin using an ELISA technique (section 3.4.2). Staining was quantitated 
using a scanning densitometer at 595nm. 
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With active pepsin alone, a clear band was observed (Fig. 3.18a), 14mm from the 
interface and at the molecular weight for pepsin (35000). When active pepsin was run 
with the effusion supernatant a band was observed (Fig. 3.18b) in the same position as 
with pepsin alone but with a stronger intensity of staining, indicating increased antibody 
binding. The effusion does therefore not inhibit the movement of pepsin in SDS PAGE. 
With pH9 denatured pepsin there was no clear band, instead a range of low molecular 
weight fragments were present, still staining positive for the pepsin antibody (Fig. 
3.18c). Denatured pepsin with the effusion supernatant produced a similar pattern of 
low molecular weight fragments as denatured pepsin alone but with a stronger intensity 
of staining (Fig. 3.18d). The low molecular weight material was not seen in Fig 3.18b 
due to a four-fold reduction in the scale in order to fit the peak on the graph. 
These results demonstrate that pepsin is present in effusions but is mostly denatured, 
however it still reacts with the pepsin antibody. 
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Figure 3.18 Separation of active and denatured pepsin with and without effusion 
material after SDS PAGE, Western blotting and probing with pepsin antibody 
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3.5.8 Immunohistochemical analysis of middle ear biopsies 
Three formalin-fixed, paraffin-embedded middle ear biopsy samples were used to assess 
whether the tissue itself was capable of secreting pepsin. Human gastric (corpus region) 
and colonic mucosa sections were used as positive and negative controls respectively. 
To observe the general histological architecture of the tissue sections, slides were 
stained with haematoxylin and eosin. In gastric mucosa the gastric glands were 
observed from the muscularis mucosa to the lumen (Fig. 3.19a). Some respiratory 
epithelium was observed in the middle ear mucosa sections (Fig. 3.19b & 3.19c) which 
is stratified columnar secretory epithelium in the middle ear, no cilia were seen in these 
samples. The lamina propria showed evidence of an inflammatory infiltrate. 
To assess the ability of the tissue to secrete pepsin, slides were incubated with the 
monospecific antiserum to pepsin followed by an appropriate HRP-conjugated 
secondary antibody (as previously described). DAB was used for colour development. 
Reactivity with the pepsin antibody was observed in gastric mucosa in the gastric glands 
(Fig. 3.20a) compared to the gastric mucosa sections incubated without the pepsin 
antibody (Fig. 3.20b). Pepsin is secreted from chief cells that are located towards the 
base of the gastric glands in gastric mucosa. There was no reactivity with the pepsin 
antibody in the middle ear biopsy sections (Fig. 3.20c), demonstrating that the middle 
ear does not secrete pepsin/pepsinogen. 
Reactivity of the human colonic mucosa with the pepsin antibody was negative (Fig. 
3.20d), demonstrating that colonic mucosa does not secrete pepsin. 
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Figure 3.19 Photomicrographs of cryostat sections of human gastric and middle 
ear mucosa following haemotoxylin and eosin staining 
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Figure 3.20 Photomicrographs of cryostat sections of human gastric, colonic and 
middle ear samples following immunohistochemistry using the pepsin antibody 
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b) Human gastric mucosa (x200) without pepsin antibody 
c) Human middle ear mucosa (x200) with pepsin antibody. 
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3.6 Summary of acidic proteinase activity vs. total protein content of middle ear 
effusions 
The supernatants of sixty-five effusions were analysed for acidic proteinase activity 
(section 3.2) and total protein content (section 3.4). 
Acidic proteinase activity was measured using the N-terminal assay at pH2.2. 
Thirty-five effusions were homogenised at pH2.2. Pepsin-like activity (from pepsin and 
pepsinogen) was present in eleven (31 %) of these. The amount of active pepsin ranged 
from 0.551-57.93µgm1"i effusion. 
Thirty effusion supernatants were exposed to pH8 buffer before being returned to pH2.2 
for the assay. Pepsin like activity (derived from pepsinogen) was found in eight (27%) 
of these. The amount of active pepsin ranged from 3.996-147.4µgml" effusion. 
Total pepsin/pepsinogen protein present in each of the sixty-five effusions was 
measured using a monospecific antibody raised to pepsin (porcine stomach). The 
antibody could not differentiate between the two proteins. Fifty-nine out of sixty-five 
effusions gave a positive result with the pepsin antiserum. Pepsin/pepsinogen protein 
was present in the range 0.8-213.9µg/ml effusion (mean=43.9; SD=57.2) for the 
positive effusions (n=59). Interference due to fibrinogen was not taken into account. 
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3.7 Discussion 
The present study is an investigation of the role of gastro-oesophageal reflux in OME. 
The aim was to analyse effusions for the presence of acidic proteinase activity, and if 
present, to determine the identity and source of the activity, whether from reflux of 
gastric contents or due to a transudate of plasma into the middle ear cleft. Pepsinogen is 
normally present in blood serum. 
The supernatants of sixty-five effusions were tested for the presence of acidic proteinase 
activity (N-terminal assay) and total pepsin/pepsinogen protein content (ELISA). The 
majority of effusions contained pepsin/pepsinogen protein, however in only 29% of 
effusions was any acidic proteinase activity detected. 
The pH of middle ear effusions was assessed in two ways, when measured as neat 
effusions (both from -20°C storage or from effusions directly after removal) using 
universal indicator paper the pH range was pH7-9 and when measured as a homogenate 
in I ml deionised water using a pocket pH meter, the pH range was pH7.4-8.3. This is 
comparable to previously published data (Wezyk and Makowski, 2000) in a study of 
middle ear effusions from 112 children where the pH ranged from pH7-10 when 
measured using indicator paper. In that study, a positive correlation existed between the 
age of the children and the effusion pH, older children had effusions with higher pH. 
The pH of effusions was so high that most pepsin would be irreversibly inhibited, 
explaining the high levels of pepsin/pepsinogen and denatured pepsin protein (ELISA) 
yet low levels of active enzyme (N-terminal assay). 
The pH profiles of porcine pepsin A and pepsin from human gastric juice showed that 
pepsin in gastric juice could retain its activity at pH2.2 after exposure to a higher pH 
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(pH7.0) than porcine pepsin A alone (pH6.6) and was not completely inactivated until 
pH7.8 compared to pH7.1 for porcine pepsin. These pH profiles show that although 
most pepsin in effusions would be irreversibly inhibited, pepsin may retain some 
activity under these conditions and in effusions the pepsin could be protected against a 
pH that would normally denature the enzyme. 
In both the porcine pepsin and human gastric juice pH profiles, a reduction in activity 
was observed with incubation at pH2.2 that was more marked in the gastric juice 
samples than the porcine pepsin solutions, most likely due to the much higher 
concentration of enzyme present. Pepsin digests protein with a pH optimum for albumin 
of 1.8 to 2.3 (Hirschowitz, 1984) therefore the apparent reduced activity is almost 
certainly due to auto digestion of the pepsin during the 20-hour pH exposure stage of 
the assay, as even at 4°C some activity would be expected. Porcine pepsin was used as 
standard in the N-terminal assay as it has been shown to have pepsin activity 
comparable with the major human pepsin, Pepsin 3 (Pearson et al., 1986). 
In a previous study (Piper and Fenton, 1965), a pH stability curve using human pepsin 
(homogenate of human gastric fundic mucosa) demonstrated that 100% of pepsin was 
stable at pH as high as pH6 (100% of peptic activity retained when measured at pH2.2). 
If the pH was increased above pH6, pepsin became progressively unstable until pH8 
when all the enzyme was unstable and irreversibly inactivated. In the Piper study, 
pepsin was only exposed to pH levels in increments of 0.5 and for just ten minutes 
before titration back to pH2.2 and activity was measured using radio-labelled serum 
albumin (Klotz and Duvall, 1957). 
It was noticed that incubation of human pepsin at pH7.2 at intervals of one to sixty 
minutes followed by titration to pH2.2 and measurement of peptic activity, produced a 
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similar degree of pepsin denaturation leading to the conclusion that pepsin inactivation 
by a suitably high pH is almost instantaneous. 
Acidic proteinase activity is difficult to measure in middle ear effusions because even 
using the supernatant after centrifugation, the effusion components (to varying levels) 
mask detection of pepsin activity. An inverse correlation existed between the amount of 
effusion material present and the percentage of pepsin activity detected. As 
demonstrated by the assays in section 3.3.4, the amount of enzyme inhibition possible 
due to effusion material present (at levels comparable to that present in the N-terminal 
assay) ranged from 33-66% in the effusion pool homogenised at pH2.2 and 19-36% in 
the effusion pool homogenised at pH8. The extent of this range can be explained due to 
the two different pools of effusions used in the two studies having potentially different 
composition and also that pre-treatment of effusions at pH8 may reduce the protection 
properties of the effusions. While the effusions are exposed to pH8 there may be 
degradation of, or structural changes in, the components within the effusion that are 
responsible for masking pepsin such as protein or glycoprotein, by enzymes with a 
neutral pH optimum. Evidence for neutral proteinase activity in effusions has been 
previously demonstrated (Carrie et al., 1992). Studies have shown that the pH of middle 
ear effusions is pH7-9, however degradation of the effusion in the middle ear does not 
occur, most likely because the enzymes cannot penetrate the mucoid effusion. In the 
current study a dilute solution of effusion is made, allowing enzyme access to all of the 
effusion. 
A previous study has shown that mucin is the only component in effusions that 
determines viscosity (Carrie et al., 1992) and it is most likely the presence of mucin that 
is inhibiting the enzyme. It has also been demonstrated that middle ear effusion 
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homogenates have the ability to inhibit DNase activity by up to 91% (Piezhong et al., 
2002). The present study shows that effusions have the potential to inhibit acidic 
proteinase activity and the level to which this is achieved may depend on the mucin 
composition of the particular effusion. High viscosity (high mucin content) effusions 
may have a greater ability to inhibit acidic proteinase activity than those with low 
viscosity (low mucin content). 
It has also been demonstrated that after exposure of a known amount of pepsin (within 
effusion supernatants or gastric juice) to pH8, there is still a small amount (up to 6%) of 
acidic proteinase activity measurable at pH2.2 whereas pepsin in buffer alone is 
completely inactivated. This could also be due to the protective properties of the 
effusion and would account for the fact that some of the pH8 dialysed effusions in the 
N-terminal assay still had activity higher than the level for serum pepsinogen alone. A 
comparison of the pH profiles for gastric juice and porcine pepsin shows that gastric 
juice is stable at a higher pH than porcine pepsin alone by 0.5 of a pH unit. The addition 
of other solutes in the effusion could further stabilise the pepsin. 
To advance this study, one should investigate whether the presence of both gastric juice 
components and middle ear effusion components protect human pepsins (in gastric 
juice) from complete denaturation during 20-hour storage at pH8. This could be done by 
adding fresh human gastric juice with known acidic proteinase activity to effusion 
supernatants at pH7, pH8 and pH9 and storing the samples along with effusion 
supernatants alone and gastric juice alone (as controls) at their respective pHs for 20 
hours. After returning the samples to pH2.2, acidic proteinase activity of the effusion 
supernatants (with and without gastric juice) and of human gastric juice alone should be 
measured using the N-terminal assay to see if more proteinase activity is detected in the 
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gastric juice when effusion components were present and the ability of pH9 to denature 
pepsin. 
It must not be ignored that the acidic proteinase activity detected may be in part due to 
other acidic proteinases apart from pepsin and the possibility of the presence of bacterial 
acid proteinases cannot be completely ruled out. None have been identified so far. 
In the present study it was shown that the pepsin antiserum recognised both pepsin and 
pepsinogen and was not capable of distinguishing between the two proteins. The 
concentration of pepsin/pepsinogen measured in the effusions was up to 1000 times 
higher than the levels found in serum (reference concentrations 49.8-86.6ngm1"' 
(Brunner et al., 1995)). Serum pepsinogen levels are well characterised and 
measurement of pepsinogen in adult serum in the current study fell into the normal 
range for adults. The level of pepsinogen in serum from children was not measured in 
the current study and a further study may involve analysis of both effusions and serum 
for pepsinogen in children. Albumin and fibrinogen levels in effusions were of the same 
order as those found in serum (reference concentrations 35-45mgm1"' and 2.2-4.6mgm1'' 
respectively). This data shows that serum factors are not being concentrated in the 
effusions and that the pepsin detected in middle ear effusions is unlikely to have come 
from a transudate of plasma. The only other sources are reflux of gastric contents or 
secretion of pepsin by the middle ear mucosa. 
There was no cross reactivity between the pepsin antiserum and either albumin or 
7-globulins however concentration dependent cross reactivity was observed with 
fibrinogen. Antibody binding of 20% of that for 1 gg of porcine pepsin was observed for 
200µg of fibrinogen. After analysis of the fibrinogen preparation using SDS PAGE it 
was demonstrated that no visible impurities were present at molecular weights 
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corresponding to those of pepsin/pepsinogen and that the antibody binding was not due 
to contamination of the fibrinogen with pepsin/pepsinogen. There was no significant 
correlation between pepsin/pepsinogen levels (measured with the pepsin antiserum) and 
fibrinogen levels (measured with the fibrinogen antiserum) in the same effusions, 
showing that the cross reactivity of fibrinogen with the pepsin antiserum was not linear 
(uniform). 
Further measurement of the degree of cross reactivity of fibrinogen with the pepsin 
antibody was analysed in two ways, using a theoretical calculation and also by ratio 
experiments. Theoretical cross reactivity was based on the assumption that the pepsin 
antibody would react with all the fibrinogen and pepsin/pepsinogen. The pepsin 
antibody binding equivalent to the presence of fibrinogen was subtracted from the total 
pepsin antibody binding per effusion and the amount of pepsin/pepsinogen present in 
each effusion was re-calculated using the corresponding standard curves. After 
recalculation it was observed that the N-terminal assay results and ELISA results did 
not agree. Some effusions that contained acidic proteinase activity and had measurable 
levels of pepsin/pepsinogen protein now appeared to lack pepsin/pepsinogen protein 
content. However, 69% of effusions still had measurable levels of pepsin/pepsinogen 
protein after recalculation and these levels remained significantly higher than serum 
pepsinogen levels. 
Measured (actual) cross reactivity experiments were used to determine the extent of the 
cross-reactivity using mixtures of pepsin and fibrinogen in a series of weight: weight 
ratios. Overall interference of fibrinogen decreased as the amount of fibrinogen present 
increased. At lower ratios (1: 5 and 1: 10 of pepsin: fibrinogen) the interference due to 
fibrinogen decreased as the amount of pepsin present increased, within the same ratio. 
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At high ratios (1: 100 and 1: 1000) the interference due to fibrinogen became strongly 
negative. 
The ratio of pepsinogen to fibrinogen in human serum is 1: 16000 and using the above 
experiments it was calculated that the amount of fibrinogen present in the effusions 
would not artificially raise the pepsin/pepsinogen levels measured, in fact it may lead to 
an underestimation and therefore the pepsin/pepsinogen data from the ELISA studies 
were not altered to account for interference. 
SDS PAGE and Western blotting of effusion supernatants using the pepsin antibody 
have demonstrated that pepsin is present in effusions but is mostly in a denatured form, 
separating into a range of low molecular weight material with a similar pattern to pepsin 
that had been exposed to pH9 for 48 hours. This material was still detected by the 
pepsin antibody. 
Haematoxylin and eosin staining of middle ear mucosa biopsy samples demonstrated 
that the architecture of the tissue was still sufficiently intact to be able to be used for 
immunohistochemistry. 
Immunohistochemical analysis of biopsy samples demonstrated that the middle ear is 
not capable of secreting pepsin/pepsinogen as no antibody binding was detected, 
whereas intense staining of the gastric mucosa tissue was observed with the pepsin 
antibody. 
The above data is strong evidence that gastro-pharyngeal reflux may have a role in 
OME. 
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To further confirm the role of reflux in OME, it would be possible to analyse effusions 
for the presence of other components of gastric juice not present in serum, such as 
gastric lipase or intrinsic factor. 
Gastric lipase is a 379 amino acid glycosylated polypeptide with a pH optimum of 
pH3.5-7.0 (Gargouri et al., 1989) It is exclusively located in chief cells of the fundic 
mucosa and always found together with pepsin (Moreau et al., 1989). A polyclonal anti- 
human gastric lipase antibody has been made (personal communication, Professor R. 
Laugier) and it is possible that this could be used to measure gastric lipase in effusions. 
Intrinsic factor is a 341 to 351 amino acid glycosylated polypeptide, secreted by the 
parietal cells (Hoedemaker et al., 1966). The use of immunocytochemistry however, has 
shown it is also found in some chief cells and in the secretory ducts of salivary glands. It 
is possible that intrinsic factor could be measured in effusions using a rapid charcoal 
assay (Gottlieb et al., 1965), or by ELISA using mouse anti-intrinsic factor monoclonal 
antibody as the primary antibody. This antibody is commercially available. 
In a first reflux event, when gastric acid and pepsin are refluxed from the nasopharynx 
into the Eustachian tube and middle ear, the pH would be acidic. Transient damage 
would be caused to the Eustachian tube and the middle ear mucosa before it could be 
neutralised. If neutralisation only reached pH7, pepsin in the gastric juice would not be 
completely and irreversibly inhibited. This enzyme could then be re-activated by a 
second reflux event containing more acid and pepsin and cause further damage. 
91% of effusions contain pepsin/pepsinogen at levels that makes the source almost 
certainly gastric juice. Gastric reflux may therefore be the primary factor in the 
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initiation of OME, instigating a cascade of inflammatory events leading to the 
conditions seen in the disease. 
The relationship between OME and GOR is becoming increasingly important in 
paediatric otolaryngology however as yet there are few experimental models that 
demonstrate this relationship. Two recent studies (Heavner et al., 2001 a, Heavner, 2001 
#478) have demonstrated that repeated transtympanic exposure of rat middle ear to 
simulated GOR causes transient abnormal Eustachian tube function, displaying an 
inability to appropriately rectify applied positive or negative pressure from the middle 
ear. An inability to equilibrate middle ear negative pressure is regarded as the primary 
deficit in Eustachian tube dysfunction. These researchers acknowledged the fact that 
transtympanic exposure to the test solution was non-physiologic and that the distal 
portion of the Eustachian tube had more contact than the proximal nasopharyngeal 
portion. A more relevant model would be one in which gastric juice components were 
directly placed into the nasopharynx. This would simulate GOR as it moves into the 
nasopharynx. 
Clinicians have reported patients presenting with therapy resistant middle ear disease 
who, on referral to a gastroenterologist and subsequently being prescribed acid- 
suppressive therapy and made aware of anti-reflux measures, have had their symptoms 
removed (Poelmans et al., 2001). In these cases the middle ear disease was thought to 
be associated with Eustachian tube pathological changes caused by mucosal injury from 
GORD. 
From nasopharyngeal monitoring studies and endoscopy, it has been shown that acid, 
and maybe other irritative agents from the digestive tract, are able to produce or 
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perpetuate inflammation at every site in the larynx (Contencin et al., 1995). OME and 
its possible infectious complications may be the outcome of GOR-induced 
nasopharyngeal reflux with a local chronic inflammatory process. Successful treatment 
of OME with anti-reflux therapy may have potential. 
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CHAPTER 4 
PRODUCTION OF A 
MUC5B STANDARD FROM 
HUMAN WHOLE SALIVA 
Chapter 4 Production of a MUC5B standard from 
human whole saliva 
4.1 Introduction 
Human saliva is a specialised, dilute aqueous secretion produced by mucous and serous 
cells in the three pairs of major salivary glands (parotid, submandibular and sublingual) 
and the numerous minor ones (labial, buccal, lingual and glosso palatine). The 
composition of saliva changes throughout the day depending on the relative contribution 
and composition of the constituent gland secretions. In the resting state, the visco-elastic 
submandibular-sublingual saliva constitutes much of the fluid in the mouth. The minor 
glands keep the buccal, labial and palatine epithelial tissues moist. Under stimulated 
conditions, parotid saliva can be up to 70% of the total saliva present (Veerman et al., 
1996) resulting in a less visco-elastic, more liquid-like secretion. 
Mucus glycoproteins (mucins) are a major constituent of saliva and are secreted in a 
soluble form. They account for 7-26% of total salivary protein (Fox et al., 1985). 
Mucins have a multifunctional role in the oral cavity: they lubricate oral surfaces, 
provide a protective barrier between hard and soft tissues and the external environment 
and aid in mastication and swallowing (Tabak, 1995). Salivary mucins also have the 
ability to bind to and agglutinate microbes (Scannapieco, 1994) acting as components of 
the innate host defence system in the oral cavity. 
Biochemical studies have shown that two major mucin populations are present in 
human saliva: MG1 (high M,. mucins) and MG2 (low Mr mucins) (Prakobphol et al., 
1982). MG1 is more abundant than MG2 (0.23 and 0.13gml-' saliva, respectively) 
(Rayment et al., 2000). 
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MG1 is a large polymeric glycoprotein with a molecular weight of over 106Da. It is 
composed of 15% protein, 78% carbohydrate and 7% sulphate (Levine et al., 1987). 
The oligosaccharide moiety is very heterogeneous, with carbohydrate chains ranging in 
size from 4-16 sugar residues (Loomis et al., 1987). MG1 glycosylation and sulphation 
appear to be characteristic for the type of salivary gland (Veerman et al., 1992). MG1 
resembles mucins in other parts of the human body in size and conformation. In situ 
hybridisation and immunohistochemical studies have shown that MUCSB is expressed 
in the mucous acini of all salivary glands, suggesting that MUC5B represents a major 
fraction of MG1 (Cohen et al., 1990; Nielsen et al., 1996; Nielsen et al., 1997). 
Northern blot analysis of human sublingual and submandibular glands using probes for 
MUC2-6 demonstrated that RNA from both glands contained very low levels of MUC4 
transcripts in addition to high levels of MUC5B transcripts in RNA from sublingual 
gland and lower levels of MUC5B transcripts from submandibular gland. This data 
suggests that MUC4 may be a minor component of MG 1 (Troxler et al., 1997) but there 
is evidence for transmembrane regions in the coding sequence of MUC4, suggesting it 
is a membrane bound mucin (Moniaux et al., 1999). It is possible that the MUC4 
detected is a cleavage product rather than a secreted mucin; a similar situation to that 
which occurs with MUC 1 in the breast (Boshell et al., 1992). MUC 1 is a membrane- 
bound mucin whose sequence includes a transmembrane domain (Gendler and Spicer, 
1995). It is expressed on normal breast epithelium (Gendler et al., 1990) yet a soluble 
form exists in bodily fluids, for example in breast milk. There is evidence to suggest 
that the mucin is released from the membrane by the action of a protease, rather than 
being actively secreted (Boshell et al., 1992). 
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MG2 is a small, monomeric glycoprotein with a molecular weight of 1.25 x 105Da 
(Biesbrock et al., 1991). It is composed of 30.4% protein, 68% carbohydrate and 1.6% 
sulphate (Prakobphol et al., 1982). It does not polymerise, existing as a single 
polypeptide chain, an exception among the secreted mucins. MG2 has a lower number 
of 0-linked carbohydrate units than MG1, ranging in size from 2-7 residues (Levine et 
al., 1987). These carbohydrate units have been structurally defined (Reddy et al., 1985). 
At least two isoforms of MG2 can be distinguished (MG2a and MG2b) in human 
submandibular-sublingual saliva that differ in the amounts of fucose and sialic acid 
present (Ramasubbu et al., 1991). MG2 has been fully sequenced and is encoded by the 
MUC7 gene, localised on chromosome 4g13-q21 (Bobek et al., 1996). In situ 
hybridisation has shown MUC7 expression to be present in serous cells within the 
submandibular and sublingual glands (Nielsen et al., 1996). Evidence suggests that 
these structurally distinct mucins play different roles within the oral cavity. The 
enhanced rheological properties of the larger mucins lend themselves to coating 
functions whereas the smaller mucins have been shown to interact with a number of oral 
microorganisms in the soluble phase of saliva (Tabak, 1995). 
It has been demonstrated that MUC5B is a major fraction of the high K. salivary mucin 
(Desseyn et al., 1997; Nielsen et al., 1997; Thornton et al., 1999) therefore isolation and 
purification of this mucin would provide a good standard for MUC5B in quantifying the 
glycoproteins present in middle ear effusions (Hutton et al., 1998a) by ELISA. 
Previous methods to isolate the high Mr mucin from saliva have relied on the use of 4- 
8M guanidine hydrochloride (GuHCI) (Troxler et al., 1995; Mehrotra et al., 1998; 
Wickstrom et al., 2000), a chaotropic agent, as it was shown that using non-dissociative 
conditions, the low and high M, mucins co-purify as they have a tendency to form 
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multi-molecular aggregates (Nieuw Amerongen et al., 1995). GuHCI is a protein 
denaturant and therefore inhibits proteolysis. Treatment of isolated mucin with 4M 
GuHCI has been shown to lead to non-covalent aggregation (Snary et al., 1974) and the 
mucin was found to be of higher molecular weight than mucin isolated in salt solutions. 
The aggregates do not form gels at glycoprotein concentrations (above 30mg/ml) 
similar to that found in mucus in vivo (Hutton et al., 1983) suggesting that the mucin 
molecules have been altered in some way. For the above reasons, GuHC1 is not 
involved in the isolation of high M, mucin described in this chapter. 
The aim of this study was to separate MG1 from MG2 in human whole saliva. As 
MUC5B is a major component of MG1, a relatively pure MUC5B preparation would be 
obtained. 
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4.2 Preparation of human salivary mucus 
4.2.1 Purification of mucin by equilibrium density gradient ultracentrifugation in CsCI 
Human whole saliva was obtained from subjects chewing on Parafilm to induce 
secretions. Samples were collected into an equal volume of ice cold 0.067M phosphate 
buffer containing protease inhibitors (Fitzgerald et al., 1987). The saliva/buffer mixture 
was homogenised for 3-5 minutes using a Silverson mixer-emulsifier and the resulting 
homogenate centrifuged in an Eppendorf 5810R centrifuge at 9000rpm and 4°C for 1 
hour to remove unwanted cells and debris. The supernatant was filtered through glass 
wool to remove particulate matter and adjusted to a density of 1.42gm1"1 by addition of 
CsCl. Following ultra centrifugation at 100,000g and 4°C for 48 hours; the resulting 
gradient was divided into nine equal fractions. The density of each fraction was 
measured followed by exhaustive dialysis against distilled water at 4°C. Aliquots of 
each fraction were taken for the estimation of glycoprotein, protein and nucleic acid. 
Glycoprotein was determined using the PAS method (Mantle and Allen, 1978) and 
protein and nucleic acid were estimated by optical density measurements. 
A typical analysis of human whole salivary mucus (Figure 4.1) after equilibrium density 
ultracentrifugation in CsCI showed that there was a clear separation of glycoprotein in 
fractions 6-8 with density range 1.42-1.48gml"'. Contaminating protein (fractions 1-5) 
was discarded and fraction 9 is generally unused as it is the nucleic acid-containing 
fraction. From the results it was observed that saliva contained little or no DNA, this is 
because a secretion was collected rather than being scraped from the mucosa so few 
cells would be present. It appears that fractions 1 to 3 contained nucleic acid, but this is 
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due to the protein present also having some absorbance at OD260nm. Mucin-rich 
fractions 6-8 were pooled, exhaustively dialysed against distilled water, freeze dried and 
stored at -20°C. 
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Figure 4.1 Analysis of human salivary mucus after equilibrium density 
ultracentrifugation in CsCI. 
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(V) are shown. Protein and nucleic acid concentration were calculated after measuring 
absorbance at OD280nm and OD260nm respectively then extrapolating from a 
nomograph based on the extinction coefficients for enolase and DNA (Warburg and 
Christian, 1942). 
150 
123456789 
fraction number 
4.2.2 Isolation of purified high molecular weight mucin by gel filtration 
Gel filtration on Sepharose CL-4B was used to attempt to separate high molecular 
weight mucin (MUC5B) from low molecular weight mucin (MUC7) assumed to be 
present in the CsCI density centrifugation. 
Samples (lml) of CsCI purified salivary mucin (2mgm1'1,2.5mgml"' and 
3mgml-1) were loaded onto a Sepharose CL-4B gel filtration column (30 x 1.5cm) 
eluted with 0.2M sodium chloride (NaCl) containing 0.02% (w/v) sodium azide (NaN3) 
by downward flow. Fractions (lml) were collected and assayed for glycoprotein using 
the PAS method (Mantle and Allen, 1978). The elution profiles (n=3) showed a single 
population of glycoprotein to be produced, eluting in the void volume (V0) of the 
column, with a small shoulder (Figure 4.2) in the partially included volume. This may 
be due to the two mucins not separating properly because of the short column length or 
overloading of the column with sample or due to in vivo degradation products. 
To overcome this problem, Sepharose CL-2B was used which has beads with a larger 
pore size which would allow material eluting in the excluded volume on the Sepharose 
CL-4B column to be included on the CL-2B column and give two clear mucin 
populations. A longer column and smaller sample application were used to improve the 
separation characteristics. 
Samples (2ml) of mucin (lmgml"1) were loaded onto a Sepharose CL-2B gel filtration 
column (130 x 1.5cm) at 4°C. Mucin was eluted by upward flow of 0.2M NaCl 
containing 0.02% (w/v) NaN3 using a peristaltic pump. Fractions (3ml) were collected 
and assayed for glycoprotein using the PAS method as before. This was repeated twice 
and on each occasion the majority of the glycoprotein eluted in the void volume of the 
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column, Vo (Figure 4.3). Using Sepharose CL-2B column the salivary mucins showed a 
greater amount of material extending into the column volume than when CL-4B was 
used but there was still no clear separation of the two mucin populations. 
It would seem that without the presence of GuHCI, gel filtration seems to be 
unsuccessful in the separation of high and low molecular weight mucins as it appears 
that the two main mucins in saliva, MUC5B and MUC7 are being co-eluted. 
The CsCI fractionated mucin was significantly excluded (58% of eluted material) from 
the Sepharose CL-2B column with a tail of glycoprotein into the partially included 
volume (42%). The presence of lower molecular weight material is unlikely to be due to 
in vitro degradation because of inclusion of the cocktail of inhibitors in the isolation 
procedure and therefore likely to be due to in vivo products, some of which may 
represent degradation, present in the preparation from the collection stage. 
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Figure 4.2 Elution profile of iml of 2.5mgm1'1 human salivary mucin (purified 
using CsC1 density centrifugation) after gel filtration on Sepharose CL-4B. 
03nn 
C 
d 
O 
a 0 
0 
Volume eluted (ml) 
Fractions assayed for glycoprotein using PAS method (Mantle and Allen, 1978). Vo is 
the void volume of the column. VT is the total volume of the column. 
153 
0 10 20 30 40 50 60 70 80 
Figure 4.3 Elution profile of 2ml of lmgml"1 human salivary mucin (purified 
using CsCl density centrifugation) after gel filtration on Sepharose CL-2B. 
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the void volume of the column. VT is the total volume of the column. 
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4.2.3 SDS PAGE of salivary mucin preparations 
SDS PAGE was used to confirm the size and degradation state of the salivary mucin 
preparation. Samples (1 µl) of salivary mucin (5mgml' non-reducing or reducing buffer) 
were subjected to gel electrophoresis using a 4-15% gradient gel. Gels were stained for 
glycoprotein using the PAS method (Van Seuningen and Davril, 1992) and scanned at 
555nm. 
Following gel electrophoresis, purified salivary mucin largely remained (86±1.4% (n=2) 
of total mucin) within the stacking gel as two distinct peaks around the point of 
application (Figure 4.4A). All peaks within the stacking gel were denoted as band "a". 
A small proportion of mucin, clearly separate from band "a" and representing lower 
molecular size material, peaked in the running gel adjacent to the interface of the 
stacking and running gel. All material within the running gel close to the interface was 
denoted band "b". 
Following reduction of purified salivary mucin with 5% mercaptoethanol for 2 minutes 
at 100°C, the proportion of material in band "a" dropped from 86% to 28%, a drop of 
67%, indicating substantial breakdown of purified salivary mucin (Figure 4.4B). It was 
observed that some material had moved within the stacking gel (band "a""), 
demonstrating partial reduction. There was a corresponding increase (from 14% to 62%) 
in the proportion of low molecular size material in band "b" peaking adjacent to the 
interface and an appearance of lower molecular weight mucin (band "c"), 10% of the 
total material, extending further into the running gel than observed with the non-reduced 
salivary mucin preparation. 
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Figure 4.4 
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Graph A represents purified mucin (using CsCI density centrifugation) in non-reducing buffer. 
Graph B represents purified mucin after reduction with mercaptoethanol (x4 expansion). Band 
"a": mucin within the stacking gel, band "b": mucin spreading into the running gel from the 
interface. Band "a"": partially reduced material within the stacking gel. Band "c": lower 
molecular weight mucin extending further into the running gel than observed in the non-reduced 
preparation. The dashed line shows the interface of the stacking and running gel. 
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4.3 Antibody studies: detection of MUC5B and MUC7 in human saliva 
4.3.1 Presence of MUC5B and MUC7 in CsCI purified salivary mucin 
Samples of CsCI purified salivary mucin were blotted onto 0.45µm pore size 
nitrocellulose membranes and probed with antibodies raised to the human MUC5B and 
MUC7 gene products. The synthetic peptide used to generate the MUC7 polyclonal 
antiserum (section 2.4.2.1) was used as a positive control in the MUC7 ELISA and as a 
negative control in the MUC5B ELISA. Reactivity of the salivary mucins with the 
antibodies was determined using an ELISA slot blot assay and membranes were 
scanned at 595nm. 
MUC5B 
Purified salivary mucin (two preparations) was assayed for the presence of the MUC5B 
protein core using the TEPA antibody (section 2.4.2.1). This polyclonal antiserum was 
raised in rabbits to purified mucin from thick effusions of anatomically normal children 
and has previously been shown to react strongly with the MUC5B gene product in 
saliva. It is possible however that TEPA could react with MUC7 in the salivary mucins 
if MUC7 was present in the thick effusion mucin from which this polyclonal antibody 
was prepared. 
The salivary mucin from both preparations bound the TEPA antibody to a similar 
degree (Figure 4.5A). Saturation occurred after 0.1µg salivary mucin per well. There 
was no binding between the MUC7 peptide and the TEPA antibody. 
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MUC7 
A polyclonal antiserum raised in rabbits to a peptide sequence from the 
C-terminal domain of the human MUC7 gene product was used to probe mucins from 
both salivary mucin preparations, with up to 10µg material present per well. 
There was no binding by either mucin preparation to the MUC7 antiserum, however the 
MUC7 peptide reacted well with the antiserum (Figure 4.5B). Saturation occurred after 
1 µg MUC7 peptide per well. 
From these results it seemed that either MUC7 was not adhering to the nitrocellulose 
membrane due to its relatively small size or that the mucin had a lower buoyant density 
and was present in a fraction that was not pooled, i. e. not in fractions 5-8. 
4.3.2 Presence of MUC7 in whole saliva 
Human whole saliva was obtained from six subjects chewing Parafilm to induce 
secretion. Diluted (1 in 100 using PBS) whole saliva samples were blotted onto 
nitrocellulose membranes and probed with the antibody raised to the human MUC7 
gene product. 
Antibody binding was observed to varying degrees with all whole saliva samples 
(Figure 4.6). It was not possible to quantify the amount of MUC7 present in the saliva 
of each subject due to the use of a MUC7 peptide rather than a MUC7 mucin standard 
therefore the data are expressed as relative antibody reactivity (area under the peak from 
the Shimadzu scan). 
MUC7 can be detected in human whole saliva but not in purified mucin from saliva 
therefore MUC7 must be being lost in the CsCl purification stage, possibly due to its 
lower buoyant density. 
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Figure 4.5 
A) TEPA antibody binding to CsCI purified salivary mucin. 
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Figure 4.6 MUC7 polyclonal antibody binding to diluted whole saliva 
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Whole saliva was collected from six subjects, diluted in PBS and probed with the 
antibody raised to MUC7. Antibody binding was observed in samples from all donors. 
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4.3.3 Analysis of fractions from CsCI gradient 
Human whole saliva was collected and purified as previously described (Section 4.1.1). 
Following CsCI density gradient centrifugation, the resulting gradient was divided into 
nine equal fractions of 3.9m1. The empty centrifuge tubes were washed out with a 
further 3.9m1 of distilled water after mild agitation. This was labelled as fraction 0. It 
has been previously documented that MUC7 is a sticky mucin (Bolscher et al., 1999) 
and fraction 0 was used to measure the amount of material remaining in the centrifuge 
tube after fractionation. Each fraction was kept separate and exhaustively dialysed 
against distilled water, freeze-dried and stored at -20°C. 
Samples of each fraction were blotted onto 0.45µm pore size nitrocellulose membranes 
and probed with antibodies raised to the human MUC5B and MUC7 gene products as 
previously described (Section 4.3.1) in a slot blot ELISA. The MUC7 peptide and CsCI 
purified salivary mucin (shown to be mainly MUC5B and containing no MUC7) were 
used as positive or negative controls in each assay. Reactivity of each fraction with the 
antibodies was determined using an ELISA slot blot assay and membranes were 
scanned at 595nm. 
MUC5B 
TEPA antibody binding was observed in all fractions 1-9 and 0 (Figure 4.7), in the 
current saliva preparation most MUC5B was present in fractions 4-7. There was no 
reactivity between the MUC7 peptide and the TEPA antibody (negative control), this 
data is not shown. 
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MUC7 
The MUC7 antiserum reacted well with the MUC7 peptide and not at all with the 
purified salivary mucin (negative control) (Figure 4.8). The membrane was scanned 
using different parameters to those in Figure 4.5, which explains the apparent difference 
in reactivity with the MUC7 antibody in the two assays. MUC7 mucin was detected in 
fractions 1-5 and 0. It was necessary to use a much greater amount of material on the 
slot blot to obtain reactivity with the antibody in the linear range of the standard curve 
against the MUC7 peptide than in the MUC5B ELISA (Figure 4.7) as it was calculated 
that one unit of peptide contained approximately 62.5 times more epitope than one unit 
of pure MUC7 (MUC7 peptide has a molecular weight of 2000 compared to the MUC7 
product molecular weight of 1.25 x 105). 
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Figure 4.7 Distribution of MUC5B in 9 fractions after CsCI density gradient 
centrifugation 
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Samples of each fraction from CsC1 density gradient were probed with MUC5B 
antibody in an ELISA assay and reactivity of each fraction was determined. 0.1 and I µg 
of material was sufficient to obtain antibody reactivity with the MUC5B antibody 
(TEPA). Binding was observed in all fractions, 1-9 and 0. 
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Figure 4.8 Distribution of MUC7 in 9 fractions after CsCI density gradient 
centrifugation 
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Samples of each fraction from CsCI density gradient were probed with MUC7 antibody 
in an ELISA assay and reactivity of each fraction was determined. It was necessary to 
use 10 and 20µg of fraction material in the ELISA in order to obtain reactivity with the 
MUC7 antibody. Binding was observed in fractions 1-5 and 0. 
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4.4 Discussion 
Salivary mucin purified by CsCI density gradient centrifugation was found to be highly 
reactive towards the anti MUC5B antisera (TEPA) and had no reactivity with the anti 
MUC7 antisera. This purified mucin preparation contained a significant amount of 
MUC5B and either no MUC7 or levels below detection and therefore can be used as a 
MUC5B standard in the quantification of this mucin in middle ear effusions. This is the 
first evidence that TEPA does not contain antibodies to MUC7, as the MUC7 peptide 
did not react with the antibody, however reactivity with MUC4 cannot be ruled out. 
After CsCI density gradient centrifugation of whole saliva, the distribution of 
components of salivary mucus was found to be similar to that which is typically found 
in glycoprotein-containing secretions (Creeth and Denborough, 1970; Denborough et 
al., 1971). Protein was present in the least dense fractions, mostly in fractions 1 and 2 
and very little or no nucleic acid was present. Glycoprotein was present in the lower, 
more dense fractions of the CsCI gradient. To obtain a salivary mucin preparation, 
thought to contain both the high and low molecular weight mucins found in saliva, the 
glycoprotein-rich fractions were pooled. 
It was expected that after gel filtration of the purified salivary mucin using a Sepharose 
CL-4B or CL-2B column eluted in sodium chloride azide, two distinct populations 
would be observed, corresponding to the MGl (MUC5B-containing) and MG2 (MUC7- 
containing) mucins in saliva. Instead, a single population of mucin was consistently 
produced which eluted in or close to the void volume of the column. The elution 
profiles produced from the short Sepharose CL-4B column shall not be discussed 
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further due to the possibility of the column being overloaded and not having sufficient 
volume available for diffusion to separate the mucins. 
From the Sepharose CL-2B column (130 x 1.5cm), the mucin population was 58% 
excluded with a tail of glycoprotein into the included volume. This is evidence of high 
molecular weight mucin within the preparation and also of the presence of some smaller 
molecular weight mucin molecules. 
Previous methods of separating the high and low molecular weight mucins in saliva 
have generally depended on the use of gel filtration columns eluted with guanidine 
hydrochloride (GuHCI) (Ramasubbu et al., 1991; Mehrotra et al., 1998; Wickstrom et 
al., 1998) and their results suggest that GuHCI is necessary for the separation of 
salivary mucin into its high and low molecular weight components. MUC7 has been 
labelled a `sticky' mucin (Bolscher et al., 1999) and the use of CHAPS in gel filtration 
columns appears to have aided the separation of the two populations. CHAPS is a 
zwitterionic detergent that disrupts hydrophobic interactions both within and between 
molecules. 
Due to the tendency of multi-molecular aggregate formation to occur when GuHCI is 
used in the isolation of high M, mucin and the effect this has on the properties and size 
of mucin molecules (Snary et al., 1974; Hutton et al., 1983; Hutton et al., 1988), GuHCI 
was not used in this study. The aim was to purify MUC5B mucin from whole saliva to 
be used as a glycoprotein standard and therefore all attempts were made to keep the 
epitope to which the antibody is raised intact. 
SDS PAGE gives further evidence regarding the degradation state of the mucin 
preparation; this has previously been validated as a method of measuring the 
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proportions of polymeric and degraded mucin (Rankin et al., 1995). 86±1.4% of the 
mucin was of high molecular size and remained at the point of application in the 
stacking gel of a 4-15% polyacrylamide gel. This is a much larger amount of high 
molecular size mucin than when gel filtration with Sepharose CL-2B is used. Gel 
filtration is based on the area available for diffusion of the molecules and there is 
potential for the shoulder to `spread'. With SDS PAGE there is an absolute cut off point 
at a particular percentage of polyacrylamide so the material must either remain in the 
stacking gel at the point of application or move into the running gel. 
After reduction using mercaptoethanol for 2 minutes at 100°C, there was a decrease in 
the purified mucin size, however 28% of the mucin still remained in the stacking gel, 
suggesting reduction was not complete. The change of size with reduction is evidence 
of a polymeric structure based on disulphide bridges, a structure previously reported for 
MUC5B (Loomis et al., 1987). These results are similar to those obtained in a study 
(Kawagishi et al., 1990) where purified high molecular weight mucin samples from 
submandibular-sublingual saliva were reduced using 0.2M mercaptoethanol for 2 hours 
at 37°C before electrophoresis. Glycoprotein was assayed using the PAS-Schiffs 
method. Non-reduced mucin all remained in the stacking gel whereas with the (reduced) 
mucin exposed to mercaptoethanol, the glycoprotein staining was less intense in the 
stacking gel and material was also present at the interface and in the running gel. The 
material in the running gel was defined as a `link component' and was approximately 
150,000 Da. 
The results in both this study and others demonstrate partial dissociation of the mucin 
into its structural subunits, which is characteristic of many polymeric secreted mucins 
and is indicative of a breakdown of polymeric structure by cleavage of subunit 
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disulphide bridges in the non-glycosylated regions of the protein core. For complete 
dissociation of the mucin preparation into subunits, mercaptoethanol exposure time 
must be longer, up to 48 hours (Pearson et al., 1981). 
Antibody studies 
Analysis of mucins present in purified salivary mucin, human whole saliva and the 
separate fractions of a CsCl gradient after ultra centrifugation was undertaken using the 
TEPA antiserum (high MUC5B specificity) and an anti-MUC7 antiserum. 
The specificity of the TEPA polyclonal antiserum has been determined by 
immunohistochemical and papain digestion studies (Hutton et al., 1998b) and almost 
certainly recognises a protein epitope in the non-tandem repeat region of MUC5B 
(Hutton et al., 1998a). The anti-MUC7 polyclonal antiserum was raised to a peptide 
sequence at the C terminal end of the MUC7 molecule (Bobek et al., 1993). It was 
found to react with MUC7 specifically and neither purification nor concentration of the 
salivary samples tested was necessary for detection of MUC7 (Bolscher et al., 1999). 
CsCl purified salivary mucin reacted with the anti-human MUC5B antibody, TEPA but 
not with the anti-human MUC7 antiserum, suggesting that the purified mucin consisted 
of mainly the MUC5B gene product and thus providing a significantly pure standard. It 
has been documented that MUC4 is also present as a minor component of the high 
molecular weight mucins (MG1) (Troxler et al., 1997) as a very weak signal was 
generated by a MUC4 probe with RNA from sublingual and submandibular glands. 
Although there is evidence to suggest that MUC4 is a membrane-associated mucin due 
to the presence of a membrane-spanning hydrophobic domain (Moniaux et al., 1999), it 
may also be present in a soluble form or as a cleavage product like MUC 1 (Boshell et 
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al., 1992). In conclusion, the salivary mucin preparation may not be 100% MUC5B and 
this should be taken into account when measuring levels of this mucin in other samples. 
Human whole saliva was found to react with the anti-MUC7 antiserum in samples from 
six individuals, confirming the presence of MUC7 in whole saliva and the apparent loss 
of this mucin during the purification stages. At present, no MUC7 standard is available, 
so quantification of mucin levels is not possible, only a comparison of MUC7 levels 
between individuals. 
Analysis of the nine individual fractions and the washout fraction from the CsCI 
gradient showed the distribution of MUC5B to be in the fractions with higher density 
(1.45-1.55gm1"1) as previously demonstrated. MUC7 was detected in fractions 1-5, the 
lower density fractions. A significant amount of MUC7 had remained in the centrifuge 
tubes after fractionation as the washout fraction (fraction 0) contained a relatively large 
amount of MUC7. As MUC7 has been reported to be sticky, this could be the reason for 
the considerable amount of MUC7 remaining in the centrifuge tubes. It is possible that 
MUC7 is interacting with other components in the preparation such as bacterial cell 
wall material that would be present at the top of the gradient in fraction 1. The ionic 
strength in this fraction would be only 1.3gml"', which may not be enough to dissociate 
the mucin from other protein/lipid components. Also, potentially there are breakdown 
products of MUC7 present in a range of sizes that would appear higher up the gradient 
than the whole MUC7 molecule. A much smaller amount of MUC5B had been left in 
the centrifuge tubes. No cross reactivity was observed between the MUC7 peptide and 
the TEPA antibody showing that the TEPA antibody was recognising MUC5B and 
possibly MUC4 and that mucins in middle ear effusions do not contain MUC7. There 
was no binding between the CsCI purified salivary mucin and the MUC7 antibody 
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confirming that although MUC7 is present in whole saliva it is absent from the CsCI 
purified high density mucin preparation. In the first salivary mucin preparation (section 
4.2.1), fractions 6-8 were the glycoprotein-rich fractions yet in the second preparation 
(section 4.3.3) the glycoprotein was mainly found in fractions 4-7. This can be 
explained by slight differences in the starting densities of the supernatants before 
caesium chloride density gradient ultra centrifugation. The glycoprotein is always 
present at the same buoyant density after centrifugation; however the fractions in which 
it is present can vary depending on the starting density of the supernatant. 
MUC7 is a small, monomeric glycoprotein which is much less glycosylated than 
MUC5B (Levine et al., 1987). The buoyant density of proteins in aqueous caesium 
chloride is approximately 1.3gml"1 and that of carbohydrate is approximately 1.6gm1"' 
(Creeth and Denborough, 1970) therefore the less glycosylated glycoprotein, MUC7 
appears at a lower density than MUC5B. 
It is not possible to directly compare the levels of MUC5B to MUC7 due to the relative 
reactivity with their respective antibodies and mucin standards are necessary. The ratio 
of MUCSB to MUC7 found in different studies varies depending on the collection 
protocols used, either human whole saliva or specific glandular secretions, this is due to 
the two mucin populations, MGI and MG2 being differentially expressed by the major 
and minor salivary glands. If the subjects are stimulated to produce saliva by the use of 
acetic acid, then their salivary mucin profile may be different from saliva from subjects 
produced under non-stimulated conditions. It has been demonstrated that the relative 
contribution of each salivary gland to the total saliva present changes depending on 
gland stimulation (Veerman et al., 1996). 
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In conclusion, the separation of a high molecular weight mucin from human whole 
saliva has been achieved using CsCI density gradient centrifugation. This mucin reacts 
very well with the TEPA antibody and appears to be a good, relatively pure and 
polymeric MUC5B standard. This will be used to quantify the amount of MUC5B gene 
product present in middle ear effusions of patients with otitis media with effusion. 
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CHAPTER 5 
CHARACTERISATION AND 
ANALYSIS OF 
MIDDLE EAR EFFUSIONS 
Chapter 5 Characterisation and analysis of middle ear effusions 
5.1 Introduction 
Middle ear effusions are viscous, mucin-rich secretions that accumulate in the middle 
ear cleft after a change in the mucosal epithelium from a columnar to a secretory type. 
This change occurs after inflammation of the middle ear, which can be caused by many 
factors including bacteria and their products, Eustachian tube dysfunction or by the 
presence of gastric refluxate. Due to their high viscosity the effusions are not cleared by 
the mucociliary transport system, as the cilia cannot deform the effusions in order that 
they be moved. Mucins are a major component of middle ear effusions (up to 32% of 
non-dialysable solids) and are responsible for their rheological properties (Carrie et al., 
1992). 
Previous studies regarding the analysis of mucins in the middle ear have involved in situ 
hybridisation to assess mucin gene expression in human middle ear mucosa 
(transcription) and immunohistochemistry and slot blot ELISA to measure the gene 
products present in the tissue and in the secretion respectively (translation). 
In situ hybridisation 
In a study by Severn (Severn et at, 1999) middle ear biopsy sections from patients 
undergoing middle ear surgery for OME were analysed for the expression of MUCI, 
MUC2, MUC3, MUC4, MUC5AC, MUCSB, MUC6 and MUC7 and all mucin genes 
except MUC3 and MUC6 were found to be expressed in the tissues. MUCI, MUC2, 
MUC4 and MUC5AC were expressed at the surface of the epithelium (MUC2 and 
MUC5AC in goblet cells) and were ranked (by intensity of expression and number of 
samples expressing the gene) as MUC4 > MUC5AC > MUCI > MUC2. MUCSB, 
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MUC4 and MUC7 were expressed in the submucosal glands in the rank order MUC5B 
> MUC4 > MUC7. In this study, MUC4 was found to be most consistently expressed, 
however there is strong evidence to suggest that MUC4 is a membrane-bound mucin 
(Moniaux et al., 1999) and it is possible that this mucin has a role in a glycocalyx that 
could protect the mucosa of the middle ear. Apart from MUC4, the mucin genes that 
were expressed in the highest intensity were MUC5B and MUC5AC, which are known 
to be secreted mucins (Gendler and Spicer, 1995). This study demonstrated that there 
was a broad range of mucin genes expressed by the inflamed middle ear mucosa and 
that the expression was generally related to a particular cell type as MUC5AC was 
found in goblet cells and MUC5B found in mucus glands. 
Kawano and co-workers (Kawano et al., 2000) detected MUC5B mucin gene 
expression only in cells located in gland-like structures in the submucosal area of 
middle ear mucosal specimens from patients undergoing middle ear surgery for OME. 
This study did not measure expression of any other mucin genes. 
Lin and co-workers (Lin et al., 2001) analysed middle ear tissue specimens (from 
subjects with and without OME) for the presence of MUCI, MUC2, MUC3, MUC5AC, 
MUC5B and MUC6 mucin mRNA. There is very little data regarding mucin gene 
expression in the normal middle ear and this study gives a comparison between the 
normal and diseased (inflamed) ears. In the normal tissues, only the MUC5B gene was 
expressed but in the inflamed ears expression of MUC5B and MUC4 mucin genes was 
detected. Extensive and strong positive signals with MUC5B mucin antisense riboprobe 
and extensive positive signals with MUC4 antisense riboprobe were demonstrated but 
the tissue distribution of these signals was not recorded. 
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There seems to be a general consensus from in situ hybridisation studies that in the 
inflamed middle ear MUC5B gene expression is detected in the submucosal glands and 
is at a higher level than in the normal, uninflamed ear (Lin et al., 2001). These studies 
by Lin et al. and Severn et al. (Severn et al., 1999) have demonstrated that other mucin 
genes are also expressed in the inflamed ear. From the ranking of levels of expression 
(Severn et al., 1999) it can be seen that there is greater expression of the secreted 
mucins than the membrane associated mucins (with the exception of MUC4). It has 
previously been shown that tissue expression does not always correlate with the 
presence of the relevant gene product in the secretion (Thornton et al., 1996) and this is 
demonstrated by a comparison of the results from in situ hybridisation to 
immunohistochemistry and slot blot ELISA studies on middle ear biopsy sections and 
middle ear effusions. 
Immunohistochemistry 
Hutton et al. (Hutton et al., 1998b) analysed middle ear mucosa sections from surgical 
tissue sections for expression of MUC5B and MUC5AC using relevant antibodies and 
found MUC5AC protein present in goblet cells alone and MUC5B protein present only 
in submucosal mucus glands. A similar result was recently obtained by Chung et al. 
(Chung et al., 2002) after middle ear mucosa sections were probed with a monoclonal 
anti-MUC5AC antibody and a positive reaction was observed in the goblet cells. These 
studies agree with the in situ hybridisation results in that the mucin genes MUCSB and 
MUC5AC are expressed by the inflamed middle ear mucosa and that the secreted 
protein products can be detected in the submucosal mucus glands and goblet cells of the 
mucosa. 
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Lin et al. (Lin et al., 2001) demonstrated by immunohistochemistry that there was 
extensive expression of MUCSB and MUC4 in the inflamed middle ear epithelium 
compared to a weak expression of MUC5B in the normal middle ear epithelium and no 
other glycoprotein was detected. This data demonstrates both an upregulation in gene 
expression and a change in the pattern of expression. 
ELISA 
Purified mucin from middle ear effusions has been analysed to identify the mucins 
present in the secretion. To date the mucins present have only been measured in 
effusion pools (Hutton et al., 1998a; Lin et al., 2001) and never in individual secretions. 
In the study by Lin (Lin et al., 2001), middle ear effusions were suspended in guanidine 
hydrochloride (GuHC1) and incubated for 24 hours with dithiothreitol (DTT), a reducing 
agent, and a cocktail of proteolytic inhibitors. Insoluble substances and debris were 
removed by centrifugation at 8000g for 20 minutes then the samples were subjected to 
purification by caesium chloride density gradient centrifugation and the mucin rich 
fractions were pooled. Mucin-rich fractions were defined as those fractions with a 
density of 1.35 to 1.45gm1"1 and a hexose to protein ratio of 2: 1 or above and the mucin 
was probed with antibodies raised to MUC5B and MUC4 in a 96 well plate direct 
ELISA where the sample or standard was loaded directly onto the plate without capture 
by an antibody. 
The MUC5B and MUC4 antibodies reacted positively with the mucin however MUC4 
had only one third of the reactivity of MUC5B. These were the only two mucins 
measured. In this study, DTT and GuHCI were used in the isolation of the mucin and it 
has been shown that the use of GuHCI can lead to alterations in the mucin molecules as 
mucins isolated in GuHCI do not form gels at concentrations similar to those found in 
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mucus in vivo (Hutton et al., 1983). DTT is a reducing agent that changes the polymeric 
structure of the mucin by breaking disulphide bridges between mucin molecules. This 
could affect the buoyant density of the mucins so that after caesium chloride density 
centrifugation some of the mucins may be present at a lower or higher buoyant density 
than the range set for the presence of mucin and therefore would not be tested. 
Hutton et al. measured the mucin content of two pools of middle ear effusions from 
anatomically normal children, one pool containing effusions classified as thick (mucoid) 
and the other containing thin (serous) effusions. The effusions were solubilised by 
homogenisation in 0.067M sodium phosphate buffer, pH6.7 containing a cocktail of 
proteolytic inhibitors so that the mucins were present in as undegraded a state as 
possible. Soluble mucin was purified by two caesium chloride density gradient 
centrifugation stages. The purified mucins were deglycosylated and probed with 
antibodies raised to the non-glycosylated regions of MUC5AC, MUC5B and MUC2 
and to the tandem repeat sequence of MUC 1 in a slot blot ELISA. 
The MUC5AC antibody recognised epitopes in mucin from both the thick and thin 
effusion pools but the thick effusion mucin was approximately three times more reactive 
than thin effusion mucin. Mucin from both effusion pools reacted with the MUC5B 
antibody, the thin effusion pool again had only a third of the reactivity of the thick 
effusion pool. No reactivity was found with either effusion pool against MUCI or 
MUC2. This study suggests that MUC5AC and MUC5B are the mucins present in 
middle ear effusions, with MUC5B being the major secretion and MUC5AC present at 
much lower levels (accounting for a maximum of 15% of the effusion weight) and 
shows that it is important to identify the mucin gene products present in mucus 
secretions as well as to identify the genes expressed. 
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Kawano and co-workers (Kawano et al., 2000) showed that an increase in MUC5B 
mucin mRNA transcripts had a statistically significant correlation with leukocyte 
numbers in the submucosa, suggesting that inflammatory cell products such as 
cytokines and other mediators could upregulate expression of the MUC5B mucin gene 
in the middle ear cleft. 
Many inflammatory mediators have been identified in middle ear effusions such as 
arachidonic acid metabolites, histamine, surface cell adhesion molecules and chemokine 
RANTES (regulated upon activation, normal T cell expressed and secreted) (Jung, 
1988; Skoner et at, 1988; Bundo et at, 1996; Schousboe et at, 2001b). Several 
cytokines have also been measured, including IL-1p, IL-2, IL-6, IL-8, IFNy and TNFa 
(Yellon et al., 1991; Himi et at, 1992; Yellon et al., 1992; Maxwell et al., 1994; 
Takeuchi et at, 1994; Yellon et al., 1995; Pospiech et at, 2000; Skotnicka and 
Hassman, 2000; Schousboe et at, 2001 a) and there is evidence to support a regulatory 
role of cytokines in the expression of inflammation in OME (Yellon et al., 1995) via 
their ability to stimulate chemotaxis, immunoglobulin production, lymphocyte 
proliferation and other cytokine production. Cytokines have the potential to contribute 
to the pathology of otitis media as demonstrated by the induction of mucus 
hypersecretion in a rat model in vivo and in a human colon carcinoma-derived mucus 
secreting cell line in vitro (Lin et al., 2000; Smirnova et al., 2001; Smirnova et al., 
2002a) and could therefore participate in the production of mucin rich effusions in the 
middle ear cleft in OME. 
The pro-inflammatory cytokines TNF-a, IL-lß, IL-6 and IL-8 are likely to play a central 
role in middle ear inflammation and in the stimulation of the pathological background 
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of OME (Fig. 5.1), as they are present in middle ear effusions at high concentrations. 
The incidence and highest mean concentration values are shown in Table 5.1. 
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Figure 5.1 Summary of the pro-inflammatory cytokine network in middle ear 
inflammation (from Smirnova et al. (Smirnova et al., 2002b)) 
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Table 5.1 Concentration of cytokines in middle ear effusions 
Concentration pgmg'1 protein Incidence Reference 
TNFa 234.2 ± 109.1 63 - 91 % (Yellon et al., 
1991; Johnson et 
al., 1997) 
IL-10 4076 ± 1510 51 - 97% (Yellon et al., 
1991; Johnson et 
al., 1997) 
IL-6 173.9 ± 74.7 36 - 83% (Yellon et al., 
1992) 
IL-8 4805 ± 913 92 - 100% (Maxwell et al., 
1994; Johnson et 
al., 1997) 
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IL-6 and IL-8 are considered to be the secondary pro-inflammatory cytokines, whose 
secretion is stimulated by TNF-a and IL-10. Concentrations of IL-6 and IL-8 in middle 
ear effusions are shown to positively correlate with IL-1ß and TNF-a (Maxwell et al., 
1994; Yellon et at, 1995; Skotnicka and Hassman, 2000) demonstrating the inter- 
connection of cytokine production during the pathogenesis of OME. 
A human colon carcinoma-derived mucus secreting cell line (HT29-MTX), which 
produces a homogenous monolayer of goblet cells secreting MUC5AC and MUC5B 
and therefore is similar to the middle ear mucosa, has been used to study the effect of 
TNF-a, IL-6 and IL-8 on mucin gene expression in time response studies (Smimova et 
al., 2000; Smimova et aZ, 2001; Smimova et al., 2002a). The cell line was stimulated 
with known concentrations of human recombinant TNF-a, IL-6 or IL-8 and mucin 
secretion was quantitated in the culture medium using an ELISA at regular time 
intervals, using antibodies directed against MUC5AC and MUCSB. The results were as 
shown below: 
Cytokine Mucin Maximum Persistence of Mucin level over 
secretion secretion time secretion control cells: 
detected MUC5AC, MUC5B 
TNF-a 2 hr 7 hr 36 hr 56%, 15% 
IL-6 4 hr 24 hr 72 hr 33%, 9.6% 
IL-8 12 hr 72 hr 5 days 24%, 15% 
The above data demonstrates that mucin secretion is induced in different ways. TNF-a 
induced a rapid, short-term mucin secretion, stimulation of mucin secretion by IL-6 was 
delayed and more prolonged and IL-8 had the most delayed and prolonged effect. These 
results suggest that TNF-a could be important in the first stage of the inflammatory 
process in the middle ear due to the high and rapid stimulation of mucin secretion. IL-6 
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may be responsible for maintaining the inflammation due to the lower level of mucin 
and prolonged mucin secretion and IL-8 may contribute to the maintenance of chronic 
OME by inducing prolonged mucin secretion from the goblet cell population. All 
cytokines induced higher levels of MUC5AC secretion than MUC5B secretion, 
suggesting that the mucin genes are induced in different ways and are unlikely to be 
controlled in the same manner. 
The above studies demonstrate that in the HT29-MTX cell line, the proinflammatory 
cytokines upregulate mucin production, in particular MUC5AC, at different rates, for 
different periods of time and to different levels. 
The work described in this chapter involves the biochemical and rheological analysis of 
individual middle ear effusions to investigate if there are correlations between effusion 
specific viscosity, mucin content (MUC5B and MUC5AC) and cytokine levels that are 
significant and can be related to the in vitro situation. 
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5.2 Analysis of the glycoprotein component of middle ear effusions 
5.2.1 Middle ear effusion preparation 
Serous and mucoid middle ear effusions were randomly chosen from -20°C storage, 
thawed at 4°C and individually hand homogenised in a known amount of ice-cold 
0.067M phosphate buffer, pH6.5 containing a proteolytic inhibitor cocktail (Fitzgerald 
et al., 1987) (section 2.3.2) before analysis. Effusion sample volumes are very small and 
in some cases too viscous for accurate viscosity measurements, therefore a dilution in 
proteolytic inhibitor buffer was necessary. The storage temperature and a proteolytic 
inhibitor cocktail were used to ensure the samples were exposed to minimal in vitro 
degradation by endogenous enzymes that could affect their viscosity. 
5.2.2 Does the presence of proteoiytic Inhibitor buffer affect measurement of effusion 
parameters? 
5.2.2.1 Effusion non-dialysable solids 
The content of non-dialysable solids (NDS) in effusions homogenised in proteolytic 
inhibitor buffer (n=54) was determined by weighing the lyophilised homogenates after 
exhaustive dialysis at 4°C against distilled water and freeze drying (section 2.5.2). This 
was compared to lyophilised effusions homogenised in distilled water (n=11). The 
content of NDS in effusions homogenised in inhibitor buffer ranged from 0.49 to 
41.3mg per effusion with a mean of 12.79 ± 1.21 (n=54) (mean ±I SEM (n)). The 
amount of NDS in effusions homogenised in distilled water ranged from 3.9 to 29.4mg 
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per effusion with a mean of 14.18 f 2.14 (n=11) (Figure 5.2). There was no significant 
difference in NDS content between the two groups (P=0.628, unpaired t test). 
5.2.2.2 Pig gastric mucin 
Aliquots (4O0µ1) of a lmgml"' solution of papain digested SIGMA pig gastric mucin 
were added to 2m1 of proteolytic inhibitor buffer (n=6) or distilled water (n=4). The 
glycoprotein content of the lyophilised samples was determined after exhaustive dialysis 
at 4°C against distilled water and freeze drying, using the modified PAS method 
(Mantle and Allen, 1978) (section 2.4.4) with papain digested SIGMA gastric mucin as 
a standard. 
The average amount of glycoprotein detected after exposure to proteolytic inhibitor 
buffer was 85.85% compared to 82.3% with glycoprotein solubilised in distilled water 
(data not shown). Pig gastric mucin appears to be unaffected by treatment with 
proteolytic inhibitors and is therefore detected in the PAS assay at a similar level to 
glycoprotein present in distilled water. 
5.2.2.3 Glycoprotein content of effusion non-dialysable solids 
The glycoprotein content of effusion NDS was estimated, after resolubilising a known 
amount of each effusion NDS in distilled water, by the modified PAS method (Mantle 
and Allen, 1978). 54 effusions were originally homogenised in proteolytic inhibitor 
buffer and 11 were homogenised in distilled water, the glycoprotein content of effusions 
in the two groups were compared. 
The glycoprotein content of NDS from effusions homogenised in inhibitor buffer 
ranged from 2.34 to 18.76% of NDS with a mean of 5.61 ± 0.39 (n=54). The 
glycoprotein content of NDS from effusions homogenised in distilled water ranged from 
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15.54 to 48.55% of NDS with a mean of 32.97 ± 3.31 (n=11) (Figure 5.3). There was a 
significant difference in glycoprotein content of NDS between the two groups 
(P<0.0001, unpaired t test). The addition of proteolytic inhibitors during isolation gives 
a 5.9 fold underestimation of the glycoprotein content, consequently for all further 
experiments using effusion mucin isolated in proteolytic inhibitor buffer, the values 
derived from the PAS assay have been corrected by this factor. 
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Figure 5.2 Non-dialysable solids (NDS) content (mg) of effusions 
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Effusions homogenised in proteolytic inhibitor buffer (s) n=54, or distilled water (A) 
n=11, dialysed, freeze dried and weighed. There was no significant difference in NDS 
content between the two groups (P=0.628, unpaired t test). 
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Figure 5.3 Glycoprotein content of effusion non-dialysable solids (NDS) 
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A known amount of each effusion NDS, previously homogenised in proteolytic 
inhibitor buffer (a) n=54 or in distilled water (A) n=11, was resolubilised and analysed 
for the presence of glycoprotein using the PAS method (Mantle and Allen, 1978). There 
was a significant difference in glycoprotein content of NDS between the two groups 
(P<0.0001, unpaired t test) leading to an approximate 5.9 fold underestimation in 
glycoprotein content in those samples homogenised in proteolytic inhibitor buffer. 
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5.2.3 Rheoiogicai properties and glycoprotein composition of effusions 
5.2.3.1 Effusion rheology 
In the following study a reduced number of effusions (n=50) were used because all 
parameters were not measured in all samples. Thirty-six of these effusions were 
classified by clinical inspection as mucoid (thick), the remainder were serous (thin). 
The specific viscosities of homogenised effusions (n=50) were measured at pH6.5 and 
37°C in the presence of proteolytic inhibitors using a Contraves low shear viscometer 
(section 2.5.1). The viscosities of the homogenates varied between 0.06 and 0.22 with a 
mean of 0.11 ± 0.017 (n=11) for serous effusions and between 0.12 and 5.0 with a mean 
of 1.24 ± 0.21 (n=39) for mucoid effusions. There was a significant difference 
(P=0.0061, unpaired t test) between the viscosities of the two types of effusion. 
In order to ascertain which of the components present in the effusions influence the 
viscosity, the content of each component was plotted against specific viscosity and the 
statistical correlation was determined. 
5.2.3.2 Effusion non-dialysable solids 
The content of NDS in the effusions was determined as before by weighing the 
lyophilised homogenates after exhaustive dialysis against distilled water at 4°C and 
freeze-drying. The NDS ranged from 0.49 to 41.3mg with a mean of 13.29 ± 1.27 
(n=50). 
There was a significant correlation between the specific viscosity of each effusion 
homogenate and the NDS content (P=0.0002, Pearson correlation) (Figure 5.4). This 
result demonstrates a dilution effect, as viscosity depends on a number of parameters 
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including the concentration of the solution, in general the more concentrated the 
solution the more viscous it is. 
5.2.3.3 Effusion glycoprotein content 
The glycoprotein content of the effusion homogenates was determined by the modified 
PAS method (Mantle and Allen, 1978), after resolubilising a known amount of each 
effusion NDS in distilled water. The glycoprotein content was expressed in mg per 
effusion and ranged from 0.31 to 13.05mg with a mean of 3.84 ± 0.44 (n=50). 
There was a significant correlation between the specific viscosity of each effusion 
homogenate and the glycoprotein content of the effusion (P=0.0026, Pearson 
correlation) (Figure 5.5). This can easily be explained, as glycoprotein is a polymer and 
in high glycoprotein concentration solutions, such as in middle ear effusions, 
interactions between the polymer chains will increase the viscosity of the solution. 
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Figure 5.4 The relationship between specific viscosity at pH6.5,37°C of middle 
ear effusion homogenates and NDS content 
.! B 
a 
Non-dialysable solids content (mg) per effusion (0) was plotted against specific 
viscosity. There was a significant correlation between the two parameters (P=0.0002, 
Pearson correlation). 
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Figure 5.5 The relationship between specific viscosity at pH6.5,37°C of middle 
ear effusion homogenates and glycoprotein content 
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Glycoprotein content (mg) per effusion (s) was plotted against specific viscosity. There 
was a significant correlation between the two parameters (P=0.0026, Pearson 
correlation). 
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5.2.3.4 Purification and analysis of mucin from effusions 
For the analysis of mucin from effusions the thick effusion samples only (n=36) were 
used as they contain more mucin. It has been previously demonstrated that thin 
effusions have only 57% of the mucin of thick effusions (Fitzgerald et al., 1988). 
The remaining lyophilised material from each thick effusion was solubilised in 0.2M 
NaC1/0.02% NaN3 and caesium chloride was added to give a starting density of 
1.42gm1"t. The effusions were centrifuged at 100,000g for 48h at 4°C using a fixed 
angle rotor (section 2.5.3). This CsCI purification procedure gives clear separation of 
glycoprotein material from protein contamination. The content of each centrifuge tube 
was separated into nine equal fractions, the density of each fraction was measured and 
those with densities of 1.42-1.55gm1"l (the characteristic buoyant density range for 
glycoprotein (Fitzgerald et al., 1987)) were pooled for each effusion. After exhaustive 
dialysis at 4°C against distilled water and freeze-drying, the glycoprotein present in 
each effusion was blotted onto nitrocellulose sheets (0.45µm) and incubated overnight 
at 4°C in PBS containing 2% (w/v) BSA. The glycoprotein was then probed with 
antibodies raised to the human MUC5AC (NCL-HGM-45M1) and MUC5B gene 
products (TEPA) (section 2.4.2.1) in a slot blot ELISA assay along with the appropriate 
CsCI purified standards (pig gastric mucin for MUC5AC and human salivary mucin for 
MUC5B (Chapter 4)). Antibody binding was measured with the relevant secondary 
antibodies conjugated to peroxidase with H202 as substrate and 3,3'-diaminobenzidine 
hydrochloride for colour development. Staining of the slots was quantitated using a 
Shimadzu scanning densitometer at 595nm. 
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From the ELISAs, the amount of MUC5B and MUC5AC present in 100µg of each CsC1 
purified effusion was determined, expressed as a percentage, and then the content (mg) 
of each mucin per effusion was calculated from the total glycoprotein content (Table 
5.2). Two of the 36 effusions were excluded from the data as the levels of MUC5B fell 
out of the normal range and were 6.5 and 20.6-fold higher than the others. 
MUC5B was present in all 34 effusions in the range 0.006 to 11.35mg with a mean of 
2.13 ± 0.46 (n=34). 
MUC5AC was present in thirty-two of thirty-four effusions in the range 0.002 to 
1.56mg with a mean of 0.16 ± 0.06 (n=32). MUCSAC was present in much smaller 
amounts than MUCSB. 
The mucin content of each effusion was plotted against specific viscosity and the 
statistical correlation determined. There was a significant correlation between MUC5B 
and specific viscosity (P<0.0001, Pearson correlation) (Figure 5.6) but no correlation 
existed between MUC5AC and specific viscosity (P=0.503, Pearson correlation) (Figure 
5.7). 
The above data demonstrates that effusion viscosity is related to the amount of MUC5B 
present (without taking into account the concentration). Effusion volumes varied 
between 0.042 and 0.51 ml and were solubilised in 2ml proteolytic inhibitor buffer 
therefore volume differences would have only a small effect on mucin concentrations. 
The amount of glycoprotein present in the effusions is important and the above data can 
also be expressed using the mucin concentration of the homogenates as they were 
measured. The mucin concentration of each effusion was calculated (mg MUCSB or 
MUCSAC per effusion / effusion homogenate volume) and plotted against specific 
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viscosity. The statistical correlation was determined and the results demonstrated that 
there was a significant correlation between MUC5B concentration and specific viscosity 
(P=0.0009, Pearson correlation) (Figure 5.8) but no correlation existed between 
MUC5AC concentration and specific viscosity (P=0.7155, Pearson correlation) (Figure 
5.9). 
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Table 5.2 MUC5B and MUC5AC content of effusions 
Mucin (µg) in 100µg CsC1 purified mucin 
MUC5B MUC5AC 
Mucin (mg) per effusion 
MUC5B MUC5AC 
90 4.4 0.929 0.045 
4.5 2.9 0.042 0.027 
35 5.1 0.853 0.126 
44 0.05 1.33 0.0016 
38 1.1 0.24 0.0073 
26 2.4 0.78 0.0731 
88 2.4 1.072 0.0287 
31 1.4 1.014 0.0437 
5.8 2.9 0.13 0.0676 
90.2 4.6 7.30 0.372 
104.7 3.8 6.91 0.254 
0.18 0.2 0.0056 0.007 
27.4 7.4 0.32 0.087 
17.4 0.6 1.54 0.0566 
14.7 1.9 1.59 0.203 
122.2 0.9 8.29 0.061 
0.8 0 0.047 0 
28 0 3.02 0 
63 32.1 3.06 1.56 
87 10.2 11.35 1.33 
95 17.7 4.06 0.757 
22.8 0.75 0.81 0.264 
101.2 0.9 3.91 0.357 
3.9 0.083 0.18 0.0038 
148.6 0.92 4.05 0.025 
125.5 11.1 1.76 0.156 
4.6 0.24 0.21 0.011 
24.5 2.03 0.56 0.046 
98 1.2 3.29 0.040 
102.3 0.75 2.14 0.0157 
28.4 0.82 0.29 0.008 
51 1.2 1.02 0.023 
20 1.24 0.32 0.0198 
4.3 0.18 0.13 0.0052 
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Figure 5.6 The relationship between specific viscosity at pH6.5,37°C of middle 
ear effusion homogenates and MUC5B content 
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CsCI purified mucins were blotted onto nitrocellulose membranes and tested for 
MUC5B by reactivity with TEPA in a slot blot ELISA. Staining of the slots was 
quantitated and the amount of MUC5B present in each effusion was calculated and 
plotted against specific viscosity. A significant correlation was observed between 
MUC5B and specific viscosity (P<0.0001, Pearson correlation). 
196 
0123456789 10 11 12 
MUC6B content (mg) 
Figure 5.7 The relationship between specific viscosity at pH6.5,37°C of middle 
ear effusion homogenates and MUC5AC content 
2 
8 
0 
CsC1 purified mucins were blotted onto nitrocellulose membranes and tested for 
MUC5AC by reactivity with NCL-HGM-45M1 in a slot blot ELISA. Staining of the 
slots was quantitated and the amount of MUC5AC present in each effusion was 
calculated and plotted against specific viscosity. There was no significant correlation 
between MUC5AC and specific viscosity (P=0.503, Pearson correlation). 
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Figure 5.8 The relationship between specific viscosity at pH6.5,37°C of middle 
ear effusion homogenates and MUCSB concentration 
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The MUC5B concentration of each effusion homogenate was calculated using the 
effusion homogenate volume and plotted against specific viscosity. A significant 
correlation was observed between MUC5B concentration and specific viscosity 
(P=0.0009, Pearson correlation). 
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Figure 5.9 The relationship between specific viscosity at pH6.5,37°C of middle 
ear effusion homogenates and MUC5AC concentration 
.0 
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The MUC5AC concentration of each effusion homogenate was calculated using the 
effusion homogenate volume and plotted against specific viscosity. No significant 
correlation was observed between MUC5AC concentration and specific viscosity 
(P=0.7155, Pearson correlation). 
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5.2.4 SDS PAGE of mucin from effusions 
SDS PAGE was used to confirm the size and degradation state of the mucin from thick 
effusions. Effusion mucin purified by CsC1 density centrifugation that remained after 
ELISA (section 5.2.3.4) was used. Samples (1µl) of effusion mucin (10mgm1'1 non- 
reducing buffer) were subjected to gel electrophoresis using a 4-15% gradient gel. Gels 
were stained for glycoprotein using the PAS method (Van Seuningen and Davril, 1992) 
and scanned at 555nm. 
Following gel electrophoresis, purified effusion mucin largely remained (83.5 ± 2.4%) 
within the stacking gel as two peaks around the point of application (Figure 5.10). All 
peaks within the stacking gel were denoted as band "a". A small proportion of mucin 
(approximately 16%), clearly separate from band "a" and representing lower molecular 
size material, peaked in the running gel adjacent to the interface of the stacking and 
running gel. This material was denoted band "b". There was no other PAS staining 
material present further into the running gel than band "°b", which showed the purified 
mucins to be free of any smaller molecular weight glycoproteins. All effusions tested 
gave a similar pattern. 
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Figure 5.10 SDS PAGE of non-reduced CsCI purified effusion mucin from thick 
effusions 
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Purified mucin, (after CsCI centrifugation) in non-reducing buffer from two different 
thick effusions. Band "a", mucin within stacking gel, band "b", mucin spreading into 
the running gel from the interface. The dashed line shows the position of the interface 
between the stacking and running gel. 
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5.3 Analysis of cytokines present in middle ear effusions 
5.3.1 Middle ear effusion preparation 
A subset of thick middle ear effusions (n=14) from the glycoprotein study (as described 
above) were also analysed for the presence of the cytokines interleukin-6 (IL-6) and 
interleukin-8 (IL-8) and the total protein content of the effusions was measured. After 
viscosity was measured but before the dialysis and freeze-drying stages, a 400111 aliquot 
of each effusion homogenate was removed. This aliquot was used to measure the 
cytokine and protein levels in the effusions. Since the dilution of samples varied, all 
data were expressed as pg (or µg) per mg NDS. 
5.3.2 Effusion rheoloay 
The measured viscosities of individual effusions were expressed as reduced specific 
viscosity (specific viscosity/concentration of NDS) to control for any hydration changes 
in the effusions on storage. This was necessary in order to directly compare the effusion 
parameters measured in this part of the study. 
5.3.3 Effusion protein content 
The protein content of the effusion homogenates was assayed using the method of 
Bradford (Bradford, 1976) (section 2.4.5), after diluting the samples in a known amount 
of 0.2M NaCI/0.02% NaN3. Bovine serum albumin was used as a standard. The protein 
content was expressed in µgmg'1 NDS. Protein content ranged from 649 to 961 µgmg"1 
NDS with a mean of 791 ± 29 (n=14). 
There was no correlation between the reduced specific viscosity and the protein content 
of each effusion homogenate (P=0.79, Pearson correlation) (Figure 5.11). 
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Figure 5.11 The relationship between reduced specific viscosity of effusion 
homogenates and protein content 
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Protein content µgmg"' NDS (u) for each effusion homogenate (n=14) was plotted 
against reduced specific viscosity. There was no correlation between the two parameters 
(P=0.79, Pearson correlation) 
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5.3.4 Effusion cytokine content 
The IL-6 and IL-8 content of effusions were measured by probing known volumes of 
the effusion homogenates and relevant standards with antibodies raised to the human 
IL-6 and IL-8 gene products using a quantitative sandwich enzyme immunoassay 
technique (section 2.4.3). Each cytokine was expressed as pgmg"' NDS. 
IL-6 ranged from 1.5 to 558.5pgmg"' NDS with a mean of 178 t 42.5 (n=14). IL-8 
ranged from 61.8 to 17130pgmg"' NDS with a mean of 4020 t 1317 (n=14). The 
content of the cytokines in each effusion were plotted against each other and against 
reduced specific viscosity to determine if any correlation existed. 
There was a significant correlation between the IL-6 and IL-8 content in effusions 
(P=0.0149, Pearson correlation) (Figure 5.12). This result demonstrates that one of these 
cytokines may be regulated by the other or that they are both regulated by a common 
factor such as another cytokine. There was no correlation between IL-6 and reduced 
specific viscosity (Figure 5.13), however a significant correlation did exist between IL-8 
and reduced specific viscosity (P=0.0267, Pearson correlation) (Figure 5.14) if one 
point was excluded. 
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Previous studies have expressed cytokine levels in effusions per mg protein and the 
results were also presented in this way to enable a direct comparison between this and 
previous results. 
Effusion IL-6 per mg protein IL-8 per mg protein 
1 47.32 813.99 
2 120.41 930.10 
3 224.38 1456.661 
4 2.27 93.05 
5 140.89 1518.05 
6 195.42 12340.02 
7 254.48 1604.40 
8 90.64 13922.66 
9 513.92 5323.46 
10 124.84 1176.32 
11 246.12 7640.05 
12 30.33 522.29 
13 542.54 5594.24 
14 615.10 18869.25 
IL-6 ranged from 2.27 - 615.1pgmg't protein with a mean of 224.9 ± 52.62 (n=14). 
IL-8 ranged from 93.05 to 18 870pgmg"1 protein with a mean of 5129 ± 1593 (n=14). 
The IL-6 content of effusions was generally much lower than IL-8 content, irrespective 
of the method of expressing the data. 
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Previous studies have reported IL-6 levels in effusions of 173.9 ± 75pgmg-1 protein 
(Yellon et aZ, 1992) and IL-8 levels of 4805 ± 913pgmg"t protein and 575 ± 50pgmg"1 
protein (Maxwell et al., 1994; Johnson et al., 1997) and the results shown in this current 
study fit very well with the above. 
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Figure 5.12 Correlation of IL-6 and IL-8 content in effusions 
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IL-6 content of effusions (pgmg" NDS) was plotted against IL-8 content (pgmg"' NDS) 
(. ) and the statistical correlation was determined. There was a significant correlation 
between the levels of the two cytokines (P=0.0149, Pearson correlation). 
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Figure 5.13 The relationship between reduced specific viscosity at pH6.5,37°C 
of middle ear effusion homogenates and IL-6 content 
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IL-6 content of effusions (pgmg"1 NDS) was plotted against reduced specific viscosity 
(u) and the statistical correlation was determined. There was no correlation between the 
IL-6 content and reduced specific viscosity in effusions (P=0.599, Pearson correlation). 
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Figure 5.14 The relationship between specific viscosity at pH6.5,37°C of middle 
ear effusion homogenates and IL-8 content 
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IL-8 content of effusions (pgmg4 NDS) was plotted against reduced specific viscosity 
(. ) and the statistical correlation was determined. There was a significant correlation 
between the IL-8 content and reduced specific viscosity in effusions (P=0.0267, Pearson 
correlation), but only when one point (circled) was excluded. 
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5.3.5 Is there a relationship between cytokine levels and the amount and type of mucin 
present in effusions? 
The MUC5B and MUC5AC content of each effusion (previously measured in section 
5.2.3.3 but calculated as mgmg-t NDS for this part of the study) were plotted against 
both the IL-6 and IL-8 content and the statistical correlations were determined. 
Parameters P value Is correlation significant? 
MUC5B and IL-6 1 0.6169 No 
MUC5B and IL-8 0.5085 No 
MUC5AC and IL-6 0.6220 No 
MUC5AC and IL-8 0.004 Yes 
MUC5AC had a significant correlation against IL-8 content in effusions (Figure 5.15), 
but only when one point was excluded, (which was the same point as excluded in Figure 
5.14). There were no other significant correlations between the parameters. 
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Figure 5.15 Correlation of MUC5AC and IL-8 content of effusion homogenates 
Cl) 
G 
Z 
v 
V 
V 
i 
IL-8 (pgn 1 NOS) 
IL-8 content of effusions (pgmg-1 NDS) was plotted against MUC5B content (mgmg'' 
NDS) (. ) and the statistical correlation was determined. There was a significant 
correlation between the IL-8 content and MUC5B in effusions (P=0.004, Pearson 
correlation), but only when one point (circled) was excluded. 
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5.4 Discussion 
In this study, the rheological and biochemical properties of individual middle ear 
effusions were determined. 
Middle ear effusions are generally very small and viscous therefore for accurate 
viscosity measurements each sample was diluted in 2m1 0.067M phosphate buffer. The 
buffer contained a wide range of proteolytic inhibitors (Fitzgerald et al., 1987) to 
minimise in vitro degradation by endogenous enzymes, which would affect the 
rheological properties of the samples. This extraction buffer has been shown to inhibit 
in vitro proteolysis during the isolation of cartilage proteoglycans (Pearson and Mason, 
1977), which are high molecular weight glycoconjugates, as are mucin glycoproteins. 
Mild homogenisation of the effusion has been shown to be necessary to solubilised the 
entire mucin population (Fitzgerald et al., 1987). 
Samples were collected from two different centres (Freeman Hospital, Newcastle and 
Queens Medical Centre, Nottingham) and it was impossible to measure the effusion 
viscosity immediately. The samples were stored frozen at -20°C until used, conditions 
that would inevitably lead to some dehydration. This effect has been taken into account 
by the expression of biochemical analyses (cytokines and protein only) using non- 
dialysable solids. 
In the preliminary study of the effect of proteolytic inhibitors it was found that middle 
ear effusions (n=54) isolated in the presence of a cocktail of inhibitors (and after 
dialysis and freeze drying) had a significantly lower level of measurable glycoprotein 
using the PAS assay than effusions isolated in distilled water (n=11), however the 
content of NDS in the two groups were similar (11.98mg and 14.18mg, respectively). 
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There was a 5.9 fold reduction in the glycoprotein estimation in effusions isolated in the 
presence of inhibitors compared to those isolated in distilled water. Detection of a 
known amount of papain digested SIGMA pig gastric mucin alone in the same assay 
system was similar regardless of whether inhibitors were present or not and was 
therefore unaffected by treatment using inhibitors. Previous studies have demonstrated 
that up to 32% of the NDS of effusions is glycoprotein (Fitzgerald et al., 1989; Carrie et 
al., 1992). The presence of the other effusion components is probably necessary to 
cause the proteolytic inhibitor interactions. 
The PAS assay consists of two reactions, oxidation of the glycoprotein by periodic acid 
followed by the condensing of Schiffs reagent (containing colourless Fuchsin- 
leocosulphonic acid) with the periodate-oxidised glycoprotein (containing aldehyde 
groups). Sulphonic acid and a glycoprotein-Fuchsin complex is produced which is red 
in colour. Proteolytic inhibitors could prevent access of the reagents to the sugars and 
interfere with ring cleavage and aldehyde formation or they could somehow interfere 
with colour development. Regardless of the mechanisms involved, the presence of 
proteolytic inhibitors reduced the estimation of glycoprotein content in middle ear 
effusions by a factor of 5.9 in this assay. 
Few studies have been undertaken to analyse individual effusions on the basis of their 
rheological and biochemical properties and relate effusion rheology to composition 
(Carrie et al., 1992; Johnson et at, 1997). In this study the viscosity of mucoid and 
serous effusions (n=50) was measured after mild homogenisation in a phosphate buffer 
containing proteinase inhibitors. Various research groups have attempted to measure 
dynamic viscosity of effusions without dilution by subjecting a small volume of 
effusion (4µl) to cyclic deformation and observing the deformation response of the 
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effusion (Majima et al., 1988; Takahashi et al., 1990) rather than measuring viscosity 
over a range of shear rates. It is necessary to measure the viscosity of the effusions over 
a wide range of shear because the rheological properties of mucin-containing secretions 
are shear-dependent (Bell et al., 1984) therefore the Contraves low shear viscometer 
was used to measure effusion viscosity over a shear rate of 0.018s"' to 128.5s'ß in the 
current studies. Measuring only a 4µl sample rather than the entire effusion could mean 
that the rheology of this small amount would not relate to the whole effusion because of 
non-homogeneity. In the current study, as the whole effusion is measured (after dilution 
and homogenisation) a more homogeneous and therefore more accurate situation is 
obtained. 
The effusions had been classified by clinical inspection as mucoid or serous and there 
was a significant difference in viscosity between the two types (P=0.0061, unpaired t 
test). On the basis of rheological properties, the effusions represent two different groups 
(mucoid and serous) as shown by Carrie et al. (Carrie et al., 1992) and it has previously 
been demonstrated by measurement of endogenous proteinase activity in effusions 
(using the N-terminal assay at pH7.4) that the difference in viscosity is not due to the 
level of degradation of the effusion components, but rather due to the relative amounts, 
composition and structure of the components in the effusions (Carrie et al., 1992) as 
there was no significant difference in endogenous proteinase activity between the two 
types of effusion. The lack of mucin degradation in the effusions was confirmed in the 
present study using SDS PAGE, where mucin remained at the point of application or 
moved to the interface of the stacking and running gels and there was no evidence of 
smaller molecular weight glycoprotein. 
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The NDS content of effusions ranged from 0.49 to 41.3mg per effusion with a mean of 
13.29 ± 1.27 (n=50) and there was a significant difference between the content in the 
two effusion types (P=0.0381, unpaired t test) demonstrating that the mucoid effusions 
contain more material and are more concentrated than the serous effusions, which 
agrees with previous studies (Came et al., 1992; Chung et al., 2002). 
Due to the presence of proteinase inhibitors in the extraction buffer, the glycoprotein 
content was underestimated by approximately 5.9 fold. When the levels were adjusted 
to account for this the glycoprotein content of the NDS ranged from 0.31 to 13.05mg 
per effusion with a mean of 3.84 ± 0.44 (n=50). This data can also be expressed as % of 
glycoprotein per non-dialysable solids and ranged from 11 to 61 % of NDS with a mean 
of 29 ± 1.9 (n=50). As these measurements are just an estimation, they cannot be 
directly compared to previous data, however they do roughly agree (Fitzgerald et at, 
1989; Carrie et al., 1992). 
There was a significant correlation between effusion specific viscosity and total NDS 
and also between specific viscosity and glycoprotein content. Viscosity can be defined 
as resistance to flow and in polymer-containing material such as effusion homogenates 
the viscosity will depend on the concentration of the solution (the more concentrated the 
solution, the more viscous) and the shape and size of the molecules present (small 
spherical molecules will flow more easily than stiff or extended molecules such as 
mucins). Glycoprotein has been shown to be the only constituent of effusions that 
determines the specific viscosity (Fitzgerald et al., 1989; Carrie et al., 1992). 
DNA is also a polymeric component of effusions and it is possible that endogenous 
DNA could have an effect on the viscosity of effusions mediated via an interaction with 
mucin (Lethem et al., 1990) as it does in respiratory secretions from patients with cystic 
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fibrosis. In the study by Lethem et al. it was shown that 40µg of DNA per mg dry 
weight of mucus gel has a small effect on mucus gel viscosity in cystic fibrosis, 10 and 
30% for a chronic bronchitic mucus gel and a fibrotic mucus gel, respectively. However 
the DNA content of effusion homogenates has been found to be 4.5µgmg" NDS 
(Johnson et al., 1997), which is around nine times lower than the levels in the study by 
Lethem et al. and this level is not important in determining the viscosity of the 
effusions. It has also been shown that after incubation bf effusions with DNase for 24 
hours, the viscosity of the effusions remained the same (Carrie et al., 1992; Piezhong et 
al., 2000) whereas proteinase digestion of the effusion homogenate resulted in a large 
drop in viscosity resulting from degradation of the mucin polymeric structure 
(Fitzgerald et al., 1989). As there is no significant correlation between protein content 
and specific viscosity this data demonstrates that the only component of effusions 
responsible for their viscosity is mucus glycoprotein. 
CsCI density gradient centrifugation of each effusion NDS was used to separate the 
effusion components by their buoyant densities. The fractions with densities of 
1.42-1.55gm1'' were pooled for each effusion as these were known to be the 
glycoprotein-containing fractions (Fitzgerald et al., 1987) and this mucin-rich material 
was used to determine the mucin gene products present in the effusions and also to look 
at the degradation state of the mucin. 
SDS PAGE was used to demonstrate the degradation state of the mucin from different 
effusions as this method has previously been validated for measuring the proportions of 
polymeric and degraded mucin (Rankin et al., 1995). Due to the storage conditions of 
the effusions before analysis (-20°C) and the presence of proteinase inhibitors before 
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viscosity measurements were taken, the effusions should have been subjected to 
minimal in vitro degradation. 
83.5% ± 2.4% of the mucin from effusions was of high molecular size and remained at 
the point of application in the stacking gel of a 4-15% polyacrylamide gel. The 
remainder of the material was present in the running gel adjacent to the interface of the 
stacking and running gels. There is little evidence of degradation of the mucin in the 
effusions and any differences in viscosity cannot be accounted for by changes in 
polymeric structure of the mucin. The lack of mucin degradation shown in these 
effusions would mean that they could remain viscous for long periods of time, leading 
to the long-term lack of mucociliary clearance. 
Analysis of the purified mucin from individual effusions was undertaken using the 
TEPA antiserum (high MUC5B specificity as discussed in Chapter 4) and anti-human 
gastric mucin antibody NCL-HGM-45M1 (which recognises an epitope in the non- 
glycosylated part of MUC5AC). Only effusions classified as mucoid were used in this 
study as they contain more mucin than serous effusions (Fitzgerald et al., 1988). Two 
effusions were excluded from the study as the levels of MUC5B measured fell out of 
the normal range and were 6.5 and 20.6-fold higher than the others. 
MUC5B was present in all effusions measured in the range 0.006-11.35µg per effusion 
with a mean of 2.13 ± 0.46 (n=34). MUC5AC was present in 32 of 34 effusions in the 
range 0.002-1.56µg per effusion with a mean of 0.16 ± 0.06 (n=32). There was 
approximately thirteen times more MUC5B present compared to MUC5AC in the 
effusions positive for both with the range (MUC5B: MUC5AC) 1: 1 to 160: 1. 
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These results agree with the study by Hutton et al. (Hutton et al., 1998a) where mucin 
from `thick' and `thin' effusion pools were analysed for the presence of MUC5B and 
MUC5AC using relevant antibodies in an ELISA. Only a maximum of 15% of the thick 
mucin weight was calculated to be MUC5AC and was therefore a minor mucin in the 
secretions. There was a strong reaction between the mucin and the MUC5B antibody. 
This antibody reacts well with human salivary mucin, of which MUC5B is the major 
mucin and studies documented in this thesis have demonstrated that the MUC5B 
antibody does not react with MUC7 the minor mucin component in saliva. These data 
suggest that the human middle ear mucosa in glue ear secretes more than one mucin and 
that MUC5B is a major component whilst MUC5AC is a minor one. 
MUC5AC is a normal respiratory epithelium mucin and has been shown to be present in 
airway secretions pooled from healthy individuals (Thornton et al., 1996). MUC5AC 
gene expression has not been detected in middle ear mucosa samples from patients 
without middle ear disease (Lin et al., 2001) using in situ hybridisation but mucin gene 
expression and the translation product have been found in middle ear mucosa from 
patients with otitis media with effusion (Hutton et al., 1998b; Severn et al., 1999) using 
immunohistochemistry and in situ hybridisation. The middle ear epithelium has been 
classified as a modified respiratory epithelium and therefore may not secrete MUC5AC 
in the normal situation. If this is the case then the effusion may have resulted from both 
an upregulation in gene expression (increased MUC5B production) and an alteration in 
the pattern of expression (MUC5AC secreted in the inflamed ear but not the normal 
undiseased ear). 
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To date there are no studies documented where individual effusions have been analysed 
for the content of MUC5B and MUC5AC and related to the effusion viscosity. 
In this study there was a significant correlation between MUC5B and specific viscosity 
(P<0.0001, Pearson correlation) but no correlation existed between MUC5AC and 
specific viscosity (P=0.503, Pearson correlation). This data, as well as the high content 
of MUC5B in individual effusions suggest that MUC5B is the mucin responsible for 
effusion viscosity, preventing the mucociliary transport system from clearing the mucus 
from the middle ear and therefore responsible for the build up of a middle ear effusion. 
It has been shown that expression of the MUC5B gene in middle ear mucosa epithelium 
correlates with the expression of inflammatory molecules (Kawano et al., 2000), 
suggesting that inflammation may initiate and maintain the hypersecretory state of the 
middle ear mucosa, leading to the chronicity of OME. 
MUC5B hypersecretion would appear to be a problem in OME, so the design of specific 
intervention aimed at the MUC5B secretion should be considered. There are two main 
ways in which this may be achieved, by the use of mucolytics or antisense 
deoxynucleotides. 
Mucolytic therapy has been used to modify the mucin within the effusion and thereby 
change the rheological properties allowing removal of the effusion by the mucociliary 
clearance mechanism from the middle ear cleft. Agents used have been 
N-acetylcysteine, S-carboxymethylcysteine and Nacystelyn. The therapy has been 
reported to have had limited success (Taylor and Dareshani, 1975; Ramsden et al., 
1977; Hughes, 1984) because if the mucolytic agent reduces the viscosity too much, 
then the mucociliary transport system cannot clear the effusion as it becomes too thin 
and it was reported from in vitro studies that after a 24 hour period, the viscosity of the 
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effusion increases due to denaturation and aggregation of protein components (Pearson 
et al., 1997). The concentration of the mucolytic reaching the middle ear and the time it 
will remain is not known yet is important as some mucolytic agents are cytotoxic over 
certain concentrations (Pearson et al., 1997). 
Antisense deoxynucleotides are sections of DNA, 12 to 30 nucleotides in length that 
interfere in a sequence specific manner with processes such as the translation of mRNA 
into protein. They are made to identify a particular target, such as a mucin gene and can 
block expression of the specific gene within the cell by binding the complementary 
mRNA sequence, thereby preventing the translation of mRNA. They must be stable in 
vivo and also must be able to enter the target cell and be retained there (Stein and 
Cheng, 1993). They are currently under investigation in a number of different fields 
including oncology, cardiovascular diseases and infectious diseases (Agrawal and Iyer, 
1995; Wagner and Flanagan, 1997). They would only be of use in OME if they could 
target the middle ear in particular and would reduce the level of mucus secretion but not 
remove it altogether as it plays a vital part in the mucociliary escalator. If the antisense 
deoxynucleotides had no specific target organ they could reduce secretion of the 
particular mucin, such as MUC5B throughout the body. MUC5B is also secreted in 
saliva, in the lungs and in bile and reduction 
in mucin secretion in these areas could 
have serious consequences. 
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A subset of effusions (n=14, mucoid) for which MUC5B and MUC5AC content was 
known, were also analysed for the presence of the cytokines IL-6 and IL-8. Cytokine 
levels and protein content were measured in the effusion homogenate immediately after 
viscosity measurements were taken. All data were expressed per mg NDS to account for 
any changes in hydration that may have occurred during storage of the effusions. 
The protein content of effusions varied between 649-961 ggmg" NDS. These values are 
very high in comparison with levels previously measured in effusions of 
1-266µgmg"' NDS (Johnson et al., 1997) and 57-230µgmg'1 NDS (Carrie et al., 1992). 
This could be due to two reasons: 
1. The above studies measured protein content in NDS, whereas in the current 
study the protein was measured in the entire homogenate therefore it is possible 
that components were present in the homogenates that could interfere in the 
assay which were removed in the dialysis stage in the previous studies. 
2. In the current study, dilutions of up to four hundred fold of the homogenates 
were made which were necessary to obtain results relative to the standard curve 
in the protein assay. This could also lead to inaccuracies in the measurement of 
total protein content. 
The levels of cytokines IL-6 and IL-8 were measured in effusions. They are present in 
high concentrations in effusions and are known to be the secondary cytokines activated 
in the cascade by TNF-a and IL-1ß (Maxwell et al., 1994; Sato et al., 1999; Skotnicka 
and Hassman, 2000). They have been shown using in vitro studies to induce mucin 
secretion (MUC5AC and MUC5B) at different stages and to different levels after 
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stimulation of a mucus-producing colon carcinoma cell line (HT29-MTX) (Smirnova et 
al., 2001; Smirnova et al., 2002a). 
IL-6 content in 14 effusions ranged from 1.5-558.5pgmg"1 NDS with a mean of 178 f 
42.5 (n=14) NDS and IL-8 content in the same effusions ranged from 
61.6-17130pgmg-' NDS with a mean of 4020 ± 1317 (n=14). There is generally a much 
greater amount of IL-8 in the effusions than IL-6. Previous studies have expressed 
cytokine levels per mg protein in the effusions and therefore to directly compare the 
results from this study with others the data has also been expressed in this way. IL-6 
content had a mean of 224.9pgmg'1 protein and the mean value for IL-8 was 
5129pgmg"1 protein. Previous studies have shown the mean IL-6 content in effusions to 
be 173.9pgmg'1 protein (Yellon et al., 1992) and the mean IL-8 content to be 
4805pgmg"1 protein (Maxwell et al., 1994), which are levels consistent with those found 
in the current study. Other studies have found lower levels of IL-8 ranging from 559 to 
617pgmg"I protein (Hotomi et al., 1994; Johnson et al., 1997; Pospiech et al., 2000), 
which is around eight-fold lower than the current study. The effusion reflects the 
contents present at effusion removal and the stage of the inflammatory cascade at this 
point is unknown therefore it is understandable that the cytokine levels will vary 
between samples. It is also possible that the effusion could be protecting cytokines from 
degradation and this could explain the very high cytokine levels in a subset of effusions 
(for example in effusions 6,8 and 14, section 5.3.4). Retention of cytokines in the 
middle ear cleft may result in an ongoing inflammatory state with the cytokines 
continuing to stimulate cells and their products in the middle ear cleft. 
There was a significant correlation (P=0.0149) between levels of IL-6 and IL-8 in 
effusions and this has previously been demonstrated in a chinchilla otitis media model 
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after inoculation by Streptococcus pneumoniae (Sato et al., 1999). It is possible that 
there is a correlation between the cytokine levels as they are both secondary cytokines 
in the inflammatory cascade and may be stimulated at similar times by the primary 
cytokines IL-10 and TNF-a, or it may be that one cytokine could stimulate the secretion 
of the other. It has been shown in vitro that inflammatory cells such as TNF-a and IL-1 
can stimulate mucosal cells to secrete cytokines (Smirnova et al., 2002a). 
IL-6 and IL-8 levels were plotted against MUC5B and MUC5AC content and effusion 
viscosity and the statistical correlations were determined. There was a significant 
correlation between reduced specific viscosity (specific viscosity mg"' NDS) and IL-8 
content pgmg"1 NDS (P=0.0267) and also MUC5AC content and IL-8 content pgmg" 
NDS (P=0.004). Both of these correlations were significant only when one data point 
was excluded. There were no other significant correlations between mucin gene 
products and cytokine levels. This data agrees with the in vitro studies by Smirnova and 
co-workers (Smirnova et at, 2001; Smirnova et at, 2002a) in that the induction of 
MUC5AC was much greater than that of MUC5B in the presence of IL-6 and IL-8. The 
in vitro data suggests that IL-6 and IL-8 may have different roles in the middle ear. IL-6 
is produced at a lower level than IL-8 in the middle ear and may be responsible for the 
maintenance of inflammation and prolonging mucin secretion. IL-8 may contribute to 
the maintenance of chronic OME by inducing a prolonged mucin secretion, which is 
delayed compared to the induction by other cytokines. 
In middle ear effusions there is no knowledge of the stage of disease progression as the 
effusion is analysed on removal and it is not possible to investigate if the in vivo 
situation mirrors the in vitro experiments. 
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As the absolute amount of IL-8 correlates with the reduced specific viscosity of the 
effusions and with levels of MUC5AC it may be that MUC5AC is produced in response 
to IL-8 in the middle ear and that another stimulus or other cytokines are responsible for 
the upregulation of MUC5B. The reason for the correlation between IL-8 and MUC5AC 
could be that in the normal uninflamed ear it has been reported that MUC5AC is absent 
(Lin et al., 2001) and that in the diseased state MUC5AC secretion increases with the 
presence of IL-8. MUC5B however is expressed at a low level in the normal ear and in 
the diseased ear the effect of IL-8 on MUC5B is smaller and starts at a much higher 
level and this starting level masks the effect of IL-8. 
Further investigations should focus on the measurement of all cytokine levels in 
effusions and relating these to the MUC5B and MUC5AC levels. If a correlation 
between MUC5B, the major mucin, and a particular cytokine is significant then it may 
be possible to target this cytokine and reduce the induction of MUC5B gene expression. 
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CHAPTER 6 
GENERAL DISCUSSION 
Chapter 6 General Discussion 
The middle ear is an air-filled chamber containing the auditory ossicles, connected to 
the nasopharynx by the Eustachian tube. The middle ear secretes mucus, which provides 
a protective barrier against invading particles and microorganisms and dehydration. The 
mucus is an integral part of the mucociliary escalator, which transports trapped particles 
towards the nasopharynx via ciliary beating. Mucins have been shown to be solely 
responsible for the viscoelastic properties of mucus (Fitzgerald et al., 1989; Carrie et 
al., 1992) therefore any change in the quantity or type of mucin secreted could alter the 
clearance of mucus from the middle ear and result in a pathological condition. 
Otitis media with effusion (OME) is defined as inflammation of the middle ear with the 
accumulation of a viscous mucin-rich effusion in the middle ear cleft without signs or 
symptoms of active infection (Bluestone, 1999). In the disease, inflammation is the 
initiator of a hypersecretory state that occurs as a result of mucosal differentiation. An 
increase in the number of goblet cells in the epithelium and submucosal glands is 
observed resulting in hypersecretion of mucus. The increase in the number of secretory 
cells parallels a decrease in the number of ciliated cells (Inagaki et al., 1988) and the 
effusion that accumulates is unable to be cleared and remains in the middle ear cleft. 
The effusion dampens mobility of the auditory ossicles and impedes sound 
transmission, resulting in hearing loss whilst the effusion is present. 
Due to lack of availability of normal middle ear mucosa, there is little data regarding the 
mucin genes expressed in the undiseased state. Lin et al. (Lin et al., 2001) reported the 
expression of the MUC5B gene and the presence of the gene product in normal middle 
ear mucosa, however gene products present in the normal mucus secretion were not 
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measured. In middle ear mucosa samples from children with OME, expression of 
MUC1, MUC2, MUC5AC, MUC5B and MUC7 was detected using in situ 
hybridisation, the highest intensity of expression was observed with the secreted mucins 
MUC5B in submucosal glands and MUC5AC in goblet cells and the membrane bound 
mucin MUC4 present at the surface epithelium (Severn et al., 1999; Kawano et al., 
2000). Using immunohistochemical analysis, MUC5AC and MUC5B gene products 
were detected in middle ear mucosa (Hutton et al., 1998b) with the same cell 
distribution as observed using in situ hybridisation, demonstrating that gene expression 
is related to cell type. Tissue expression does not always correlate with the gene product 
in the secretion (Thornton et al., 1996) therefore it was necessary to analyse the mucin 
gene products present in effusions. Previous studies using pooled effusions have shown 
that MUC5B and MUC5AC are present (Hutton et al., 1998a) however the work 
presented in this thesis is the first study using individual effusions. 
It was demonstrated using dilute solution viscosity studies that the specific viscosity of 
effusions significantly correlated with the total glycoprotein content, supporting the 
theory that mucins are responsible for the rheological properties of the effusion (Chapter 
5). The mucins present were measured following purification of effusion glycoprotein 
by CsCI equilibrium density gradient centrifugation. MUC5B was present in all 
effusions and MUC5AC was found in 94% of these. MUC5B content was on average 
thirteen times the level of MUC5AC demonstrating that MUC5B is the major mucin 
present in effusions with MUC5AC secreted at much lower levels. There was a 
significant correlation between MUC5B content and effusion specific viscosity. From 
the results presented in this thesis one can conclude that in OME there is an 
upregulation of MUCSB, the mucin secreted in the normal middle ear and also an 
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alteration in the pattern of mucin expression as MUC5AC can be detected only in the 
diseased state, however this has only been investigated in one study. Middle ear 
epithelium is modified respiratory in type and MUC5AC is a major secretion in the 
airways (Gendler and Spicer, 1995). It would be interesting to further this study by 
identifying the mucin genes expressed and secreted in the normal middle ear to clarify 
that MUC5AC is not secreted in the undiseased state, however middle ear mucosa 
specimens are generally unavailable. 
Middle ear mucin remains largely undegraded as demonstrated by SDS PAGE, this lack 
of degradation would mean that the effusions could remain viscous for long periods and 
be immovable by the cilia and therefore may be present in the middle ear for longer than 
three months. 
In order to quantify the MUC5B mucin present in effusions it was necessary to prepare 
a MUC5B standard, as there was no appropriate standard available. This was achieved 
by CsCI equilibrium density centrifugation of human saliva. There are two main 
secreted mucin populations present in human saliva, MUC5B and MUC7 (Prakobphol 
et al., 1982). There is documented evidence of MUC4, a membrane bound mucin in the 
submandibular and sublingual glands (Troxler et al., 1997) measured by Northern 
blotting and it is possible that this mucin is also present as a minor component in the 
saliva secretion if it is in a soluble form or as a cleavage product. The CsCI purified 
saliva was highly reactive against the MUC5B antisera (TEPA) and was not reactive 
with the MUC7 antisera suggesting that the purified mucin consisted of mainly the 
MUC5B gene product and was a relatively pure standard to use in the quantification of 
MUC5B. 
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OME is an inflammatory disease and many inflammatory mediators have been 
identified in the effusion including arachidonic acid metabolites, histamine, 
immunoglobulins, components of the complement system and cytokines. Cytokines are 
a group of low molecular weight glycoproteins of which IL-10, IL-2, IL-6, IL-8, IFNY 
and TNFa have been previously measured in effusions (Yellon et al., 1991; Himi et al., 
1992; Maxwell et al., 1994; Takeuchi et al., 1994; Yellon et al., 1995; Johnson et al., 
1997; Pospiech et al., 2000; Schousboe et al., 2001). In vitro studies using a human 
colon carcinoma-derived mucus secreting cell line (HT29-MTX) have shown that IL-6 
and IL-8 have the ability to stimulate MUC5AC and MUC5B secretion at different 
rates, for different periods of time and to different levels (Smirnova et al., 2001; 
Smirnova et al., 2002a; Smirnova et al., 2002b) and that they may have roles in 
different stages of the inflammatory process. In the current study, IL-6 and IL-8 levels 
were measured in effusions and compared to levels of MUC5B and MUC5AC. A 
significant correlation was observed between the IL-6 and IL-8 content of effusions 
suggesting that the cytokines are either stimulated at similar times or that one cytokine 
may stimulate the secretion of the other. The IL-8 content correlated significantly with 
MUC5AC in effusions, this agrees with the above in vitro results of Smirnova et al., 
and no other significant correlations were observed between IL-6, IL-8, MUC5B and 
MUC5AC. It may be that MUC5AC is produced in response to IL-8 in the middle ear 
and that another stimulus or other cytokines are responsible for the upregulation of 
MUC5B. It is not possible to conclude if the in vitro situation mirrors the in vivo 
situation from this study as the stage of the disease and therefore the inflammatory 
cascade is unknown at the time of effusion removal. 
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To further this work, levels of all cytokines could be measured in effusions and related 
to the presence of MUC5B and MUC5AC to investigate if any other cytokines correlate 
with MUC5AC secretion and to identify if any cytokines are linked to secretion of 
MUCSB, which is the major mucin. It would be useful to collect data on the time of 
initial diagnosis to have an idea of duration of the disease (and stage of the 
inflammatory process) in each individual. 
Mucolytic therapy has been used to treat OME by altering mucin structure within the 
effusion and thereby reducing effusion viscosity. This treatment had only limited 
success (Taylor and Dareshani, 1975; Ramsden et al., 1977; Hughes, 1984) as there is 
an optimum viscosity at which mucus is effectively transported (Silberberg, 1983) and 
if the effect of the mucolytic resulted in the effusion becoming too thin or remaining too 
viscous then it could not be removed by the cilia from the middle ear cleft. Currently 
OME is treated by surgical removal of the effusion, a process termed myringotomy, and 
insertion of a grommet into the tympanic membrane to allow aeration of the middle ear. 
This procedure treats the symptoms of OME rather than the cause. Retention of 
cytokines in the middle ear cleft may result in an ongoing inflammatory state with the 
cytokines continuing to stimulate cells and their products in the middle ear cleft, 
especially if the effusion is protecting them from degradation. It may be possible to 
target and deactivate these inflammatory mediators in the middle ear by direct injection 
through the tympanic membrane. This would reduce the inflammatory process in the 
middle ear cleft and prevent the chronic stages of OME, especially if the stimulus for 
MUC5B secretion could be identified. 
There are many inflammatory stimuli associated with OME such as bacteria and their 
products, viruses and allergy (Giebink, 1989; Arola et al., 1990; Mogi et al., 1992; Post 
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et al., 1995; Shaw et al., 1995; Liederman et al., 1998; Post et al., 1998). A link 
between OME and gastro-oesophageal reflux has also been suggested by some 
researchers (Shilkin, 1994; Halstead, 1999; Velepic et al., 2000) however a direct 
relationship has not until now been determined. In the current study, acidic proteinase 
activity was detected in 29% of effusions and pepsin/pepsinogen protein levels were up 
to 1000 times higher than serum reference levels. Albumin and fibrinogen levels in 
effusions were of the same order as serum reference levels indicating that serum 
proteins were not being concentrated up in the effusions. Preliminary 
immunohistochemical analysis of middle ear mucosa biopsies demonstrated that the 
middle ear does not secrete pepsin therefore the only likely source of pepsin is from 
reflux of gastric juice. 
The presence of acidic reflux in the nasopharynx has previously been documented in a 
24 hour pH monitoring study (Contencin and Narcy, 1991) and reflux of gastric 
contents from the nasopharynx to the middle ear is possible in infants and young 
children due to anatomic differences in the Eustachian tube in this age group compared 
to children aged seven and above (Bluestone, 1996). The Eustachian tube is shorter and 
has a lower angle of inclination in infants and young children (Sadler-Kimes et at, 
1989) thus allowing gastric contents to reach the middle ear more easily and the tensor 
veli palatini muscle, which is involved in the active opening and closing mechanism of 
the Eustachian tube is less efficient enabling unwanted secretions such as reflux or those 
containing bacteria to gain access to the middle ear. Gastric contents are acidic, 
(however due to neutralising bicarbonate in the oesophagus, they would not be as acidic 
as in the stomach) and would cause damage and inflammation in the Eustachian tube 
and middle ear leading to the accumulation of an effusion, which could block the 
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immature Eustachian tube due to the lumen being narrow. Pepsin would be inactive due 
to the high pH of the effusion. If the Eustachian tube remains unblocked and a second 
reflux event occurs, pepsin present from the previous reflux episode may be reactivated 
as the work presented in this thesis has demonstrated that effusion contents protect 
pepsin from complete denaturation at up to pH8 and further damage and inflammation 
would result. Due to the damaged mucosal epithelium, bacteria present in the middle ear 
could easily invade the tissue, cause a secondary infection and prolong the 
inflammation, leading to a chronic disease state. In conclusion, gastro-oesophageal 
reflux may be the primary factor in the initiation of OME in children as a decrease in 
the prevalence of OME correlates with the anatomical changes that occur upon maturity 
including a change in the angle of the Eustachian tube to 45° to the horizontal, an 
increase in the tube size and mechanical efficiency for tubal opening (Sadler-Kimes et 
al., 1989). Anti-reflux therapy could be particularly relevant in the group of children 
who require repeated grommet insertion or have therapy resistant middle ear disease as 
they may be suffering from OME induced by persistent gastric reflux and anti-reflux 
therapy would potentially cure the disease. 
To further this work, effusions could be analysed for other components of gastric juice 
such as gastric lipase or intrinsic factor to further confirm the role of reflux in OME. 
Few long-term studies on OME have taken place due to the lack of a suitable and 
reliable model. It may be possible to set up an animal model for reflux by instilling 
gastric juice into the middle ear via the Eustachian tube and observe whether an effusion 
develops rather than as Heavner et al. (Heavner et al., 2001 a; Heavner et al., 2001 b) 
where a rat model was exposed to gastric juice components via the tympanic membrane, 
which is non-physiological. 
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The overall conclusions from this PhD study are that OME is an inflammatory disease 
resulting in hypersecretion of mucus. The effusion is viscous and has high mucin 
content, most of which consists of MUC5B however MUC5AC is also present as a 
minor mucin. Gastro-oesophageal reflux may be the primary cause of OME, instigating 
a cascade of inflammatory events leading to the conditions seen in the disease. 
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